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Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory 
tract disease among infants, young children and immunocompromised 
individuals. Natural infection with RSV results in incomplete immunity 
and reinfection may occur frequently throughout life. For this reason, RSV 
infection forms a serious threat in chronically ill adults and the elderly [1]. 
Recent studies have demonstrated that RSV also makes a major contribution 
to mortality among the elderly, indeed to similar extents as does influenza 
[2]. Presently, the only approved medication against RSV infection is a 
prophylactic monoclonal antibody, i.e. Palivizumab, which is given as a 
prophylaxis to high-risk infants. Despite the identification and isolation of 
the virus in 1956, efforts to develop a safe vaccine have been unsuccessful 
so far. In a clinical trial conducted in young children in the 1960s, a formalin-
inactivated RSV (FI-RSV) vaccine did not protect against infection, but rather 
caused enhanced respiratory disease (ERD) upon subsequent exposure of 
the vaccinees to the natural virus. The finding that inactivated RSV vaccines 
may prime for ERD has contributed significantly to the delay of their further 
development. With the recent identification of new-generation adjuvants 
and immunomodulators, such as innate receptor ligands, the interest in 
inactivated RSV vaccine development has renewed. An attractive approach 
to the development of a safe and effective RSV vaccine, may be the use of 
innate receptor ligands as adjuvants in a mucosally (e.g. intranasally; IN) 
administered RSV vaccine. 
Respiratory Syncytial Virus
RSV is an enveloped negative-sense non-segmented single-stranded 
(ss) RNA virus of belonging to the Pneumovirus genus of the family 
Paramyxoviridae. This family also comprises other major human pathogens 
such as Measles, Mumps and parainfluenza virus [3]. Two serotypes of  RSV 
have been recognized, i.e. RSV A and RSV B [4]. 
 The RSV genome contains 10 genes of 15,200 nucleotides encoding 
11 proteins [5]. RSV consists of a nucleocapsid surrounded by a lipid 
envelope with a diameter of 150-300 nm (Figure 1: RSV particle and RSV-
genome). RSV expresses two non-structural proteins, NS1 and NS2. These 
are detected only in RSV-infected cells and are not packaged into the virion. 
They mainly serve to inhibit type I interferon responses [6]. Eight RSV 
proteins are present in the virion particles. Among these structural proteins, 
three are membrane proteins:  the attachment protein G, the fusion protein 
F and the small hydrophobic protein (SH). The heavily glycosylated G 
protein is responsible for viral attachment to the cell. The F protein not 
only contributes to binding of the virus to cells, but also plays a crucial role 
during virus entry by mediating fusion of the viral envelope with the cell 
membrane, thereby allowing deposition of the viral genome into the cytosol 
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[7]. Besides this, the F protein is a mediator of syncytium formation [5]. The 
function of the SH protein, which is predominantly found in the infected-cell 
membrane, is unknown [8]. The remaining viral structural proteins are the 
matrix protein (M), the nucleocapsid protein (N), the RNA-dependent RNA 
polymerase (L), the phosphoprotein (P) and the M2 gene product M2-1: 
all these proteins reside inside the viral particle. Whether the M2-2 gene 
product is packaged in the virion is currently unknown [9]. 
 The function of the matrix (M) protein is to connect the viral 
nucleocapsid with the lipid envelopes and it is also responsible for viral 
particle assembly. The M2-2 protein is involved in regulation of viral 
transcription [10]. M2-1 functions as transcription-elongation factor [11]. 
The nucleocapsid protein (N) and phosphoprotein (P) are essential for 
transcriptional activity, while the L protein has RNA polymerase activity.    
Figure 1: Schematic representation of the RSV virion and genome composition




RSV infections have a world-wide distribution. In temperate climates, 
infections are confined to the winter season. In tropical climates, RSV 
infections may occur throughout the year, but can be more frequent in the 
rainy season in some geographical areas [12-14]. Although infection can be 
established in several laboratory animals, natural infection with RSV seems 
to be limited to humans and apes [15]. RSV transmission occurs through 
direct contact or contact with contaminated surfaces that harbor respiratory 
secretions. The virus can survive for several hours on toys or other objects, 
which explains the high rate of nosocomial RSV infections particularly in 
pediatric wards. The incubation period for RSV infection ranges between 2 
and 7 days [16]. Almost 70% of newborns are infected in the first year of 
their life. By 2 years of age almost all children have been infected and over 
50% will have been infected twice [17]. RSV infections are common in the 
population and re-infections probably occur frequently. In a study conducted 
by Hall et al., almost 25% of adult volunteers could be re-infected with RSV 
of the same group, two months after a natural infection [18].  
 RSV infection is the most important cause of severe respiratory 
illness in infants and young children and is the most frequent cause of 
hospitalization of infants and young children in industrialized countries 
[19]. RSV infections differ in disease severity, ranging from a mild cold 
to bronchiolitis or pneumonia. Approximately 3% of infants infected with 
RSV requires hospitalization due to respiratory failure and feeding problems 
[20]. Among hospitalized infants, 20% needs mechanical ventilation [21]. 
The highest morbidity of RSV disease is seen in children below the age of 6 
months [22] and in children with underlying risk factors such as prematurity 
[23], broncho-pulmonary dysplasia [24], congenital heart disease with 
increased pulmonary circulation [25] or immune deficiency [26]. According 
to the WHO, the global RSV disease burden is estimated at 64 million cases 
and 160,000 deaths each year. In USA alone, approximately 85,000 to 
144,000 infants are admitted to hospitals with RSV infection per year, which 
corresponds to 20-25% of pneumonia cases and up to 70% bronchiolitis 
cases in the hospital [27,28]. The elderly people are also at risk for severe 
RSV disease and 14,000 to 62,000 RSV-associated hospitalizations of the 
elderly occur in the USA with an estimated annual cost of RSV pneumonia-
related hospitalizations of $150-680 million [29,30]. 
Pathogenesis
After infection, RSV primarily replicates in the epithelial cells of the 
nasopharynx [31]. The exact mechanism by which RSV spreads to the lower 
respiratory tract is unknown. Presently, it is not clear why the disease course 
is mild in most children, but severe in a small subgroup. Different studies 
have described associations between disease severity and genes involved 
in allergic responses, like IL-4 and IL-4 receptor genes, and genes for 
inflammatory cytokines, e.g. IL-6 and IL-8 [32]. Furthermore, up-regulation 
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of chemokines during RSV infection is associated with disease severity. For 
example, CCL11 (eotaxin), RANTES (CCL5) and MIP-1α have been found 
in higher levels in cases with more severe RSV infection and ERD [33,34]. 
 Several other factors could be associated with disease severity, 
including, for example, environmental factors, patient intrinsic factors, 
virus strain type and viral load. Environmental factors like a high number 
of siblings, attendance of day-care centers and socio-economic status 
can enhance the chance of early exposure and may increase the risk 
of developing lower respiratory tract disease [35]. Other factors like 
geographical area, parental smoking and the use of wood-burning stoves 
have also been linked to an enhanced risk of severe RSV infections [36-
39]. Patient-intrinsic factors like a compromised respiratory function, e.g. 
bronchopulmonary dysplasia (BPD) [40], or congenital heart disease with 
increased pulmonary circulation may significantly enhance the risk to develop 
severe RSV infection [41]. It is reported in some studies that RSV-strain A 
is responsible for more severe disease [42], while other studies report no 
difference between RSV A and B strains [43,44]. Furthermore, the course of 
lower respiratory disease was found to be associated with a high viral load 
[45]. Finally, RSV-specific immunity induced by vaccination may also be 
involved in immunopathological mechanisms leading to enhanced disease. 
This hypothesis is mainly based on experimental animal data [46], and on 
observations from a clinical trial where, as indicated above, infants were 
vaccinated with a formalin-inactivated candidate vaccine (FI-RSV), which 
resulted in ERD upon natural infection [47-49]. The notion that inactivated-
RSV preparations can prime for ERD is one of the factors that has delayed 
the development of an effective RSV vaccine. 
Immune responses after RSV infection
Innate immune responses
Innate immunity provides the first line of resistance to infectious diseases. 
During a natural RSV episode, the virus mainly infects airway epithelial 
cells from alveoli and small airways [50]. These epithelial cells, together 
with specialized dendritic cells (DC) and macrophages, are the first cells 
that respond to the infection [51]. For example, RSV can be recognized 
by three classes of pattern recognition receptors (PRRs), including Toll-
Like Receptors (TLRs), NOD-Like Receptors (NLRs) and RIG-Like Receptors 
(RLRs). TLRs are found on a wide range of cells such as macrophages, DCs, 
epithelial cells, eosinophils and neutrophils. A number of TLRs are activated 
during RSV infection, including TLR2, TLR3, TLR4 and TLR7 [52]. TLR2 
is expressed on the surface of immune cells, but also on epithelial cells, 
mostly in conjunction with other receptors such as TLR1, TLR6, CD36, CD14 
or dectin-1 [52]. Recent studies have indicated that TLR2 is involved in RSV 
recognition and subsequent innate immune activation and suggest that TLR2 
may be a functional receptor for RSV [52]. TLR3 is an intracellular receptor 
that recognizes double-stranded RNA (dsRNA), which is produced during RSV 
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replication. TLR4 is activated on the cell surface upon binding of the RSV-F 
protein using CD14 as co-receptor [53,54]. Activation of TLR4 and CD14 
by RSV-F protein leads to an NF-κB-mediated inflammatory response and 
innate immune responses [55] and increased TLR4 expression in epithelial 
cells [56]. RSV particles contain ssRNA that is being recognized via TLR7 
after entry of the viral genome into the cell cytosol [52]. Furthermore, RSV 
infection may also stimulate NOD2 expression, which activates IRF3 and 
type-I IFN production within 2h post-infection, whereas other PRRs (e.g. 
RIG-I)  activate the IRF3-IFN pathways later on during infection [57]. The 
latter pathways serve to induce a general antiviral state through production 
of type I IFNs. Innate immunity also primes the adaptive immune system in 
such a way that it can induce effective immune responses to clear the virus 
and also provide protection against reinfection [58].
Acquired cellular immunity
Virus-specific T cells (CD4+ and CD8+ T cells) play a prominent role in the 
clinical outcome of RSV infection. Previously, it has been described that 
in children with normal T cell responses, virus excretion stops within 1-3 
weeks, while children who do not mount an adequate cellular immune 
response, may shed virus for prolonged periods of times [59]. Furthermore, 
patients with impaired T cell immunity display more severe disease and 
enhanced virus shedding [26]. RSV-induced respiratory disease in infants 
also correlates with decreased frequencies of T cells in the lungs of these 
children [60].
Role of CD4+ T cells 
T-helper (Th) cells are generally classified into Th1, Th2 and Th17 subsets 
on the basis of their cytokine secretion profiles. For example, Th1 cells are 
known to secrete IL-2, IFN-γ and TNF-α; Th2 cells secrete IL-4, IL-5, IL-6, 
IL-10 and IL-13 while Th17 cells secrete IL-17.[[61]. The general view is 
that an effective protection against RSV, for example, induced by infection 
or vaccination, relies on a virus-specific T cell responses skewed towards 
Th1-type response [46]. RSV has evolved mechanisms, however, that skew 
towards less effective Th2-type responses upon infection [62]. 
 In human studies, contradictory observations have been made 
regarding the role of CD4+ T cells. RSV infection in infants has been reported 
to lead to induction of higher levels of Th2-type immune responses (e.g. 
with IL-4 production) and lower levels of Th1-type responses (e.g. with 
IFN-γ production) [63]. It has also reported, however, that in young infants, 
IFN-γ is the predominant cytokine produced by T cells regardless of clinical 
severity [64]. In another study, an enhanced IFN-γ production was found 
in nasopharyngeal washes of children exhibiting severe disease symptoms 
compared to those with mild disease [65]. In contrast, yet another study 
demonstrated that RSV infection of infants younger than 3 months induced 
increased levels of IL-4 in nasopharyngeal washes, followed by marked 
eosinophilia and establishment of Th2-type responses that were associated 
with enhanced disease [66]. 
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It has been reported that vaccination of mice with inactivated vaccines, 
including FI-RSV or RSV-G protein, elicited Th2-cytokine expression upon 
infection with live RSV [67-70]. Additionally, vaccination of mice or cotton 
rats with FI-RSV was linked with enhanced lung pathology characterized by 
infiltration of eosinophils [67,71], and this enhanced pathology was reduced 
by simultaneous administration of IL-4- or IL-10-specific monoclonal 
antibodies (mAb), but not by IFN-γ- or IL-2-specific mAb [72]. This 
suggests that Th2-type cytokines, but not Th1-type cytokines, are involved 
in enhanced disease. 
Role of CD8+ T cells 
In general, CD8+ T cells are thought to play a beneficial role in RSV-specific 
immunity [73]. CD8+ T cell responses are mostly directed against NS2, N, M, 
M2, F and SH proteins, with responses against F, N and M2 being the most 
prominent in mice [74]. It has been reported that enhanced frequencies 
of RSV-specific CD8+ T cells in infants correlate with a decreased risk for 
secondary RSV infection [75], may assist in clearance of the virus [76]. 
There is sufficient data to support the protective role of CD8+ T cells in 
RSV infection. It has been observed that RSV-specific CD8+ T cells were 
able to clear virus more rapidly than immunodeficient mice [77]. This 
has been further confirmed by cell transfer studies where RSV infection 
in immunodeficient mice was stopped by transfer of RSV-specific CD8+ T 
cells [78]. Recent studies have also demonstrated the presence of RSV-
specific CD8+ T cells in the bronchial alveolar lavage and blood of RSV-
infected infants [76]. In human studies, decreased clinical symptoms were 
observed with increased numbers of CD8+ T cells in the peripheral blood of 
previously infected adults [79]. Despite the well-established role of CD8+ T 
cells in clearing virus after RSV infection, some contribution of CD8+ T cells 
to enhanced disease in mice has also been reported, for example, when 




After primary infection, IgG antibody responses follow the initial transient 
IgM response and reach peak titers at approximately 20-30 days post-
infection, while, upon secondary infection, IgG responses are faster and 
higher in magnitude and reach peak titers in 5-7 days [81]. Serum IgG 
antibodies can transudate to the lower respiratory tract and the lungs, 
but transudation to the upper respiratory tract (i.e. nasal mucosa) is not 
efficient. It is, therefore, believed that the main function of serum IgG is 
to contribute to virus clearance from the lower airways and lungs [82,83]. 
In line with this, several studies in humans and animals indicate that RSV-
specific serum IgG titers negatively correlate with disease severity and viral 
titers in the lower respiratory tract in young children as well as in the elderly 




Secretory IgA (S-IgA) antibody responses are mainly associated with 
protection of mucosal surfaces. RSV replication occurs primarily in the 
respiratory epithelial cells that line the airways, so local S-IgA can form a first 
barrier against infection [87]. It has been reported that RSV-specific IgA is 
secreted rapidly in the upper airways following primary RSV infection in mice 
[88]. Despite the increase in IgA-secreting plasma cells after infection of 
mice, RSV-specific IgA levels appeared to wane fast over time, being largely 
undetectable by 8 weeks post–infection [89]. Reduced RSV-specific nasal 
IgA titers have been found with increased infection in human adults [84]. 
Murine studies have also demonstrated that intranasal (IN) administration 
of RSV-specific IgA monoclonal antibody prior to RSV infection could provide 
protection [90]. In mice, administration of IgA monoclonal antibody appears 
to be equally effective as IgG monoclonal antibody in providing protection 
against RSV infection [91]. Thus, S-IgA could play an important role in 
preventing RSV infection of the airways.  
                                                                       
Treatment of RSV infection
Antibody prophylaxis
RespiGam was the first antibody preparation which could reduce disease 
severity in high-risk infants [92]. A major drawback of its use was the 
requirement of the product as a large-volume intravenous infusion. With 
advances in neutralizing monoclonal antibody technology, this approach 
was further refined by the development of Palivizumab (Synagis), a 
humanized monoclonal antibody that recognizes an epitope on the RSV-F 
protein. Palivizumab is 50- to 100-fold more potent than RespiGam and 
can be administered by intramuscular injection [93]. Presently, palivizumab 
is the only approved monoclonal antibody for the prophylaxis of RSV. It 
reduces RSV-related hospitalizations by 55% [94]. It, however, has little 
effect on the replication of the virus in the upper respiratory tract of infants 
[93]. Motavizumab is an improved form of Palivizumab which elicited 20-
fold enhanced neutralization of RSV in vitro compared to Palivizumab and 
potently inhibits RSV replication in the upper respiratory tract of cotton rats 
[95]. It has, as yet, not been registered for clinical use.
Antivirals and other treatment modalities
Despite the success in development of prophylactic antibodies, as described 
above, some antiviral drugs are also being used in high-risk infants or in 
immunocompromised individuals. Ribavirin (a nucleoside analogue), is the 
only approved drug to treat RSV infections, but there is extensive debate 
about its clinical benefits in young children [96]. In addition to this classical 
antiviral treatment modality, new approaches involving like small interfering 
RNAs (siRNAs) have been explored. These approaches reduce viral protein 
production by inhibiting targeted mRNAs in a sequence-specific manner. 
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IN administration of siRNAs prior to infection, for example, inhibited RSV 
replication in mice [97,98]. 
Vaccination against RSV 
Despite more than four decades of research, a safe and effective RSV vaccine 
is not available. Attempts to develop an formalin-inactivated RSV vaccine 
were initiated in the 1960s, but with disastrous outcome as discussed in 
more detail below. Several approaches like the use of live-attenuated RSV, 
subunit or purified proteins, chimeric viruses and vector-based vaccines, 
have been or are still under development as candidate RSV vaccination 
strategies. Most of these approaches have been tested in clinical trials 
but none of them reached the required safety and efficacy standards, and 
demonstrated a variable degree of immunogenicity, stability and safety. A 
number of RSV vaccine candidates and challenges associated with their 
development are described below.
Formalin-inactivated vaccines 
Attempts to control RSV infections in newborn and young children by 
vaccination were initiated in the 1960s. Four studies were performed in 
young children who received formalin-inactivated whole RSV virus (FI-
RSV) vaccine [47-49,99]. These studies demonstrated that FI-RSV vaccine 
failed to protect upon subsequent natural infection. Rather, in many cases 
ERD was observed. In one of these studies, 80% of vaccinees required 
hospitalization, compared to only 5% of vaccinees who received a 
parainfluenza vaccine. Of the hospitalized children suffering from ERD, two 
individuals died. Upon natural virus infection, FI-RSV vaccinees experienced 
severe symptoms like pneumonia and/or bronchiolitis, while children from 
control groups experienced more mild symptoms like rhinitis, pharyngitis 
and/or bronchitis [47]. Autopsy reports from the deceased children describe 
lung infiltrates consisting mostly of neutrophils and eosinophils, indicating a 
role of host inflammatory responses in the enhancement of disease [100]. 
Further analysis of sera from FI-RSV vaccinees showed that the vaccine had 
induced poorly virus-neutralizing antibodies, which may have contributed to 
ERD by delaying virus clearance from the lungs [101].
 After this disastrous vaccine trial outcome, several studies were 
carried out in animal models to explore the etiology of the observed 
pulmonary immunopathology. Possible factors involved in priming for ERD 
by FI-RSV include disruption of protective epitopes by chemical inactivation 
of the virus, poor innate receptor activation by the vaccine resulting in 
induction of poorly neutralizing antibodies, and excessive induction of Th2-
type immune responses potentially due to the use of alum as an adjuvant 
[67,102-105]. Additionally, vaccine-induced IgE is believed to contribute to 
hypersensitivity responses associated with ERD, as demonstrated in calves 
immunized with formalin-inactivated-Bovine RSV (FI-BRSV) followed by 




Live-attenuated (LA) virus vaccines have been considered an effective 
strategy because they mimic natural virus infection and probably, following 
the use of LA vaccines, no enhanced pathology is to be expected. If the 
vaccine is delivered via the mucosal route, a balanced systemic and local 
immune response may develop including the induction of mucosal antibodies 
and cytotoxic T cells, which are known to be essential in protection against 
infection and clearance of the virus. However, with attenuated RSV vaccines, 
the balance between immunogenicity and attenuation appears difficult to 
establish [73]. Inadequate attenuation and the potential reversion of the 
vaccine virus to a wild-type form pose serious risks in terms of induction 
of pathology and potential mortality, especially in immunocompromised 
individuals [107]. The first LA vaccine, cpts248/404, was evaluated in 
infants 1-2 months of age. Vaccination resulted in a high incidence of nasal 
congestion and the virus turned out to be insufficiently attenuated for use in 
very young children [108]. Mutated strains, like those lacking the SH gene, 
did not lead to nasal congestion in infants. However, the immunity conferred 
by this vaccine did not correlate with protection [109]. Currently, a new 
live-attenuated RSV strain (MEDI-559) is in Phase II clinical evaluation in 
children (5-24 months of age) and infants (1-3 months of age). 
Subunit vaccines 
A purified RSV-F protein (PFP-2 and PFP-3) subunit vaccine adjuvanted with 
alum has been tested in pregnant women, healthy adults over 60 years of 
age and children with cystic fibrosis (CF) [110-112]. The vaccine induced 
a ≥4-fold increase in virus-specific antibodies in 95% of the vaccinated 
pregnant women, and RSV-specific antibodies in the newborns and breast 
milk from vaccinated mothers were significantly enhanced [111]. Another 
subunit vaccine comprising purified RSV-F, -G and -M proteins, has been 
evaluated in a clinical dose-ranging study in 561 adults of 65 years or older. 
The vaccine’s reactogenicity was similar to that seen with seasonal influenza 
virus vaccination. Unexpectedly, the non-adjuvanted vaccine appeared 
to be more immunogenic than the alum-adjuvanted vaccine and was the 
only formulation that induced a ≥4-fold rise in neutralizing antibody titers 
against RSV in ≥50% of the vaccinees [113]. Similar results were also 
found in another clinical trial in adults with cardiopulmonary disease, in 
which non-adjuvanted subunit vaccine was more immunogenic than an 
aluminum-phosphate-adjuvanted vaccine. This vaccine was found to be 
safe and immunogenic. However, RSV-specific antibody titers returned to 
baseline within a year, suggesting that annual vaccination would be required 
[114].
Chimeric viruses and virus-like particles
In this approach, selected RSV genes are expressed in related paramyxoviruses 
like Newcastle disease virus, bovine parainfluenza virus (PIV) or Sendai 
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virus that can be delivered to the respiratory tract. The advantage of using 
these viruses is that their replication is limited in humans as humans are not 
their natural host. A bovine PIV3 expressing the RSV-F and human PIV-F, 
(MEDI-534) is the only chimeric virus vaccine that has been evaluated in 
a clinical trial. This vaccine induced protection in African green monkeys 
upon challenge with wild-type RSV, however, the virus-neutralizing antibody 
levels were low [115]. This vaccine was also found safe and well tolerated 
in clinical trials with induction of low virus-neutralizing antibody in humans 
[116]. To further investigate the protective efficacy of this vaccine, a phase 
1/2a clinical trial is in progress [117]. Another, version of this strategy 
involves the use of virus-like particles composed of the Newcastle disease 
virus (NDV) nucleocapsid and membrane proteins and chimeric proteins of 
RSV F and G proteins fused to the transmembrane and cytoplasmic domains 
of NDV F and HN proteins, respectively, were evaluated in mice. This VLP-
based vaccine induced Th1-skewed virus neutralizing antibody titers which 
remained stable for 4 months in mice without leading to enhanced disease 
[118]. 
Replication-defective gene-based vectors
Among the several replication-defective vectors, only recombinant 
alphaviruses and adenoviruses (rAd) are presently being explored as vectors 
in RSV vaccines. Alphaviruses have been used to express several antigens, 
including antigens derived from influenza virus and cytomegalovirus 
(CMV) [119]. Alphavirus replicon particles derived from Venezuelan Equine 
Encephalitis virus (VEE) expressing the RSV-F (VRP-RSV-F) have been 
tested in mice and cotton rats after IN administration and have been shown 
to induce mucosal immune responses and provide protection against RSV 
infection [120]. Moreover, the VEE-based RSV vaccine did not induce Th2-
skewed immune responses. Recently, an RSV vaccine based on a recombinant 
adenovirus (rAd) vector has been described as a potential platform for both 
adult and pediatric vaccination and evaluated in a preclinical trial [73].
A new approach to RSV vaccination 
A general view is that LA vaccines would be most suitable for use in young 
children while inactivated (non-replicating) virus vaccines would be the 
preferred vaccine modality for use in adults and the elderly [107]. Non-
replicating RSV vaccines produced from cultured virus should, however, 
avoid the use of chemicals (i.e. formalin) to inactivate the virus, as this 
could disrupt protective epitopes and lead to induction of non-neutralizing 
antibodies [103,121]. 
 RSV virosomes are non-replicating particles and their production 
does not require harsh chemical treatment [122]. To potentiate antibody 
responses, a suitable adjuvant system should be chosen. As alum has 
been shown to have limited value when co-formulated with inactivated 
RSV vaccines [113], other adjuvants need to be explored. Innate receptor 
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ligands, like Toll-like receptor (TLR) ligands, have been shown to have great 
promise as vaccine adjuvants and are already in use in licensed vaccines 
(e.g. Cervarix). These types of adjuvants could improve the affinity of 
vaccine-induced RSV-specific antibodies and also skew cellular immune 
responses towards more effective and safe Th1-type responses [123]. 
 Finally, mucosal administration could form an attractive approach 
to vaccination against RSV. It is a highly accepted and non-invasive route 
of immunization and also could induce mucosal antibody responses (i.e. 
S-IgA) that may contribute to protection. In this strategy, innate receptor 
ligands, like TLR ligands, could be employed as they have shown to possess 
mucosal immunoadjuvant activity [124]. Therefore, mucosal immunization 
with non-replicating RSV particles, like RSV virosomes, that are adjuvanted 
with innate receptor ligands could form an attractive approach for induction 
of safe and effective RSV-specific immunity. 
Non-replicating RSV particles: virosomes
    
Virosomes are non-replicating virus particles, consisting of reconstituted 
viral membranes carrying viral surface glycoproteins [125]. Virosomes 
are produced from virus by solubilization of viral membranes by detergent 
Octaethyleneglycol mono (n-dodecyl) ether (C12E8) or 1, 2-dicaproyl-sn-
glycero-3-phosphocholine (DCPC) followed by nucleocapsid removal and 
subsequent reconstitution of the solubilized membranes [126,127]. The 
advantage of use of DCPC vs C12E8 is that it can be removed through dialysis 
due to its high critical micelle concentration (cmc) [127]. Previously, this 
approach has been used for the preparation of RSV virosomes [122]. These 
particles also provide a platform for incorporation of lipophilic adjuvants, 
like lipophilic TLR ligands, together with the viral protein antigens [122]. 
Mucosal administration of vaccine
 
Mucosal surfaces comprise the largest surface area between the body and 
the external environment. Most infectious agents like RSV enter the body at 
mucosal surfaces and therefore, mucosal immune responses at these sites 
could provide a first line of defense.  Mucosal immunization (e.g. intranasal; 
IN) can provide significant protection against RSV by inducing both systemic 
and local antibodies, particularly secretory IgA (S-IgA) and can contribute 
to inhibition of infection by respiratory pathogens [128,129]. Pathogens or 
any foreign antigen is transported across the epithelial barrier by specialized 
antigen transporting cells (i.e. M-cells). Immune responses can then be 
initiated in local lymphoid tissues that are situated in close proximity to 
the mucosal surface. In the respiratory tract this lymphoid tissue includes 
the nasal-associated lymphoid tissue (NALT) and the bronchus-associated 
lymphoid tissue (BALT). Additionally, mucosal DCs aid in transport of antigens 
to local draining lymph nodes where they activate T and B cells, leading to 
the initiation of adaptive immune responses including the induction of S-IgA 
at the mucosal surfaces [124]. The activated T and B cells also acquire 
mucosal homing properties in the draining lymph nodes from specialized 
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DCs that migrate from the mucosal tissues to these lymph nodes [130]. 
Mucosal immunization can induce both humoral and cell-mediated immune 
protection not only at the mucosal sites but also systemically [131,132]. In 
addition, mucosal immunization can induce long-term B and T cell memory 
[133,134]. This route of administration is may, therefore, be quite suitable 
for use in vaccination strategies. 
Mucosal vaccine adjuvants
 
Induction of immune responses through deposition of non-replicating vaccine 
antigens to mucosal tissues, like the nasal mucosal tissue, in general needs 
the use of antigen carrier systems and/or adjuvants [135]. Potent mucosal 
adjuvants are bacterial derived enterotoxins like cholera toxin (CT) or E. 
coli heat-labile toxin (LT). They bind via their B subunits to gangliosides 
that are present on the cell membrane of most nucleated cells [136]. These 
gangliosides are ubiquitously expressed, and so these adjuvants may be 
associated with unwanted side-effects. For example, IN immunization of a 
virosomal influenza vaccine supplemented with E. coli heat-labile toxin as 
adjuvant has resulted in facial paralysis (i.e. Bell’s palsy syndrome) in a 
number of vaccinated individuals reviewed in [124]. Another new class of 
adjuvants suitable as mucosal adjuvants is represented by TLR agonists. 
 TLRs and NLRs belong to the family of pattern recognition receptors 
(PRRs) and recognize molecules that are broadly shared by pathogens but 
distinguishable from the host molecules as described above in detail in (innate 
immune responses section). Activation of TLR/NLR leads to recruitment of 
adaptor molecules like MyD88 or TRIF that activate transcription factors 
like Nuclear Factor-kappa B (NF-κB) or IRF’s (Figure 2: TLRs/NLRs signaling 
pathways). Depending on the type of TLR/NLR ligand used, activation leads 
for example to the production of pro-inflammatory cytokines, type I IFN’s 
and the expression of co-stimulatory molecules on DCs. In this way, TLR 
engagement has the ability to direct the adaptive immune response towards 
a Th1-type reaction [137]. TLR adjuvants constitute a major class of mucosal 
adjuvants [138]. Some examples of TLR ligands that show promise for use 
in vaccines, including mucosally delivered RSV vaccines, are illustrated 
below.
MPLA 
Monophosphoryl lipid A (MPLA)  is a TLR4 ligand derived from the detoxified 
form of LPS. This is the first recognized and only TLR ligand molecule 
approved for use in humans which signals through TLR4 [139]. Currently, 
two MPLA-adjuvanted vaccines are licensed for human use: a human 
papillomavirus vaccine, Cervarix [140,141] and Fendrix, a hepatitis B 
virus (HBV) vaccine for patients with renal insufficiency [142]. A candidate 
vaccine against herpes simplex virus (HSV) also has been co-formulated 
with MPLA and has recently been tested in a phase III clinical trial. This 
formulation incorporates the adjuvant system AS04, which is composed 
of alum with MPLA [143-145]. It is important to note that MPLA has the 
capacity to suppress the symptoms of ERD when co-administered with FI-
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Figure 2: Detection of RSV by TLRs and NLRs. TLR4 is expressed on the surface of 
immune cells and recognizes RSV F protein. TLR3 is expressed in intracellular endosomes and 
recognizes dsRNA, that is produced during RSV replication. Both TLR3 and TLR4 bind with TRIF 
and also activate the kinases TBK1/IKKε and IKKα/IKKβ which result into phosphorylation and 
translocation of IRF3 and NF-κB to the nucleus. This phenomenon leads to expression of IFN-
α/β and pro-inflammatory cytokines. TLR7 recognizes the ssRNA of RSV in the intracellular 
endosomes. TLR2 and TLR4 on the surface of immune cells and TLR7 inside the cells signal 
through MyD88-dependent pathway, leading to the translocation of NF-κB. This leads to the 
release of IFN-α/β and pro-inflammatory cytokines. NOD2 may recognize the ssRNA of RSV 
and activate the downstream NF-κB and IRF3 pathways by making a complex with the MAVS 
adaptor that localizes to the mitochondrial membrane (Adapted from [52]).
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RSV to cotton rats [146,147], which underlines its potentially beneficial role 
as an adjuvant in RSV vaccines.
 
CpG 
CpG DNAs are synthetic oligonucleotides that contain unmethylated CpG 
dinucleotides and are recognized by Toll-Like receptor 9 (TLR9) [148]. TLR9 
is expressed intracellularly within the endosomal cell compartment and 
functions to alert the immune system to viral and bacterial infections by 
binding to DNA rich in CpG motifs. TLR9 is expressed by different cells of 
the immune system such as macrophages, B cells, DCs, monocytes and NK 
cells. CpG DNA has been reported to induce Th1-skewed immune responses 
and may also act as promising mucosal adjuvant [149,150]. CpG DNA has 
been found to induce Th1-skewed immune responses in animal studies after 
mucosal administration together with the vaccine antigens [149,151-153]. 
Pam3CSK4
N-pamitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-
seryl-[S]-(lysyl)3-lysine (Pam3CSK4), for example,  is a synthetic triacylated 
lipopeptide with a similar bioactivity as lipopeptides from Gram-negative 
bacteria [154]. It can be easily incorporated in virosomal membranes upon 
their reconstitution [122]. It is being recognized through TLR2 at the cell 
surface [155] and has been shown to possess beneficial adjuvant effects for 
use, for example, in vaccines [156]. When incorporated in RSV-virosomes, 
Pam3CSK4 enhances RSV-specific serum IgG and Th1 responses upon 
intramuscular immunization [122]. 
L18-MDP
L18-MDP is a synthetic derivative of 6-O-stearoyl-N-Acetyl-muramyl-
L-alanyl-D-isoglutamine (muramyl-di-peptide; MDP). L18 refers to the 
stearoyl fatty acid attached to MDP. MDP belongs to another class of innate 
receptors ligands that activate NOD-like receptors (NLRs). NLRs are located 
in the cytosol and consist of three domains characterized by an N-terminal 
effector and a central nucleotide-binding domain (NBD) as well as C-terminal 
multiple leucine-rich repeats (LRR) [157,158]. NOD1- and NOD2-receptors 
are known to recognize fragments of bacterial peptidoglycans (PGN), like 
MDP motifs [159]. (L18-)MDP induces pro-inflammatory cytokines and 
antibacterial responses through activation of NF-κB and mitogen-activated 
protein kinase (MAPK) signaling pathways [159]. L18-MDP (a NOD2 ligand) 
has been found 10 times more efficient than MDP to induce NF-κB activation 
in vitro and also showed the highest activity in mice [160]. Furthermore, 




Scope and outline of this thesis 
Mucosal administration represents an attractive potential approach to 
vaccination against RSV. In this strategy, innate receptor ligands, like TLR 
or NLR ligands, could be employed since these have been shown to possess 
mucosal immunoadjuvant activity. In this thesis, the use of TLR/NLR ligands 
in non-replicating RSV vaccines, administered intranasally (IN) to mice and 
cotton rats, is explored. 
 Chapter 2 describes an exploratory study investigating the capacity 
of  a widely used TLR ligand (CpG ODN) alone, or supplemented with a NOD2 
ligand (L18-MDP), to enhance systemic and mucosal antibody responses 
when simply mixed with a model antigen (inactivated RSV particles) upon 
IN administration to mice. 
 Subsequently, in order to formulate an RSV vaccine with built-
in adjuvant activity, RSV virosomes were produced with lipophilic TLR 
ligands, such as Pam3CSK4 and/or L18-MDP, incorporated in the virosomal 
membranes (Chapter 3). Their immunopotentiating capacity was tested 
in vitro and in vivo in mice (Chapter 3). Also, the protective capacity of 
this vaccine was assessed after IN administration to cotton rats, an animal 
model that is more permissive for RSV infection (Chapter 4). 
 An attractive TLR adjuvant for use in a virosomal RSV vaccine is 
MPLA, not only because it is lipophilic allowing its incorporation in virosomal 
membranes, but also because it is already used in registered human 
vaccines. Its use as an adjuvant in an IN virosomal RSV vaccine was 
therefore explored in Chapter 5.   
 Finally, since the elderly represent an important target population 
for a non-replicating RSV vaccine, the capacity of RSV virosomes with 
incorporated MPLA to induce immunity in an aged immune system was 
investigated. To this end, the vaccine was tested in aged cotton rats with or 
without pre-existing immunity to RSV (Chapter 6).  
 In Chapter 7, the results are summarized and discussed and future 
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Respiratory syncytial virus (RSV) infection is the most important viral cause 
of severe respiratory disease in infants and children worldwide and also 
forms a serious threat in the elderly. The development of RSV vaccine, 
however, has been hampered by the disastrous outcome of an earlier trial 
using an inactivated and parenterally administered RSV vaccine which did 
not confer protection but rather primed for enhanced disease upon natural 
infection. Mucosal administration does not seem to prime for enhanced 
disease, but non-replicating RSV antigen does not induce a strong mucosal 
immune response. We therefore investigated if mucosal immunization with 
inactivated RSV supplemented with innate receptor ligands, TLR9 (CpG 
ODN) and NOD2 (L18-MDP) through the upper or total respiratory tract is an 
effective and safe approach to induce RSV-specific immunity.  Our data show 
that beta-propiolactone (BPL) inactivated RSV (BPL-RSV) supplemented 
with CpG ODN and L18-MDP potentiates activation of antigen-presenting 
cells (APC) in vitro, as demonstrated by NF-кB induction in a model APC 
cell line. In vivo, BPL-RSV supplemented with CpG ODN/L18-MDP ligands 
induces local IgA responses and augments Th1-signature IgG2a subtype 
responses after total respiratory tract (TRT), but less efficient after upper 
respiratory tract (intranasal,IN) immunization. Addition of TLR9/NOD2 
ligands to the inactivated RSV also promoted affinity maturation of RSV-
specific IgG antibodies and shifted T cell responses from mainly IL-5-
secreting cells to predominantly IFN-γ-producing cells, indicating a Th1-
skewed response. This effect was seen for both IN and TRT immunization. 
Finally, BPL-RSV supplemented with TLR9/NOD2 ligands significantly 
improved the protection efficacy against a challenge with infectious virus, 
without stimulating enhanced disease as evidenced by lack of eotaxin 
mRNA expression and eosinophil infiltration in the lung. We conclude that 
mucosal immunization with inactivated RSV antigen supplemented with 
TLR9/NOD2 ligands is a promising approach to induce effective RSV-specific 
immunity without priming for enhanced disease. 
39
Adjuvant activity of CpG/L18-MDP added to inactivated RSV
1. Introduction
Respiratory syncytial virus (RSV) is the main cause of lower respiratory 
tract infections among infants and young children. Since natural infection 
with RSV results in incomplete immunity, reinfection occurs frequently 
throughout life. For this reason, RSV infection also represents a serious 
threat in chronically ill adults and the elderly [1]. Recent studies have 
demonstrated that RSV makes a major contribution to mortality in the 
elderly, as does influenza [2]. However, despite the impact of RSV infection, 
a safe and efficacious vaccine is not available.
 RSV vaccine development has been hampered by the disastrous 
outcome of a clinical trial with formalin-inactivated RSV (FI-RSV) vaccine 
in infants in the 1960s. It appeared that vaccination with FI-RSV did not 
confer protection but rather primed for enhanced disease upon exposure to 
live RSV, leading to the death of two children [3]. The enhanced disease was 
linked to severe immunopathology, with hallmarks such as peribronchiolar 
inflammation, airway obstruction, abundant neutrophils and eosinophils 
and local immune complex deposition [4]. Later studies in mice showed 
that FI-RSV-primed cellular immune responses are strongly skewed towards 
a Th2-type upon RSV challenge [5]. Such responses were accompanied 
by persistent chemokine responses, e.g. CCL11 (eotaxin), with influx of 
eosinophils [6,7]. Not only FI-RSV vaccine, but also other types of non-
replicating RSV vaccines, including whole virus vaccines inactivated by other 
treatments than formaldehyde (e.g. UV-treated RSV particles), can prime 
for enhanced disease in animal models. This property has been particularly 
attributed to a lack of antibody affinity maturation induced by these types 
of vaccines, leading to production of poorly neutralizing antibodies, just as 
in the case of FI-RSV vaccine [8].
 Mucosal immunization routes may reduce the risk of enhanced disease 
and increase vaccine efficacy. Unlike parenteral immunization, mucosal 
immunization does not readily prime for enhanced disease in animal models 
[9]. Moreover, mucosal immunization might further promote vaccine efficacy 
by induction of mucosal IgA, which can act as a first-line immune defense 
against the virus. Several lines of evidence suggest that RSV-specific IgA 
antibodies are secreted rapidly in the upper airways following a primary 
RSV infection in mice [10]. These RSV-specific IgA antibodies have been 
shown to confer protection against RSV in mice, although in humans their 
role in protection has remained unclear [11-14]. Optimal induction of such 
mucosal immune responses, including mucosal IgA in the respiratory tract, 
requires local deposition of antigen [15]. It is unknown however which part 
of the respiratory tract, e.g. the upper respiratory tract or lower respiratory 
tract, should be targeted for induction of sufficiently protective and safe 
RSV-specific immunity. Thus, mucosal immunization through the respiratory 
tract could enhance safety and efficacy of immunization against RSV, but 
needs further exploration with respect to the site of antigen deposition for 
induction of maximum immune responses.
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In addition to use of alternative vaccination routes, i.e. mucosal vaccination, 
supplementation of the RSV antigen with adjuvants might prevent priming 
for enhanced disease. For example, addition of innate receptor ligands, 
such as TLR ligands, to non-replicating RSV particles may lead to Th1-
skewed responses, which prevent priming for enhanced disease [16-18]. 
In a previous study, we showed that incorporation of the TLR2 ligand 
(Pam3CSK4) in a virosomal RSV vaccine skewed responses to a protective 
and safe Th1-type response [18]. Importantly, addition of TLR ligands to 
inactivated RSV effectively induces antibody affinity maturation, leading to 
strongly neutralizing antibodies without priming for enhanced disease [8]. 
Interestingly, TLR ligand-induced Th1 responses have been reported to be 
synergistically enhanced by NOD2 ligands, another class of innate receptor 
ligands [19]. Importantly, both TLR and NOD2 ligands may act as mucosal 
adjuvants also [20,21]. Thus, mucosal immunization with non-replicating 
RSV antigen supplemented with TLR9/NOD2 ligands, may well represent 
a safe approach to induce RSV-specific immunity. It may also be highly 
effective through induction of mucosal RSV-specific IgA antibodies [22-24]. 
 In the present study, we investigated whether administration of 
beta-propiolactone (BPL)-inactivated whole RSV (BPL-RSV) supplemented 
with CpG oligodeoxynucleotides (CpG ODN) and L18-muramyl dipeptide 
(L18-MDP) to the upper or total respiratory tract of mice would form an 
effective and safe approach to induce RSV-specific immunity. 
2. Materials and Methods
2.1 Preparation of inactivated RSV 
Purified RSV (A2 strain; American Type Culture Collection, ATCC) was kindly 
donated by Mymetics BV, Leiden, The Netherlands. BPL-inactivated RSV 
was produced by inactivating the virus with 0.025% BPL (Acros Organics, 
Amsterdam, The Netherlands) for 16 h at 4oC under gentle shaking followed 
by 2 h of incubation at 37oC to inactivate the BPL. Then, inactivated virus 
was dialysed against HNE buffer containing 5 mM Hepes, 145 mM NaCl, 1 
mM EDTA (pH 7.6). Formalin-inactivated RSV (FI-RSV) vaccine absorbed to 
aluminium hydroxide was prepared as described before [18]. 
2.2 Macrophage NF-κB activation by vaccine formulations in vitro
 
RAW-BlueTM cells (mouse macrophage reporter cell line; InvivoGen, Toulouse, 
France) were used to measure vaccine/innate receptor ligand-induced NF-
κB activation. RAW-blue cells express all TLR (with the exception of TLR5) as 
well as RIG-I, MDA5, NOD1 and NOD2. Cells were placed in 96-wells plates at 
1x105 cells/well. Next, cells were co-incubated with different concentrations 
of CpG ODN (ODN1826, TCCATGACGTTCCTGACGTT; Eurogentec, Maastricht, 
The Netherlands) and L18-MDP (6-o-stearoyl-N-Acetyl-muramyl-L-alanyl-
D-isoglutamine; InvivoGen, Toulouse, France) with or without BPL-RSV 
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(10 μg/mL) overnight at 37oC, 5% CO2 atmosphere. NF-κB activation 
was determined by a colorimetric assay, measuring substrate cleavage 
by alkaline phosphatase in the supernatant. This enzyme is produced and 
secreted by RAW-Blue cells after induction of the NF-κB-responsive reporter 
gene in these cells. 
2.3 Immunization schedule and RSV challenge
Animal experiments were evaluated and approved by the Committee for 
Animal Experimentation of the University Medical Center Groningen, 
University of Groningen, The Netherlands, according to the guidelines 
provided by the Dutch Animal Protection Act. Female specified-pathogen-
free BALB/c OlaHsd mice (6-8 weeks old) purchased from Harlan, Zeist, 
The Netherlands, were used for all immunization experiments. Mice 
were immunized either with BPL-RSV (5 μg) alone or mixed with innate 
receptor ligands, i.e. 4 μg CpG ODN and 0.1 μg L18-MDP. Mice (6 mice 
per group) were immunized on days 0 and 21, under isoflurane anesthesia 
by intranasal inoculation of 10 μL (intranasal immunization confining the 
inoculum to the upper respiratory tract, i.e. nasal cavity, only; IN;[25]) 
or 50 μL (total respiratory tract immunization; TRT;[25]). In experiments 
investigating lung cytokine levels and the influx of eosinophils in the lungs, 
a control group was immunized with formalin-inactivated RSV vaccine by 
intramuscular injection of 25 μL of FI-RSV absorbed to aluminium hydroxide 
(see above). All mice were challenged with live virus by administration of 
5 x 10 μL (2 x 106 TCID50) of virus in the nose under isoflurane anesthesia. 
2.4 Collection of blood samples and mucosal washes
 Blood samples were drawn twice during the experiment: on day 28 before 
challenge by orbital puncture and on day 32 by heart puncture. Sera were 
obtained after centrifugation of coagulated blood at 12,000 rpm for 10 min, 
and samples were stored at –20oC until further analysis. Bronchoalveolar 
lavages (BAL) and nasal washes were performed as previously described 
[26]. Briefly, lung lavages were performed by gentle injection of 1 mL 
PBS into the lungs with a syringe connected to the trachea, followed by 
subsequent aspiration of 1 mL of the wash fluid. Nasal washes were done 
by injection of 0.5 mL PBS retrograde via the trachea into the naso-pharynx 
and the lavage fluid was collected at the nostrils. Cellular components in the 
washes were removed by low-speed centrifugation and used for cytospots 
(see below) or discarded. The supernatants were stored at –20oC until 
further analysis. 
2.5 Antibody titer determination through ELISA
The antibody response to RSV was determined using enzyme-linked 
immunosorbent assay (ELISA). ELISA plates (Greiner Bio-one, Alphen a/d 
Rijn, The Netherlands) were coated with BPL-RSV at 0.5 μg protein per well 
in coating buffer (0.05M carbonate–bicarbonate, pH 9.6–9.8) overnight at 
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37oC. Plates were washed three times with coating buffer and blocked with 
a 2.5% solution of Protifar Plus (Nutricia, Zoetermeer, The Netherlands) in 
coating buffer for 45 min at 37oC, then washed twice with coating buffer 
and three times with PBS Tween (PBST), containing 0.05% Tween 20 
(Merck, Schiphol-Rijk, The Netherlands). Serial two-fold dilutions of serum 
samples (for IgG, IgG1 and Ig2a) and BAL and nasal wash samples (for 
IgA determination) were applied to the plates and incubated for 90 min. 
Plates were washed three times with PBST and incubated with a 1:5000 
dilution of horseradish-peroxidase conjugated goat anti-mouse IgG, IgG1, 
IgG2a or IgA; Southern Biotech, Birmingham, AL, USA) for 60 min at 37oC. 
Subsequently, the plates were washed three times with PBST and three 
times with PBS. After aspiration, o-Phenylenediamine (OPD; Sigma-Aldrich, 
St Louis, MO, USA) in 50 mM phosphate buffer pH 5.6 with 0.02% H2O2 was 
added and wells were incubated for 30 min. Then, the reaction was stopped 
by adding 50 μL 2M H2SO4 per well and the optical densities (OD) of the 
wells at 492 nm was determined. IgA levels were expressed as OD-values 
of undiluted samples. IgG levels were expressed as titers and defined as 
the reciprocal of the highest dilution that gave an OD value of at least 0.2. 
2.6 Antibody affinity measurement
Antibody affinity was determined in pooled sera. Pooled sera from different 
mouse groups were adjusted such that they contained a comparable titer 
of RSV-specific antibodies. These antibodies were first allowed to bind to 
the wells of RSV-coated ELISA plates and subsequently the wells were 
washed with different concentrations of urea solution. Then, antibodies that 
remained bound to the RSV-coated plates were determined by standard 
methods, as described above. The percentage of bound antibodies was 
calculated by comparing levels of bound antibodies after normal washes 
with levels after urea-buffer washes.  
2.7 IFN-γ and IL-5 detection in stimulated splenocyte supernatants and BAL
Four days after the virus challenge, mice were sacrificed and spleens were 
harvested separately in 15 mL tubes containing Iscove’s Modified Dulbecco’s 
Medium (IMDM; Invitrogen, Breda, The Netherlands) supplemented with 1% 
Penicillin/Streptomycin and 0.1% beta-mercaptoethanol (Invitrogen, Breda, 
The Netherlands) and 10% FCS (Lonza-Biowhittaker, Basel, Switzerland). 
Then, spleens were processed individually for in vitro stimulation. Briefly, 
washed spleens were passed through a 70 µm mesh (BD Biosciences, 
Heidelberg, Germany) using sterile 3 mL syringe plungers. Subsequently, 
erythrocytes were lysed by incubating with hypotonic medium (0.83 % 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2) for 5 min on ice. The cells were 
washed with IMDM, counted and brought to appropriate concentrations. 
Fresh spleen cells were seeded into 96-well plates at a concentration of 
2×106 cells/mL and stimulated with BPL-RSV (10 µg/mL) in IMDM/10% 
FCS in triplicates and incubated at 37oC in a 5% CO2 atmosphere for 72 h. 
Supernatants were harvested and stored at –20oC until further analysis. 
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IFN-γ and IL-5 cytokines were measured in supernatants of these 
stimulated splenocytes as well in BAL taken at time of sacrifice (4 days 
after challenge). For this, mouse IFN-γ- and mouse IL-5- high sensitivity 
ELISA kits (eBioscience, Vienna, Austria) were used according to the 
manufacturer’s instruction. Detection limits were 15 pg/mL and 4 pg/mL 
for IFN-γ and IL-5, respectively.
2.8 Lung viral titration
Lungs were removed aseptically from all mice following euthanasia 
and washed in Dulbecco’s Modified Essential Medium (DMEM), (PAA 
Laboratories, Colbe, Germany), supplemented with 2% FCS and 
transferred into 4 mL tubes containing 1 mL medium. Then, the lungs 
were homogenized individually with an automated Potter homogenizer 
Polytron-Aggregate® (Thomas Scientific, Swedesboro, NJ, USA), 
centrifuged at 1400 rpm for 10 min at 4oC and supernatants were 
separated. To determine viral titers, TCID50 titers were determined. 
Briefly, HEp-2 cells, 15,000 per well in DMEM with 2% FCS, were seeded 
in 96-well plates one day before and incubated overnight at 37oC in a 5% 
CO2 atmosphere. Next day, supernatants were removed from the plates 
and washed with PBS. Then, serial dilutions of the lung supernatants 
were added to the plates and incubated for 5-6 days at 37oC in a 5% CO2 
atmosphere. Then, supernatants were removed and plates were washed 
with PBS. The cells were then fixed with 1% para-formaldehyde in PBS 
for 1 h. After blocking cells with 2% skimmed milk in PBS, plates were 
incubated at RT for 2 h with a 1:400 dilution of FITC-conjugated goat 
anti-RSV antibody (Meridian life science Inc, Saco, ME, USA) and washed 
with PBS. Wells were considered positive when ≥ 1 fluorescent syncytium 
was detected. Finally, TCID50 titers were calculated by the Reed-Muench 
method using an Excel spreadsheet. 
2.9 Chemokine mRNA determination in lung through qPCR
 
Parts of the lungs were collected in 1.5 mL tubes containing 1 mL 
RNAlater, RNA stabilization reagent, (Qiagen Benelux B.V., Venlo, The 
Netherlands) and stored at –80oC till further processing. Total RNA 
was extracted with a Rneasy kit (Qiagen Benelux B.V., Venlo, The 
Netherlands) according to the manufacturer’s instructions and RNA 
concentration was determined by spectrophotometry. First-strand cDNA 
was synthesized from equal amounts of RNA with a cDNA synthesis kit 
(Thermo Scientific (Abgene), Epsom, UK). CCL11 (eotaxin) mRNA levels 
were determined by real-time PCR analysis with SYBR green Premix Taq 
(Westburg, Leusden, The Netherlands). Primer sequences used in this 
study are as follows. ß-actin sense: TAAAGACCTCTATGCCAACACAGT, 
antisense: CACGATGGAGGGGCCGGACTCTTC; CCL11 sense: TATTCCTG
CTGCTCACGGTCACTT,antisense:TCTCTTTGCCCAACCTGGTCTTGA. PCR 
reactions were performed in a StepOne real time PCR system (Applied 
44
Chapter 2 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) at recommended 
reaction conditions: 95oC for 15 min, then 40 cycles of denaturation at 95oC 
for 15 sec, annealing at 50-60oC for 30 sec and extension at 72oC. A melt 
curve analysis was performed to control the specificity of the amplification 
products. The gene-specific threshold cycle (Ct) for each sample was 
corrected by subtracting the Ct for the housekeeping gene ß-actin (ΔCt). 
Lung samples from untreated naive mice were chosen as the reference 
samples and the ΔCt for all the experiment samples were calculated by 
subtracting ΔCt for the reference samples (ΔΔCt). Then, the fold-difference 
of the test gene mRNA was calculated by using the formula 2–ΔΔCt [27].
2.10 BAL cell cytospot staining
BAL fluids were centrifuged and cell pellets were resuspended in 500 μL 
PBS. Then, these samples were spun at 300 rpm for 5 min onto glass 
slides, air dried, and subsequently fixed in 80% methanol/20% PBS (V/V) 
for 10 min at –20°C. After air drying, slides were stained for 20 min in 
May-Grunwald-Giemsa stain (Merck, Darmstadt, Germany), diluted 1:1 in 
Sørensen’s phosphate buffer (0.2 M; pH 6.6). Next, slides were rinsed in 
Sørensen’s phosphate buffer, and incubated for 15 min in Giemsa stain 
(Merck, Darmstadt, Germany) diluted 1:8 in Sørensen’s phosphate buffer. 
After washing with tap water, slides were air dried and spots were sealed 
using cover slides and Kaiser’s glycerin (Merck, Darmstadt, Germany). 
The presence of eosinophils in cytospot BAL cells was analysed by light 
microscopy.  
2.11 Data analysis
All statistical analyses were performed using Graphpad Prism v3.0 (Graphpad 
Software, Lajolla, CA, USA). Statistical significance was determined using 
unpaired Mann-Whitney U test and Wilcoxon matched paired t test. P values 
≤0.05 were considered statistically significant. 
3. Results
3.1 In vitro NF-κB activation by BPL-RSV supplemented with CpG ODN/L18-
MDP adjuvants
In order to analyse the possible synergistic activity of L18-MDP, CpG ODN 
and inactivated RSV, i.e. BPL-RSV, on activation of antigen-presenting cells 
(APC), NF-κB induction in a reporter APC (RAW-BlueTM cells) was measured 
(Figure 1). L18-MDP alone poorly induced NF-κB.  Similarly, BPL-RSV alone 
in the absence of adjuvants did not result in significant NF-κB induction 
either (Figure 1A), even not at higher concentrations (data not shown). 
L18-MDP combined with BPL-RSV, however, resulted in a synergistically 
enhanced NF-κB activation (Figure 1A). CpG ODN gave a dose-dependent 
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Figure. 1. Efficient NF-κB activation by L18-MDP in vitro occurs only in presence of 
RSV and is further enhanced by CpG ODN. Reporter gene transfected-antigen-presenting 
cells were activated with different concentrations of CpG ODN/L18-MDP alone or added to a 
fixed concentration of RSV (10 μg/mL). NF-κB activation was read out by a colorimetric assay 
measuring substrate cleavage by alkaline phosphatase, secreted after induction through the NF-
κB responsive reporter gene. Open bars represent means ± SD of cells stimulated with innate 
receptor ligands at different concentrations in the absence of RSV and black bars represent 
means ± SD of cells stimulated with innate receptor ligands at different concentrations in the 
presence of RSV (10 μg/mL). An asterisk indicates a statistically significant difference (p ≤ 
0.05; Mann Whitney U test) between responses in the absence and presence of RSV particles.
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activation of NF-κB which could be enhanced by adding L18-MDP but, again, 
only when viral particles were present (Figure 1B, 1C). Addition of L18-
MDP to CpG ODN generally resulted in increased NF-κB responses, but not 
in a synergistic way (Figure 1B, 1C). So, our in vitro data point towards a 
synergistic induction of NF-κB by combining BPL-RSV and L18-MDP together. 
We further tested combinations of BPL-RSV with CpG ODN and L18-MDP in 
mice using different methods of local administration.  
3.2 Induction of systemic IgG and mucosal IgA responses after intranasal 
(IN) or total respiratory tract (TRT) immunization
First, mice were immunized IN with vaccine formulations containing BPL-RSV 
alone or  BPL-RSV supplemented with CpG ODN alone or both CpG ODN and 
L18-MDP or PBS (control group) One week after the booster immunization, 
RSV-specific IgA was detectable only in BAL and nasal washes of mice that 
received RSV plus adjuvant (Figure 2B, C). With supplementation of L18-
MDP to the formulation of BPL-RSV and CpG ODN, a higher proportion of 
mice had a detectable IgA response in the BAL. RSV-specific serum IgG 
levels were low or undetectable in all mice (Figure 2A). Only in the group 
immunized with BPL-RSV supplemented with both CpG ODN and L18-
MDP,  IgG levels were slightly, but significantly, higher than in naïve mice 
(p<0.05; Figure 2A). As combined CpG ODN, L18-MDP and inactivated viral 
particles appeared most efficient in vitro and in vivo, we further tested this 
combination in mice comparing different methods of local administration to 
the respiratory tract.   
 To this end, mice were immunized IN or through total respiratory 
tract (TRT) immunization using BPL-RSV only or BPL-RSV supplemented 
with CpG ODN/L18-MDP ligands. TRT immunization with BPL-RSV vaccine 
supplemented with CpG ODN/L18-MDP ligands induced significantly higher 
IgG antibody responses compared to BPL-RSV vaccine alone (p<0.002; 
Figure 3A). IN immunization was less effective in IgG induction (Figure 3A). 
In order to analyse the phenotype of the immune response, Th1-signature 
IgG subtype (IgG2a) and Th2-signature IgG subtype (IgG1) antibodies were 
determined. Supplementation of BPL-RSV vaccine with CpG ODN/L18-MDP 
increased IgG2a responses, but not IgG1 responses after TRT immunization 
(p<0.002; Figure 3B). This effect was not seen after IN vaccination. Thus, 
BPL-RSV vaccine supplemented with TLR9/NOD2 ligands augments Th1-
signature IgG2a subtype responses upon mucosal immunization, particularly 
after TRT immunization. 
 In order to determine mucosal immune responses, mice were 
immunized by IN or TRT inoculation of BPL-RSV vaccine with and without 
CpG ODN/L18-MDP as described above. Four days after RSV challenge, mice 
were sacrificed and nasal wash and BAL samples were taken for analysis 
of IgA antibody levels. We found significantly increased BAL and nasal IgA 
levels in mice immunized through the TRT route with BPL-RSV supplemented 
with CpG ODN/L18-MDP compared to mice immunized with BPL-RSV only 
(p<0.004 and p<0.02 for nasal and BAL IgA, respectively; Figure 4). BAL 
and nasal IgA was induced in some of the mice that were immunized IN with 
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Figure 2. RSV-specific systemic IgG antibody responses after IN immunization. 
BALB/c mice were immunized IN with vaccine formulations containing 5 μg of BPL-RSV alone, 
5 μg BPL-RSV supplemented with CpG ODN (4 μg) and 5 μg BPL-RSV supplemented with CpG 
ODN (4 μg) and L18-MDP (0.1 μg) or PBS (control group), on day 0 and 21. One week after 
the booster immunization, RSV-specific IgG responses in serum (A), IgA in BAL (B) and IgA 
in nasal washes (C) were determined by ELISA. Data from individual mice are shown. The 
data shown are representative data of at least 2 separate experiments. Data was analysed 




BPL-RSV supplemented with CpG ODN/L18-MDP adjuvants, but not in mice 
immunized IN with BPL-RSV alone. Thus, BPL-RSV vaccine together with 
TLR9/NOD2 ligands induces local IgA responses upon mucosal immunization, 
particularly after TRT immunization. 
Figure 3. RSV-specific systemic IgG antibody responses after IN or TRT immunization. 
BALB/c mice were immunized with vaccine formulations containing 5 μg of BPL-RSV alone, 5 
μg BPL-RSV supplemented with CpG ODN (4 μg) and L18-MDP (0.1 μg) or PBS (control group), 
on day 0 and 21. One week after the booster immunization, RSV-specific IgG responses in 
serum (A) and IgG-subtypes IgG1 and IgG2a (B) were determined by ELISA. Panel A&B: Bars 
represent the geometric mean titer and standard deviation. The data shown are representative 
data of at least 2 separate experiments. Data was analysed by a Mann-Whitney U test and a 
p-value of ≤ 0.05 was considered to represent a significant difference.
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3.3 Antibody affinity measurement
Next, we investigated if supplementation of BPL-RSV with TLR9/NOD2 
ligands could increase the affinity maturation of the RSV-specific IgG 
antibodies induced by mucosal immunization. The affinity was determined 
by affinity ELISA, as described by others [8]. Pooled serum antibodies from 
Figure 4. RSV-specific mucosal IgA antibody responses after IN or TRT immunization. 
BALB/c mice were immunized with vaccine formulations containing 5 μg of BPL-RSV alone, BPL-
RSV supplemented with CpG ODN (4 μg) and L18-MDP (0.1 μg) or PBS (control), on day 0 and 
21. Four days after challenge with live RSV (day 32), RSV-specific IgA responses in BAL (A) 
and nasal washes (B) were determined by ELISA. Panel A&B: Each dot represents data from an 
individual mouse and horizontal line depicts the mean absorbance at 490 nm. The data shown 
are representative data of at least 2 separate experiments. Data was analysed by a Mann-
Whitney U test and a p-value of ≤ 0.05 was considered to represent a significant difference.
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mice TRT-vaccinated with BPL-RSV supplemented with CpG ODN/L18-MDP 
showed a higher binding capacity than pooled serum antibodies from mice 
that had received BPL-RSV only (Figure 5). Therefore, TLR9/NOD2 ligands 
promote affinity maturation of RSV-specific IgG antibodies after mucosal 
immunization. 
3.4 RSV-specific cell-mediated immune responses
To further characterize the phenotype of the cellular immune response, 
RSV-specific cytokine responses by splenocytes were measured.  Increased 
secretion of IFN-γ was seen in splenocyte cultures from mice immunized 
with BPL-RSV supplemented with CpG ODN/L18-MDP compared to cultures 
from mice that received BPL-RSV alone (p<0.004 and p<0.002 for IN 
and TRT immunization, respectively; Figure 6A). The highest production 
of IFN-γ was seen after TRT immunization. In parallel, IL-5 production 
Figure 5. Supplementation of BPL-RSV with CpG ODN/L18-MDP increases IgG 
antibody affinity.  IgG antibody affinity was determined in pooled sera from mice immunized 
with BPL-RSV alone or BPL-RSV supplemented with CpG ODN/L18-MDP. Serum IgG bound to 
RSV in ELISA plates was washed with different concentration of urea followed by detection 
of antibody using standard ELISA procedures. Each point represents the mean percentage ± 
SD of antibodies that remained bound after washes with different urea concentrations. The 
SD represents triplicates of the pooled sera. The data shown is representative of 3 separate 
measurements. An asterisk indicates a statistically significant difference (p ≤ 0.05; Wilcoxon 
matched paired t test).  
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was significantly decreased (p<0.002 and p<0.004 for IN and TRT 
immunization, respectively; Figure 6B). This was seen irrespective of the 
method of mucosal immunization, i.e. IN or TRT immunization. To know if 
splenocyte responses reflect local responses during lung infection with RSV, 
levels of IL-5 and IFN-γ and, particularly their ratio, was also determined 
in lung washes from immunized and IN-infected mice. Here, the ratios of 
IFN-γ to IL-5 in lungs of mice given BPL-RSV/CpG ODN/L18-MDP by TRT 
immunization were specifically compared with ratios determined in the lungs 
of mice immunized IM with FI-RSV. The IFN-γ to IL-5 ratio was significantly 
increased in mice that previously were TRT-immunized with BPL-RSV/CpG 
ODN/L18-MDP compared to the ratios determined in naïve (buffer) or FI-
RSV-immunized mice (p<0.05 and p<0.01 for buffer and FI-RSV groups, 
respectively; Figure 6C). Therefore, CpG ODN/L18-MDP supplemented BPL-
RSV efficiently primes for Th1-phenotype skewed responses, not only in 
recall responses of RSV-stimulated splenocytes but also in local responses 
in the lung upon infection with RSV.
3.5 Protection from live RSV challenge
In addition to immune parameters, protection against viral infection was 
measured. For this, mice were IN or TRT immunized with BPL-RSV alone or 
BPL-RSV supplemented with CpG ODN and L18-MDP on day 0 and 21. One 
week after the second immunization, mice were infected by IN inoculation of 
live virus under anesthesia and 4 days later, lung viral titers were measured. 
Mice that received inactivated RSV by TRT immunization showed significant 
lower viral titers compared to titers seen in the non-vaccinated control 
group. Notably, mice that received BPL-RSV supplemented with CpG ODN/
L18-MDP through TRT immunization had significantly decreased viral titers 
compared to mice receiving BPL-RSV only using the same route (p<0.01; 
Figure 7). IN-immunized mice also showed reduced viral titers compared to 
titers in non-immune control mice, but only when immunized with BPL-RSV 
supplemented with adjuvants (p<0.01; Figure 7). These data show that 
supplementation of mucosally-delivered BPL-RSV with TLR9/NOD2 ligands 
increases its capacity to induce protective immune responses against live 
RSV. 
3.6 Eotaxin production and eosinophil influx in lungs of infected mice
In order to monitor if the induced protective immunity was paralleled with 
a possible priming for enhanced disease, lung mRNA levels for a chemokine 
associated with enhanced disease, e.g. CCL11 (eotaxin), were determined 
4-days after infectious virus challenge. Supplementation of BPL-RSV with 
CpG ODN/L18-MDP ligands significantly reduced lung CCL11 mRNA levels 
(Figure 8). This was observed not only after TRT immunization but also after 
IN immunization (Figure 8). 
 The previous data showed that TRT immunization with BPL-RSV 
supplemented with CpG ODN/L18-MDP is the most optimal approach to 
induce high RSV-specific serum IgG and mucosal IgA antibodies, Th1-type 
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Figure 6. Ex vivo cytokine production by splenocytes in response to stimulation with 
RSV. IFN-γ (Panel A) and IL-5 (Panel B) production in splenocyte cultures after stimulation 
with BPL-RSV was determined by cytokine ELISA. Cytokines in the culture supernatants were 
assayed after 3 days of culturing. Lung cytokines in BAL of immunized mice were measured 
4 days after challenge and their ratio was calculated (Panel C). Bars and error bars represent 
means ± SD. The data shown are representative data of at least 2 separate experiments. Data 
was analysed by a Mann-Whitney U test and a p-value of ≤ 0.05 was considered to represent 
a significant difference.
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responses and protection against infection without induction of lung CCL11 
mRNA. To confirm that immunization with this formulation does not lead 
to influx of eosinophils into the lungs, cytospots of BAL cells obtained after 
challenge were analysed. They were specifically compared with BAL cells 
obtained from mice that were immunized IM with alum-absorbed FI-RSV, as 
this vaccine formulation is known to prime for immune responses that lead 
to considerable influx of eosinophils into the lung upon infection. Indeed, 
mice vaccinated with FI-RSV showed eosinophil influx into their lungs (41 ± 
7, mean % ± SD of all BAL cells). In contrast, no eosinophils were detected 
in BAL of TRT-immunized mice with BPL-RSV supplemented with CpG ODN/
L18-MDP, after challenge (0 ± 0, mean % ± SD of all BAL cells). Thus, 
mucosal immunization with BPL-RSV supplemented with CpG ODN/L18-
MDP does not prime eosinophil influx, i.e. enhanced disease.
4. Discussion
Efforts to develop an effective inactivated RSV vaccine have as yet been 
unsuccessful, in part due to the disastrous outcome of earlier clinical trials 
with FI-RSV vaccine  among naive children in the 1960s [3].  Animal studies 
later suggested that this type of inactivated RSV vaccine induces low-affinity 
antibodies and Th2-biased immune responses in immunized animals which 
fail to protect but can augment immunopathology upon natural infection 
[5]. In the present study, we investigated the combined use of a model 
inactivated RSV vaccine, i.e. BPL-RSV, supplemented with TLR9/NOD2 
ligands, with a mucosal route of vaccine administration. Our results suggest 
that this is a safe and effective approach to induce RSV-specific immunity. 
Our data show that inactivated viral particles combined with CpG ODN/
L18-MDP potently activate NF-κB in a model APC system in vitro. In vivo, 
this vaccine formulation also induced local IgA responses and high-affinity 
serum IgG and Th1-signature IgG2a antibody responses upon mucosal 
immunization, particularly after TRT immunization. Co-administered CpG 
ODN/L18-MDP shifted cellular immune responses towards a dominant 
IFN-γ-producing Th1-type  response. Finally, protection against infection 
was conferred without priming for enhanced disease. Therefore, mucosal 
immunization with inactivated RSV, supplemented with innate receptor 
ligands, appears to be a promising and safe approach to induce an effective 
RSV-specific immune response.
 Previous studies used TLR ligand-supplemented RSV to reduce 
priming for enhanced disease. For example, Johnson et al. showed that 
supplementation of CpG ODN to IM-injected FI-RSV could reduce lung 
pathology upon RSV infection of immunized mice [17]. This was paralleled 
with a more Th1-skewed response and lowered eotaxin expression in the 
lungs of infected mice. In line with these data, we show that mucosal 
immunization with a CpG ODN-containing RSV vaccine also leads to Th1-
skewed responses and lowered eotaxin expression in the lungs (Figure 6 & 
8). Prince et al., however showed that supplementation of RSV F protein 
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with CpG ODN increased lung pathology in cotton rats [28]. Possibly, cotton 
rat respond differently to CpG ODN than mice, the animal model used in our 
study and that of Johnson et al.  Alternatively, it could be due to the CpG 
ODN type used. Although Prince et al. showed that their CpG ODN induced 
cotton rat splenocyte proliferation, it was not investigated if it induces 
cytokines that are important inducers of Th1-type responses, like IL-12 
which is readily induced by the CpG ODN type used in our study and that of 
Johnson et al. i.e. CpG ODN 1826 [29]. 
 Administration of BPL-RSV through TRT immunization resulted in a 
more efficient induction of immune responses compared to administration of 
RSV antigen to the nasal cavity only, i.e. IN immunization. In anesthetized 
mice, a small inoculation volume reaches the nasal cavity only, while a 
large inoculation volume targets both the nasal cavity and total respiratory 
tract, including the lungs [20,25]. A number of factors have been described 
that contribute to a lower immunization efficacy when targeting the nasal 
Figure 7. Protection of mice from challenge with live virus. BALB/c mice were immunized 
with vaccine formulations containing 5 μg of BPL-RSV alone, BPL-RSV supplemented with 
CpG ODN (4 μg) and L18-MDP (0.1 μg) or PBS (control group), on day 0 and 21. Four days 
after challenge with live RSV (day 32), lung viral titers were determined. Viral titers are 
expressed as TCID50. Each point represents data from an individual mouse. The data shown are 
representative data of at least 2 separate experiments. Data was analysed by a Mann-Whitney 
U test and a p-value of ≤ 0.05 was considered to represent a significant difference.
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cavity. These factors include a low retention time of inoculated vaccine at 
this site, lack of uptake of vaccine antigens through M cells or penetration 
of vaccine antigens through the nasal epithelium [30]. Although mucosal 
administration of antigen can induce protective immunity, it may also lead 
to mucosal tolerance [31,32]. Our data showed that mice that received 
BPL-RSV which was confined to the nasal cavity only (IN immunization) 
primed RSV-specific T cell immunity, with particularly IL-5 secretion. 
Addition of innate receptor ligands to the antigen clearly abrogated this 
Th2-type response and skewed responses towards a Th1-phenotype (Figure 
6). However, supplementation of BPL-RSV with innate receptor ligands did 
not clearly stimulate mucosal and systemic antibody responses when the 
inoculum was targeted to the nasal cavity only.  
 Vaccine administered through TRT immunization appears to be 
more efficient in inducing effector-type immune responses, and preventing 
tolerogenic responses [33]. Indeed, our data show that efficient local and 
systemic antibody responses are induced after TRT immunization, but not 
Figure. 8. CCL11 chemokine mRNA levels in RSV-infected lungs. BALB/c mice were 
immunized according to standard procedures and mouse lungs were collected 4 days after 
challenge. Total mRNA was isolated and qPCR was performed after cDNA synthesis, to 
determine levels of CCL11 (eotaxin) mRNA. CCL11 levels in lungs of untreated naive mice 
were subtracted from the levels detected in lungs of immunized groups. Each point represents 
data from an individual mouse. The data shown are representative data of at least 2 separate 
experiments. Data was analysed by a Mann-Whitney U test and a p-value of ≤ 0.05 was 
considered to represent a significant difference.
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after IN immunization, which might be due to deposition of antigen in the 
lungs, an environment less prone to induction of tolerogenic responses [33]. 
Furthermore, it is likely that there is a slower clearance of vaccine antigen 
from the lungs as compared to the nasal cavity. Thus, our data confirm 
the findings of others [33] that the lungs are a better site for induction of 
combined mucosal and systemic immune responses as compared to the 
nasal cavity.  It is likely that activation of TLR9 and NOD2 receptors in 
alveolar macrophages and lung dendritic cells by the CpG ODN/L18-MDP is 
important in the induction of the IgA response, in a similar fashion as virus 
like particles that, through ssRNA activation of TLR7 on these cells, enhance 
local IgA responses [34].  
 Innate ligands, particularly TLR9 ligands like CpG ODN 1826, proved 
to be effective in enhancement of class-switch recombination to IgA and 
mucosal IgA responses [22,34]. It has been reported that genital tract IgA 
antibody-secreting cells (ASC) were increased in number after mucosal 
immunization of mice with recombinant glycoprotein B of herpes simplex 
virus supplemented with CpG ODN [22]. This enhanced IgA ASC response 
may be due to the ability of CpG ODN to directly activate B cells, macrophages 
and dendritic cells [35-37]. Besides CpG ODN, also NOD2 ligands, like L18-
MDP can directly enhance B cell receptor-induced B cell activation in the 
absence of T cell help [38]. The latter studies suggest that, besides T cell-
dependent pathways toward class-switch recombination to, for example, 
IgA, T cell-independent pathways exist that are initiated through innate 
receptor signaling. TLR activation, for example, induces factors inducing 
cytokines such as B-lymphocyte-Activating Factor belonging to the TNF 
superfamily (BAFF) and A-Proliferation-Inducing-Ligand (APRIL) [34,39]. A 
recent study reported that TLR ligands, i.e. bacterial RNA, deposited in the 
respiratory tract augment antibody responses by secreting BAFF and APRIL 
cytokines by activated lung DCs and macrophages [34]. Upon binding 
of DC or macrophage-derived BAFF to receptors on B cells, i.e. BAFF-R 
or Transmembrane Activator and Calcium-modulator and cyclophilin-
ligand Interactor (TACI), this factor co-stimulates B cell proliferation, Ig 
secretion and class-switch recombination towards, for example, IgA [40-
42]. Interestingly, BAFF is produced by lung dendritic cells and alveolar 
macrophages upon contact with different TLR ligands, including TLR7, 
TLR9 and TLR3 ligands [34,41,43]. BAFF may also be induced upon TRT 
immunization with BPL-RSV supplemented with CpG ODN/L18-MDP and could 
contribute to the induction of local IgA responses. Thus, co-administered 
innate receptor ligands induce potent IgA and IgG antibodies which might 
be due to activation and proliferation of B cells and possibly linked with 
secretion of BAFF/APRIL cytokines by lung DC and alveolar macrophages.
 Untill now, the relative efficacy of IgA versus IgG antibody in terms 
of RSV-neutralizing capacity has remained unclear. Although a small 
contribution of adjuvants on the innate immunity-mediated protection is 
possible, RSV-specific IgG antibodies (Figure 3) showed a clear negative 
correlation with lung viral titers (Figure 7; Spearman r -0.5965, p=0.0003), 
suggesting that antibodies are the main contributors to protection. In line 
with these data, RSV-specific IgG, either induced by parenteral vaccination, 
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administered as a monoclonal antibody through intraperitoneal (IP) injection, 
or inoculated IN, can protect mice against a TRT challenge [18,44]. Potent 
RSV-neutralizing capacity of IgA has also been demonstrated in studies that 
either studied protective effects of IN-inoculated RSV-specific IgA monoclonal 
antibody or adenoviral vector-based RSV vaccine induced mucosal IgA [45-
47].  This suggests that the presence and level of RSV-specific antibodies in 
the respiratory tract, either locally produced or transudated from the serum 
to the mucosa, is more important than the isotype of the RSV-specific 
antibody in protecting the lung from challenge with live virus of the TRT. 
It is likely that local production of RSV-specific antibody, either IgG or IgA, 
would significantly contribute to protection upon infection [48], particularly 
after natural infection which is likely to start in the upper respiratory tract. 
Thus, optimal protective immunity against RSV would probably need to 
consist of both serum IgG as well as locally produced antibodies, including 
IgG and IgA.    
 We conclude that mucosal immunization with inactivated RSV antigen 
supplemented with TLR9/NOD2 ligands is a promising approach to induce 
RSV-specific immunity. Mucosal immunization of the lower respiratory tract 
has become feasible with the recent development of dry powder inhalation 
specifically developed for vaccination [49,50]. This approach could further 
be explored by using non-replicating RSV vaccine candidates like, for 
example, RSV virosomes which can easily be equipped with lipophilic TLR 
and/or NOD2 ligands [18].
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Abstract
Introduction: RSV infection remains a serious threat to newborns and the 
elderly. Currently, there is  no vaccine available to prevent RSV infection. 
A mucosal RSV vaccine would be attractive as it could induce mucosal as 
well as systemic antibodies, capable of protecting both the upper and lower 
respiratory tract. Previously, we reported on a virosomal RSV vaccine for 
intramuscular injection with intrinsic adjuvant properties mediated by an 
incorporated lipophilic Toll-like receptor 2 (TLR2) ligand. However, it has 
not been investigated whether this virosomal RSV vaccine candidate would 
be suitable for use in mucosal immunization strategies and if additional 
incorporation of other innate receptor ligand, like NOD2 ligand, could further 
enhance the immunogenicity and protective efficacy of the vaccine. 
Objective: To explore if intranasal (IN) immunization with a virosomal RSV 
vaccine, supplemented with TLR2 and/or NOD2 ligands, is an effective 
strategy to induce RSV-specific immunity.
Methods: We produced RSV-virosomes carrying TLR2 (Pam3CSK4) and/or 
NOD2 (L18-MDP) ligands. We tested the immunopotentiating properties of 
these virosomes in vitro, using TLR2 and/or NOD2 ligand-responsive murine 
and human cell lines, and in vivo by assessing induction of protective 
antibody and cellular responses upon IN immunization of BALB/c mice.  
Results:  Incorporation of Pam3CSK4 and/or L18-MDP potentiates the capacity 
of virosomes to activate (antigen-presenting) cells in vitro, as demonstrated 
by NF-кB induction. In vivo, incorporation of Pam3CSK4 in virosomes boosted 
serum IgG antibody responses and mucosal antibody responses after IN 
immunization. While L18-MDP alone was ineffective, incorporation of L18-
MDP in Pam3CSK4-carrying virosomes further boosted mucosal antibody 
responses. Finally, IN immunization with adjuvanted virosomes, particularly 
Pam3CSK4/L18-MDP-adjuvanted-virosomes, protected mice against infection 
with RSV, without priming for enhanced disease.
Conclusion: Mucosal immunization with RSV virosomes, supplemented with 
incorporated TLR2 and/or NOD2 ligands, represents a promising approach 
to induce effective and safe RSV-specific immunity.
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1. Introduction
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract 
infections, particularly in infants and children. According to the WHO reports, 
RSV causes 64 million infections annually, leading to the hospitalization of 
18,000 - 75,000 children in the USA alone with an estimated mortality of 
160,000 [1]. Most children are infected at least once by the age of 2 and 
reinfection may occur throughout life due to incomplete immunity to RSV 
[2,3]. RSV, therefore, remains a threat at older age, particularly in risk 
groups such as the elderly and immuno-compromised individuals. Despite 
the burden of RSV disease, there is still no licensed vaccine against RSV 
infection.
 New candidate non-replicating RSV vaccines should induce protective 
immunity without priming for enhanced respiratory disease (ERD) upon 
natural infection, as did the formalin-inactivated and alum-adjuvanted 
whole RSV vaccine (FI-RSV) used in a clinical trial in the 1960s [4]. Possible 
factors involved in priming for ERD by non-replicating vaccines include 
disruption of protective epitopes by the chemical inactivation of the virus, 
poor innate receptor activation by the vaccine resulting in induction of poorly 
neutralizing antibodies and excess Th2-type responses [5,6]. Recent studies 
indicate that addition of Toll-like receptor (TLR) ligands, used as vaccine 
adjuvants, improve antibody affinity and Th1-skewing and prevent priming 
for ERD [7,8]. Furthermore, mucosal (i.e., intranasal, IN) immunization 
prevents induction of this complication and additionally induces secretory 
IgA (S-IgA) responses in the respiratory tract, which can act as a first line of 
defense against RSV [8,9]. Thus, new candidate RSV vaccines should induce 
Th1-skewed immune responses with induction of protective systemic and 
mucosal antibodies without priming for enhanced pathology upon natural 
infection. Mucosal vaccines that include TLR ligands for activation of innate 
receptors could be promising in this respect. 
 Virosomes are non-replicating virus-like particles consisting of 
reconstituted membranes of enveloped viruses [10]. The production of 
virosomes does not use chemicals (e.g. formalin) that could possibly modify 
protective epitopes. Upon production, virosomes allow the incorporation of 
lipophilic adjuvants, such as lipophilic TLR or NOD-like receptor (NLR)ligands, 
in their membranes. We previously reported on the feasibility of inclusion 
of lipophilic TLR ligand adjuvants (i.e. TLR2 ligand Pam3CSK4 and TLR4 
ligand Monophosphoryl Lipid A; MPLA) in RSV virosomes and demonstrated 
that such adjuvant-supplemented virosomes have the capacity to induce 
protective antibodies after parenteral administration to mice or cotton rats, 
without priming for enhanced disease [11,12]. However, we have not yet 
investigated whether such virosomal RSV vaccine candidates are suited for 
use in mucosal immunization strategies.
 TLR ligands have been reported to have the capacity to potentiate 
immune responses against mucosally delivered antigens [13]. In this respect, 
we found that a TLR9 ligand (i.e. CpG DNA), alone or co-formulated with 
a NOD2 ligand (i.e. L18-MDP), could boost mucosal and systemic antibody 
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responses to admixed inactivated RSV whole virions upon IN administration 
to mice [8]. However, lipophilic TLR ligands like Pam3CSK4 or MPLA can be 
much more efficiently incorporated in virosomes compared to CpG DNA 
[11,12]. The latter also would need additional incorporation of cationic lipids 
in the virosomal membrane in order to bind the negatively charged DNA 
molecules [14]. We therefore chose to explore the use of Pam3CSK4 as 
a TLR ligand adjuvant in virosomes. The TLR for Pam3CSK4, i.e. TLR2, is 
abundantly expressed on many cell types in mucosal tissues and does not 
need additional co-receptors like those described for the receptor of MPLA 
(TLR4), i.e. CD14 and MD2, that have low expression levels in mucosal 
tissues [15]. Also, other TLR2 ligands have shown promise as mucosal 
adjuvants [16-18].
 In this study, we explored the use of the TLR2 ligand Pam3CSK4 in RSV-
virosomes for potentiation of immune responses. We further investigated the 
use of a NOD2 ligand with possible mucosal immuno-adjuvant properties, 
i.e. L18-MDP [19,20], and its combined use with the TLR2 ligand, Pam3CSK4. 
The rationale for the combined use is that NOD2 ligands may synergistically 
enhance immune activation induced by TLR ligands [21-23], which would 
result in a better immunopotentiation by the mucosal virosomal RSV-vaccine. 
We demonstrate that incorporation of TLR2 ligands and/or NOD2 ligands in 
virosomes potentiates their capacity to activate a mouse macrophage cell 
line and human TLR/NOD2-expressing cells in vitro. In vivo, incorporation 
of a TLR2 ligand in virosomes boosted RSV-specific serum IgG and mucosal 
IgA responses after IN immunization of mice. While virosome incorporation 
of NOD2 ligand alone did not potentiate antibody responses, incorporation 
of NOD2 ligand in virosomes carrying a TLR2 ligand further stimulated local 
IgA and serum IgG responses. Adjuvantation of RSV virosomes with TLR2/
NOD2 ligands also primed for a Th1-skewed response. Finally, RSV virosomes 
adjuvanted with TLR2/NOD2 ligands protected mice against challenge with 
infectious RSV without inducing enhanced disease.
2. Materials and Methods
2.1 Ethics statement
All animal experiments were evaluated and approved by the Committee for 
Animal Experimentation (DEC) of the University Medical Center Groningen, 
University of Groningen, The Netherlands, according to the guidelines 
provided by the Dutch Animal Protection Act (permit number DEC 5239B). 
Immunizations and challenges were carried out under isoflurane anesthesia 
and every possible effort was made to minimize suffering of the animals.
2.2 Virus production and cell culture 
RSV strain A2 (ATCC VR 1540) was kindly donated by Mymetics BV (Leiden, 
The Netherlands). The virus was grown in roller bottles on HEp-2 cells (ATCC, 
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CL-23, Wesel, Germany) in HEp-2 medium: DMEM (Invitrogen, Breda, 
The Netherlands) supplemented with Pen/Strep, L-Glutamine, Sodium 
bicarbonate, HEPES, Sodium pyruvate, 1x non-essential amino acids (all 
from Invitrogen) and 10% FBS (Lonza-Biowhittkar, Basel, Switzerland), and 
purified by a combination of differential and rate zonal ultracentrifugation 
on sucrose gradients. Purified virus was snap-frozen in liquid nitrogen and 
stored at –80oC in 20% sucrose in HNE buffer (5 mM Hepes, 145 mM NaCl, 
1 mM EDTA, pH 7.4).  
 RAW-Blue (Mouse Macrophage Reporter Cell Line), HEK-Blue 
TLR2, HEK-Blue Null1, HEK-Blue NOD2, HEK-Blue Null2 cell lines, were 
purchased from Invivogen  (Toulouse, France) and maintained according 
to the manufacturer’s instructions. The abbreviation HEK stands for Human 
Embryonic Kidney.   
2.3 Preparation of vaccine formulations
Virosomal RSV vaccine was produced as described earlier [11]. Briefly, purified 
virus was pelleted by ultracentrifugation for 30 min at 40, 000 rpm at 4oC, 
and the pellets were suspended in sterile HNE buffer. Then, this suspension 
was mixed with an equal volume of 200 mM 1,2-dicaproyl-sn-glycero-3-
phosphocholine (DCPC) resulting in dissolution of the viral envelopes. The 
viral nucleocapsid was removed by ultracentrifugation at 50,000 rpm for 
30 min at 4oC. Then, the supernatant containing the viral envelopes was 
added to a thin film of lipids prepared in a glass tube of 2:1 molar mixture 
of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine (PE) 
(Avanti Polar Lipids, Alabaster, AL, USA) in 2:1 chloroform/methanol at 
850 nmol/mg of viral envelop proteins. The lipid mixture was evaporated 
to dryness on the wall of a glass tube and traces of the solvents were 
removed at a high vacuum. The lipopeptide adjuvant,N-pamitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-(lysyl)3-
lysine (Pam3CSK4, EMC Microcollections GmbH, Tubingen, Germany, 
lyophilized from the HCl solution), and/ or L-18 muramyldipeptide (L18-
MDP) (6-O-stearoyl-N-Acetyl-muramyl-L-alanyl-D-isoglutamine; Invivogen, 
Toulouse, France) were dissolved in 100 mM DCPC in HNE, pH 7.4 and 
the solution was filtered through a 0.22 µm filter. To prepare virosomes, 
supernatant containing the viral envelopes and DCPC was combined with 
a thin film of lipid mixture, while to prepare adjuvanted virosomes, the 
lipopeptide solutions (Pam3CSK4) and/or L18-MDP were added separately 
or  together (1 mg of adjuvant(s) per mg of viral protein). The mixture was 
incubated for 15 min at 4oC, filtered through 0.22 µm filter and dialyzed 
against 4x 2 liters of HNE buffer pH 7.4 in a sterile slide-A-lyzer (10 kD cut-
off; ThermoScientific, Etten, Leur, the Netherlands) for 48 h. The buffer was 
changed 4 times. The virosomes were harvested and protein concentration 
was determined by Bio-Rad Bradford protein assay. 
 FI-RSV vaccine was prepared according to the protocol, which was 
used for the 1960s FI-RSV vaccine preparation as reported in [24]. This 
vaccine was diluted in HNE buffer to contain 5 µg of RSV protein in 25 µL.   
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2.4 In vitro analyses 
 
The virosomal formulations were analyzed by equilibrium density gradient 
centrifugation on 10-60% sucrose gradients in HNE. The gradients were 
centrifuged for 60 h in an SW55 Ti rotor at 50000 rpm and the samples 
from the gradients were analyzed for protein, phospholipid and density (by 
refractometry). Later, each fraction was dialyzed against HNE in a slide-A-
Lyzer MINI Dialysis device (Thermo Scientific, Geel, Belgium) overnight to 
remove the sucrose. Then, samples were corrected for increase in volume 
due to dialysis and 100 µL of the samples were used to stimulate each 
cell line i.e. Mouse Macrophage Reporter Cell Line (RAW-Blue cells) and 
Human Embryonic Kidney cell lines (HEK-Blue TLR2, HEK-Blue Null1, HEK-
Blue NOD2, HEK-Blue Null2). RAW-Blue cells were used to measure vaccine/
innate receptor ligand-induced NF-κB activation. These cells express all TLRs 
(except TLR5) as well as RIG-I, MDA5, NOD1 and NOD2 and carry a NF-κB 
responsive-gene encoding secreted alkaline phosphatase. RAW-Blue Cells 
(1x105 cells/well in 100 µL) were incubated with 100 µL sample overnight 
at 37oC in a 96-well flat bottom plates in triplicate. Alkaline phosphatase 
was quantified by incubating 20 µL cell supernatants with 180 µL Quanti-
Blue (Invivogen, Toulouse, France) for 30 min at 37oC. Next, absorbance 
was measured at 630 nm through plate reader. Next, the relative amount 
of NF-κB induced by the gradient (virosomal) fractions was calculated by 
comparing to the NF-κB induced by CpG ODN, which was used as positive 
control. To study the stimulating capacity of the (virosomal) fractions to 
activate human TLR, HEK-Blue cells (HEK-TLR2, HEK-Null1, HEK-NOD2 
and HEK-Null2; 5x 104 cells/well) were incubated with 100 µL of the 
(virosomal) fractions in a 96-well flat bottom plate overnight at 37oC, 5% 
CO2 atmosphere. Secreted alkaline phosphatase was assayed as indicated 
above. The relative amount of NF-κB induced in TLR2/Null1 and NOD2/Null2 
cells was calculated by comparing to NF-κB induced by TNF-α (100 ng/mL) 
stimulation, used as positive control. 
2.5 Immunization schedule and RSV challenge
Female specified-pathogen-free BALB/c OlaHsd mice (6-8 weeks old) 
purchased from Harlan, Zeist, The Netherlands, were used for all immunization 
experiments. Mice were immunized either with RSV virosomes (5 μg) alone 
or with incorporated innate receptor ligands, i.e. TLR2 (Pam3CsK4) and/ or 
NOD2 ligands (L18-MDP) present at a 1:1 weight ratio of ligand to vaccine 
antigen, respectively. Mice (6 mice per group) were immunized on days 0 
and 21, under 3-4.5% isoflurane anesthesia in O2 by IN inoculation of 50 
μL. One group of mice was immunized with FI-RSV vaccine by intramuscular 
(IM) injection of 25 μL of FI-RSV absorbed to aluminium hydroxide (see 
above) and served as a control for vaccine-induced ERD. Another group of 
mice was immunized by IN inoculation with live-virus (1x 106 TCID50) and 
served as a control for optimal anti-viral immunity. On day 28, all mice were 
challenged with live-virus (1x 106 TCID50) by administration of 5x 10 μL of 
virus in the nose under isoflurane anesthesia. 
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2.6. Collection of blood samples and mucosal washes
Blood samples were drawn twice during the experiment: on day 28 before 
challenge by orbital puncture and day 32 by heart puncture. Sera were 
obtained after centrifugation of coagulated blood at 12,000 rpm for 10 min, 
and samples were stored at –20oC until further analysis. Bronchoalveolar 
lavages (BAL) and nasal washes were performed as previously described 
[25]. Briefly, lung lavages were performed by gentle injection of 1 mL 
PBS into the lungs with a syringe connected to the trachea, followed by 
subsequent aspiration of 1 mL of the wash fluid. Nasal washes were done 
by injection of 1 mL PBS retrograde via the trachea into the naso-pharynx 
and the lavage fluid was collected at the nostrils. The cellular components 
in the washes were removed by low-speed centrifugation. The supernatants 
were stored at –20oC until further analysis. 
2.7 Antibody titer determination through ELISA
The antibody response to RSV was determined using enzyme-linked 
immunosorbent assay (ELISA). ELISA plates (Greiner Bio-one, Alphen 
a/d Rijn, The Netherlands) were coated with beta-propiolactone (BPL) 
inactivated whole RSV (BPL-RSV) at 0.5 μg protein per well in coating buffer 
(0.05M carbonate–bicarbonate, pH 9.6–9.8) overnight at 37oC. Plates were 
washed three times with coating buffer and blocked with a 2.5% solution 
of milk powder (Protifar Plus, Nutricia, Zoetermeer, The Netherlands) in 
coating buffer for 45 min at 37oC, then washed twice with coating buffer and 
three times with PBS Tween (PBST), containing 0.05% Tween 20 (Merck, 
Schiphol-Rijk, The Netherlands). Serial two-fold dilutions of serum samples 
(for IgG, IgG1 and Ig2a, IgA, IgE) and BAL and nasal wash samples (for 
IgA, IgG determination) were applied to the plates and incubated for 90 
min. Plates were washed three times with PBST and incubated with a 1:5000 
dilution of horseradish-peroxidase conjugated goat anti-mouse IgG, IgG1, 
IgG2a or IgA; Southern Biotech, Birmingham, AL, USA) for 60 min at 37oC. 
Subsequently, the plates were washed three times with PBST and three 
times with PBS. After aspiration, o-Phenylenediamine (OPD; Sigma-Aldrich, 
St Louis, MO, USA) in 50 mM phosphate buffer pH 5.6 with 0.02% H2O2 was 
added and wells were incubated for 30 min. Then, the reaction was stopped 
by adding 50 μL 2M H2SO4 per well and the optical densities (OD) of the 
wells at 490 nm was determined. IgA levels were expressed as OD-values 
of undiluted samples. IgG levels were expressed as titers and defined as 
the reciprocal of the highest dilution that gave an OD value of at least 0.2. 
2.8 IFN-γ and IL-5 detection in stimulated splenocyte supernatants
 
Four days after the virus challenge, mice were sacrificed and spleens were 
harvested separately in 15 mL tubes containing Iscove’s Modified Dulbecco’s 
Medium (IMDM; Invitrogen, Breda, The Netherlands) supplemented with 1% 
Penicillin/Streptomycin and 0.1% beta-mercaptoethanol (Invitrogen, Breda, 
The Netherlands) and 10% FCS (Lonza-Biowhittaker, Basel, Switzerland). 
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Then, spleens were processed individually for in vitro stimulation. Briefly, 
washed spleens were passed through a 70 µm mesh (BD Biosciences, 
Heidelberg, Germany) using sterile 3 mL syringe plungers. Subsequently, 
erythrocytes were lysed by incubating with hypotonic medium (0.83% 
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2) for 5 min on ice. The cells were 
washed with IMDM, counted and brought to appropriate concentrations. 
Fresh spleen cells were seeded into 96-well plates at a concentration of 
2x 106 cells/mL and stimulated with BPL-RSV (10 µg/mL) in IMDM/10% 
FCS in triplicates and incubated at 37oC in a 5% CO2 atmosphere for 72 h. 
Supernatants were harvested and stored at –20oC until further analysis. 
IFN-γ and IL-5 cytokines were measured in supernatants of these stimulated 
splenocytes. For this, mouse IFN-γ- and mouse IL-5-high sensitivity ELISA 
kits (eBioscience, Vienna, Austria) were used according to the manufacturer’s 
instruction. Detection limits were 15 pg/mL and 4 pg/mL for IFN-γ and IL-5, 
respectively.
2.9 Lung virus titration
Lungs were removed aseptically from all mice following euthanasia and 
washed in Dulbecco’s Modified Essential Medium (DMEM), (PAA Laboratories, 
Colbe, Germany), supplemented with 2% FCS and transferred into 4 
mL tubes containing 1 mL medium. Then, the lungs were homogenized 
individually with an automated Potter homogenizer Polytron-Aggregate® 
(Thomas Scientific, Swedesboro, NJ, USA), centrifuged at 1400 rpm for 10 
min at 4oC and supernatants were separated. Virus titers were determined, 
by titration of the tissue-culture infectious dose (TCID50). Briefly, a serial two 
fold dilutions of these samples were made in 96-well plates in quadruplicates 
with 1:5 starting dilution. HEp-2 cells, (20,000 per well) were seeded to the 
virus dilutions and incubated for 5 days at 37oC in a 5% CO2 atmosphere. 
Then, supernatants were removed and plates were washed with PBS. The 
cells were then fixed with 1% para-formaldehyde in PBS for 1 h. After 
blocking cells with 2% milk powder (Protifar plus, Nutricia, Zoetermeer, 
The Netherlands) in PBS for 45 min at 37oC, plates were stained with 50 µL 
1:400 dilution of FITC-labeled goat anti-RSV antibody (Meridian life science 
Inc, Saco, ME, USA) at 37oC overnight. The next day, plates were washed 
with PBS and analyzed under fluorescent microscope. Wells were considered 
positive for infection when ≥1 fluorescent syncytium was detected. Finally, 
TCID50 titers were calculated by the Reed-Muench method using an Excel 
spreadsheet. 
2.10 Lung histopathology
The lung lobes were harvested four days post infection, inflated with 4 
% formalin in PBS for overnight and subsequently embedded in paraffin. 
Then, four µm slices were prepared, stained with standard hematoxylin 
and eosin (H & E) and were photographed using Nanozomer (Hamamatsu). 
Each lung section was analyzed for one of the following four parameters 
of pulmonary inflammatory changes: peribronchiolitis (inflammatory cells 
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surrounding a bronchiole), perivasculitis (inflammatory cells surrounding a 
small blood vessel), alveolitis (inflammatory cells within alveolar spaces), 
and interstitial pneumonitis (increased thickness of alveolar walls associated 
with inflammatory cells) by light microscopic analysis of slides.
 
2.11 Data analysis
All statistical analyses were performed using Graphpad Prism v5.0 
(Graphpad Software, San Diego California, USA). Statistical significance 
was determined using unpaired Mann-Whitney U test. P values ≤0.05 were 
considered statistically significant.
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3. Results
3.1 Characterization of virosomal formulations
Virosomal RSV formulations were prepared according to the protocol 
described in the Materials and Methods section. For all virosomal RSV-
preparations, protein and phospholipids were found to co-migrate in the 
density gradients, indicating the successful formation of virosomes (Figure 
1A). To investigate whether the lipophilic adjuvants were associated with the 
RSV virosomes, gradient fractions containing the virosomes, and top and 
bottom gradient fractions without virosomes (as controls), were tested for 
their capacity to induce NF-κB  in TLR or NOD2 receptor-expressing mouse 
macrophage cell lines in vitro. Non-adjuvanted RSV virosome fractions 
poorly induced NF-κB expression in this assay (Figure 1B). Incorporation of 
Pam3CSK4 or L18-MDP in RSV virosomes clearly potentiated the capacity of 
the virosomes to induce NF-κB (Figure 1B). Incorporation of both ligands 
in virosomes enhanced NF-κB induction compared to the NF-κB induction 
by single incorporated ligands, although not in a synergistic fashion (Figure 
1B). Top and bottom gradient fractions induced low NF-κB levels, suggesting 
that most of the added ligands was efficiently incorporated in the virosomal 
membranes. 
 Virosomal RSV formulations were also added to human cell lines that 
express single human innate receptors. Non-adjuvanted RSV virosomes again 
poorly induced NF-κB expression in TLR2 or NOD2-expressing cell lines (i.e. 
HEK-TLR2- or HEK-NOD2) cells, respectively (Figure 1C). RSV virosomes 
with incorporated Pam3CSK4 enhanced NF-κB expression in HEK-TLR2 cells, 
but not in HEK-NOD2 cells. Similarly, RSV virosomes with incorporated L18-
MDP enhanced NF-κB expression in HEK-NOD2 cells, but not in HEK-TLR2 
cells. Some residual bioactivity of L18-MDP was seen in the top fraction 
from the RSV-L18-MDP virosome density gradient, suggesting that most, 
but not all ligand was incorporated into the viral membranes. Since a large 
proportion of the lipophilic ligands was found to be incorporated into the 
viral membranes, we used non-fractionated virosomes for all subsequent 
immunization experiments. 
3.2 In vivo immunogenicity
To evaluate the immunogenicity of the virosomal preparations upon 
mucosal administration, mice were immunized intranasally (IN) with RSV 
virosomes alone or RSV virosomes with incorporated Pam3CSK4 and/or L18-
MDP. Control groups included non-immunized mice (HNE group), and mice 
immunized by live virus infection. One group of mice was immunized IM 
with FI-RSV vaccine to represent the mirror image of the FI-RSV vaccine 
used in 1960s clinical trial mentioned above. 
 Mice immunized with RSV virosomes with incorporated Pam3CSK4 
showed significantly higher IgG antibody responses compared to responses 
induced by non-adjuvanted RSV virosomes (Figure 2A). Incorporation of 
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Figure 1.  In vitro analysis of RSV virosomes and RSV virosomes adjuvanted with 
TLR2 and /or NOD2 ligands. RSV virosomes and RSV virosomes adjuvanted with TLR2 and/ 
or NOD2 ligands were spun on an equilibrium density sucrose gradient. Subsequently, density, 
phospholipids and protein concentrations of each fraction was determined. Panel A shows 
a representative profile of a virosome purification gradient. Fractions (1,5,10; representing 
bottom, virosomal and top gradient fractions, respectively) were analyzed to determine their 
capacity to activate NF-κB in mouse macrophages (RAW-Blue cells; panel B) and human 
embryonic kidney cells (HEK-Blue TLR2 & HEK-Blue NOD2 cells; panel C). The level of NF-
κB induced in RAW-blue cells was expressed as values relative to levels of NF-κB induced by 
CpG ODN, the positive control. To assess non-specific NF-κB activation by TLR2 and NOD2 
ligand-carrying virosomes in HEK cells, control cells (HEK-Blue Null1 & HEK-Blue Null2 cells, 
respectively) were incubated with the same fractions and these values were subtracted from 
values obtained with HEK-Blue TLR2 & HEK-Blue NOD2 cells, respectively. As a control, HEK-
Blue TLR2 and HEK-Blue NOD2 cells were stimulated with 100 ng/mL TNF-α. Bars represent 
the NF-κB activation relative to TNF-α control. 
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L18-MDP in virosomes also induced increased IgG antibody responses. 
Moreover, additional incorporation of L18-MDP into the Pam3CSK4-containing 
virosomes further enhanced IgG antibody responses. 
 In order to analyze the phenotype of the immune responses, 
Th1-signature IgG2a and Th2-signature IgG1 subtype antibodies were 
determined. Incorporation of Pam3CSK4 alone or combined with L18-MDP 
into RSV virosomes resulted in a significant increase of IgG2a/IgG1 ratios 
after IN-immunization of mice. Incorporation of L18-MDP alone did not result 
in an increase of IgG2a/IgG1 ratios. As expected, live RSV induced higher 
IgG2a/IgG1 ratios than FI-RSV (Figure 2B). Thus, incorporation of TLR2/
NOD2 ligands in IN-administered RSV virosomes significantly stimulates 
systemic RSV-specific IgG antibody responses with a more pronounced 
production of Th1-signature IgG2a antibodies. 
 In order to determine mucosal immune responses, nasal washes and 
BAL samples were taken for analysis of IgA and IgG antibody levels. We found 
a significant induction of nasal and BAL RSV-specific IgA antibodies in mice 
immunized IN with RSV virosomes with incorporated Pam3CSK4 or live virus 
(Figure 3A,C). Incorporation of L18-MDP in the Pam3CSK4-virosomes further 
boosted mucosal IgA antibody responses (Figure 3A,C). We also determined 
Figure 2. RSV-specific systemic IgG antibody responses after IN immunization of 
mice. BALB/c mice were immunized IN with RSV virosomal vaccine formulations (5 μg of 
protein) or HNE.  Control mouse groups were either immunized IM with FI-RSV or IN with 
live-RSV (L-RSV) on day 0 and 21. One week after the booster immunization, RSV-specific IgG 
responses in serum (A) and IgG-subtypes (IgG2a/IgG1) (B) were determined by ELISA. Panel 
A: Bars represent the geometric mean titer and standard deviation. Panel B: Bars represent the 
ratios of IgG2a/IgG1. The data shown are representative of at least 3 separate experiments. 
Data was analyzed by a Mann-Whitney U test and a p-value of ≤ 0.05 was considered to 
represent a significant difference.  * p≤0.05, ** p≤0.01.
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Figure 3. RSV-specific mucosal IgA and IgG antibody responses in nasal washes and 
BAL after IN immunization of mice. BALB/c mice were immunized IN with RSV virosomal 
vaccine formulations (5 μg of protein) or HNE.  Control mouse groups were either immunized 
IM with FI-RSV or IN with L-RSV on day 0 and 21. Four days after challenge with live RSV (day 
32), RSV-specific IgA responses in nasal washes (A), BAL (C) were determined by ELISA. RSV-
specific IgG responses in nasal washes (B) and BAL (D) were also determined. Panels A-D: 
Bars represent the mean absorbance (490 nm) and standard deviation. The data shown are 
representative data of at least 3 separate experiments.  Data was analyzed by a Mann-Whitney 
U test and a p-value of ≤ 0.05 was considered to represent a significant difference. * p≤0.05, 
** p≤0.01.
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IgG antibody levels in nasal washes and BAL. Nasal RSV-specific IgG was 
observed in all immunized groups, but the highest levels were seen in the 
groups immunized IN with virosomes adjuvanted with both ligands (Figure 
3B). Immunization with adjuvanted virosomes induced BAL IgG to similar 
levels as FI-RSV or live virus immunization. Again, additional incorporation 
of L18-MDP in Pam3CSK4-adjuvanted virosomes further boosted IgG levels 
(Figure 3D). 
 To characterize the humoral immune response in more detail, we 
analyzed RSV-specific serum IgA and IgE antibody levels. Significant levels 
of RSV-specific serum IgA were induced after immunization with live virus 
and RSV-virosomes containing Pam3CSK4, but not after immunization with 
FI-RSV or virosomes with L18-MDP. Induction of serum IgE antibodies, a 
hallmark of atopic responses, was only observed after immunization with 
FI-RSV. Thus, RSV-virosomes with incorporated TLR2/NOD2 ligands induce 
local as well as serum RSV-specific IgA and IgG antibody responses upon 
mucosal immunization and no IgE antibody responses. 
Figure 4. RSV-specific serum IgA and IgE antibody responses. BALB/c mice were 
immunized IN with RSV-virosomal vaccine formulations (5 μg of protein) or HNE. Control 
mouse groups were either immunized IM with FI-RSV or IN with L-RSV on day 0 and 21. RSV-
specific serum IgA (A) and IgE (B) were determined by ELISA. Panal A: Bars represent the 
geometric mean titer and standard deviation. Panel B: Bars represent the mean absorbance 
(490 nm) and standard deviation. The data shown are representative data of at least 2 
separate experiments.  Data was analyzed by a Mann-Whitney U test and a p-value of ≤ 0.05 
was considered to represent a significant difference. * p≤0.05, ** p≤0.01.
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3.3 RSV-specific cell-mediated immune responses
As excess Th2-skewed T cell responses may contribute to ERD, we 
investigated whether the RSV-specific T cell responses had Th1-/or Th2-
skewed phenotypes. To this end, we analyzed IFN-γ and IL-5 levels in ex vivo 
RSV-restimulated splenocytes from immunized and subsequently challenged 
mice of all groups.  Incorporation of Pam3CSK4 in virosomes induced Th1-
skewing: it significantly increased IFN-γ responses while IL-5 responses were 
significantly reduced (Figure 5). Clear-cut Th2-skewed responses, indicated 
Figure 5. Ex vivo cytokine production by splenocytes in response to stimulation with 
RSV. IFN-γ (Panel A) and IL-5 (Panel B) production in splenocyte cultures after stimulation 
with inactivated RSV was determined by cytokine ELISA. Cytokines in the culture supernatants 
were assayed after 3 days of culturing. Bars and error bars represent means ± SD. The data 
shown are representative of at least 3 separate experiments. Data was analyzed by a Mann-
Whitney U test and a p-value of ≤ 0.05 was considered to represent a significant difference.
* p≤0.05, ** p≤0.01, *** p≤0.001
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Figure 6. Protection of mice from challenge with live RSV. BALB/c mice were immunized 
IN with RSV-virosomal vaccine formulations (5 μg of protein) or HNE. Control mouse groups 
were either immunized  IM with FI-RSV or IN with L-RSV on day 0 and 21. Mice were 
challenged with live-RSV on day 28 and four days after challenge (day 32), lung viral titers 
were determined. Viral titers are expressed as TCID50. Bars and error bars represent means ± 
SD. The data shown are representative of at least 2 separate experiments. Data was analyzed 
by a Mann-Whitney U test and a p-value of ≤ 0.05 was considered to represent a significant 
difference. * p≤0.05, ** p≤0.01.
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by high IL-5 but low IFN-γ responses, were induced by FI-RSV and by L18-
MDP-adjuvanted RSV virosomes (Figure 5). Incorporation of L18-MDP in 
Pam3CSK4-adjuvanted virosomes did not lead to Th2-skewing, but appeared 
to further increase the Th1-skewing by enhancing IFN-γ secretion (Figure 
5). This, however, did not reach a statistically significant difference. Thus, 
RSV virosomes supplemented with TLR2/NOD2 ligands efficiently prime for 
safe Th1-phenotype responses upon mucosal immunization in mice. 
3.4 Protection from live RSV challenge
In addition to immune parameters, protection against viral challenge was 
investigated. For this, immunized mice were infected by IN inoculation 
of live virus, one week after the booster immunization. Four days later, 
lung viral titers were measured. All immunized mice showed significantly 
reduced viral titers compared to viral titers seen in non-immunized mice. 
Only mice immunized with RSV-virosomes with both ligands incorporated 
had undetectable viral titers (Figure 6). 
3.5. Lung pathology
To examine possible occurrence of ERD upon challenge of immunized mice, 
lungs were collected four days post-challenge virus and lung slices were 
examined. Mice immunized with FI-RSV showed clear signs of ERD, i.e. 
alveolitis and infiltration of cells in peribronchial and perivascular regions 
(Figure 7C), while non-immunized mice or mice immunized with live virus 
did not show any signs of ERD (Figure 7A, B). Lungs from mice immunized 
with non-adjuvanted virosomes, or virosomes with Pam3CSK4 and/or L18-
MDP, did not show signs of ERD either (Figure 7D-G), although some areas 
with minor infiltration were observed (Figure 7E, F). Thus, unlike IM injection 
with FI-RSV, IN immunization with (adjuvanted) RSV virosomes does not 
prime for ERD.
4. Discussion
Mucosal delivery of vaccines has been explored as a non-invasive and 
highly acceptable route of administration and can induce mucosal antibody 
responses, in addition to systemic antibody responses. Since RSV enters 
through the respiratory mucosal site, mucosal immunity at these sites would 
contribute to prevention of infection [26,27]. However, non-replicating virus 
vaccines administered through the mucosal route generally induce poor 
immune responses. This poor immunogenicity may, however, be overcome by 
co-administeration of mucosal adjuvants with the vaccine [13,28-30]. TLR2 
ligands, like MALP-2 (macrophage-activating lipopeptide-2) and zymosan, 
for example, have been reported to have good mucosal immunoadjuvant 
properties [16,17]. Here, we show that the TLR2 ligand Pam3CSK4, 
incorporated in RSV virosomes, also has mucosal immuno-adjuvant 
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Figure 7. Immunopathology after challenge. BALB/c mice were immunized as described 
above. One week after the booster immunization, mice were challenged with liveRSV (1x 106 
TCID50). Four days after challenge, one lobe of lung was harvested, sliced and stained with H&E 
for pathology analysis using light microscopy. Panels are representative pictures of the lungs of 
mice immunized with (A) HNE, (B) L-RSV, (C) FI-RSV, (D) RSV virosomes, (E) RSV virosomes + 
TLR2-L, (F) RSV virosomes + NOD2-L and (G) RSV virosomes + TLR2-L + NOD2- L immunized 
mice. Black arrows indicate alveolitis, red arrows indicate peribronchiolitis and blue arrows 
indicate perivasculitis. 
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properties. No clearcut in vivo immunoadjuvant activity was observed when 
the NOD2 ligand L18-MDP was incorporated in virosomes. However, when 
it was incorporated in virosomes carrying TLR2 ligand, a further increase 
in in vivo antibody responses and Th1-skewing was observed. This points 
to a synergistic activity of the ligands in immunopotentiation, leading to 
increased RSV-specific immunity upon IN administration of the virosomal 
RSV vaccine. From the above data we conclude that Pam3CSK4, alone or in 
combination with L18-MDP, shows promise for use as a mucosal adjuvant in 
a non-replicating virosomal RSV vaccine. 
 We have previously shown that mucosal immunization with 
inactivated RSV, supplemented with TLR9 (CpG DNA) and NOD2 (L18-MDP) 
ligands, is an effective approach for induction of RSV-specific antibodies 
and Th1-skewed T cell responses [8]. In this study, we investigated the 
virosome platform as a candidate RSV vaccine, and chose to include the 
TLR2 ligand Pam3CSK4, alone or together with L18-MDP. Pam3CSK4 is a 
synthetic triacylated lipopeptide that, unlike CpG DNA for example, readily 
associates with virosomes by partitioning into the virosomal membrane 
during the reconstitution process (Figure 1) [11]. When incorporated in RSV 
virosomes, Pam3CSK4 enhances RSV-specific serum IgG and Th1 responses 
upon intramuscular immunization [11]. One way by which it potentiates 
immune responses is through induction of proinflammatory cytokines, 
which is initiated after binding to a heterodimeric TLR2/1 receptor and 
engagement of the MyD88-mediated signaling pathway [31]. A recent study 
showed that Pam3CSK4 not only upregulates pro-inflammatory genes, but 
also genes involved in leukocyte transendothelial migration at the site of 
vaccine administration [32]. Another possible factor contributing to the 
adjuvant activity of Pam3CSK4 could be its cationic nature. This property has 
been shown to enhance binding and uptake of RSV viral particles by target 
cells [33]. In a similar fashion, it could enhance binding and uptake of 
RSV virosomes that contain Pam3CSK4 by, for example, antigen-presenting 
cells. Besides this, a number of other activities of TLR2 ligands have been 
described that could contribute to enhancement of mucosal responses. 
These include the induction of increased antigen uptake by M cells [34,35], 
induction of T cell-independent B-cell activation and maturation leading to 
enhanced antibody secretion [16], and enhancement of IgA secretion by 
B cells [18]. Thus, TLR2 ligands, including Pam3CSK4, seem highly suited 
for immunopotentiation of vaccine-induced systemic and mucosal immune 
responses upon mucosal administration. 
 Although the NOD2 ligand L18-MDP has been reported to have 
mucosal immunoadjuvant activity [19], we observed no enhancement of 
mucosal antibody responses by virosome-incorporated L18-MDP upon IN 
immunization of mice. We did, however, observe a strong Th2-skewing by 
L18-MDP (Figure 5), a feature which has been described before [36]. Both 
FI-RSV and L18-MDP-adjuvanted virosomes induced Th2-skewed T cell 
responses, but the latter did not prime for ERD (Figure 7F). Notably, in contrast 
to FI-RSV, L18-MDP-adjuvanted virosomes do not induce RSV-specific IgE 
antibodies (Figure 4B), despite the strongly Th2-skewed responses. IgE is 
an important mediator of hypersensitivity responses including ERD and this 
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may be why mice immunized with L18-MDP virosomes did not show ERD. 
The lack of IgE induction may be explained by the active suppression of 
IgE responses by MDP or its derivatives upon mucosal administration [37]. 
Thus our data suggest that, on their own, Th2 responses do not readily 
cause ERD in mice but when associated with RSV-IgE responses contribute 
to ERD.
 L18-MDP did not display Th2-skewing properties when combined 
with TLR ligands, such as CpG DNA [8] or Pam3CSK4 (Figure 5). Rather, 
L18-MDP enhances the TLR ligand-mediated activation leading to more 
pronounced RSV-specific IFN-γ secretion by splenocytes and significantly 
increased mucosal antibody responses. These data are in line with other 
studies showing that ligands for NOD-like receptors (NLR), such as NOD2, 
enhance TLR ligand-induced activation. For example, the TLR ligand induced 
activation, proliferation and survival of B cells was further enhanced by 
addition of NOD ligands [23]. Also, TLR ligand induced (Th1-skewing) 
cytokines in dendritic cells are further enhanced by supplementing with 
NOD1/NOD2 ligands [21]. Thus, RSV-specific serum and mucosal antibody 
responses and Th1 responses boosted by Pam3CSK4 can further be increased 
by addition of the NOD2 ligand L18-MDP.  
 As the respiratory tract is the port of entry for RSV, mucosal antibodies 
in the respiratory tract could significantly contribute to protection. It is likely 
that mucosal antibodies are important in protection of the upper respiratory 
tract, while serum antibodies mainly protect the lungs, as has previously 
been demonstrated for influenza infection [38]. In support of this notion, 
studies on RSV infection in adult humans and the elderly have shown that 
nasal antibodies are a better correlate of protection against RSV infection 
than serum antibodies [39]. On the other hand, high RSV-specific serum 
IgG has been shown to correlate with reduced disease severity upon RSV 
infection [40], which points to a role of serum IgG in protection of the lungs. 
In conclusion, IN-immunization with RSV virosomes with incorporated 
Pam3CSK4 alone, or combined with the NOD2 ligand L18-MDP is a promising 
strategy to induce RSV-specific immunity that includes serum and mucosal 
antibody responses and safe Th1-skewed cellular immune responses, 
without priming for enhanced disease.
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Respiratory syncytial virus (RSV) causes severe respiratory disease in infants 
and the elderly. There is no licensed RSV vaccine available. A mucosal RSV 
vaccine would be an attractive candidate as it could induce both systemic 
and mucosal antibody responses and does not readily prime for enhanced 
respiratory disease (ERD), as did the 1960s formalin-inactivated  RSV vaccine 
(FI-RSV). Earlier, we found that an intranasal (IN) vaccine consisting of RSV 
virosomes with incorporated innate receptor ligand adjuvants had the capacity 
to induce both systemic and mucosal antibody responses in mice. Here, we 
investigated whether such an approach would induce protective immunity in 
cotton rats, an animal more permissive for RSV infection than mice. To this 
end, we produced non-adjuvanted RSV virosomes, RSV virosomes carrying 
Pam3CSK4, a TLR2 ligand, and RSV virosomes carrying Pam3CSK4 together 
with L18-MDP, a NOD2 ligand. The capacity of these preparations to induce 
protective systemic (serum IgG) and mucosal (S-IgA and IgG) antibody 
responses upon IN immunization in cotton rats was investigated. Also, we 
assessed whether these preparations primed for ERD, through analysis of 
immunopathology in the lungs after live virus challenge of immunized animals. 
All responses were compared with responses induced by IM immunization 
with alum-adjuvanted FI-RSV or IN immunization with live virus. We found 
that incorporation of Pam3CSK4 in RSV virosomes potentiates systemic IgG 
and lung S-IgA antibody responses capable of inhibiting viral replication in 
cotton rat lungs. Inclusion of L18-MDP in virosomes, carrying Pam3CSK4, 
further potentiated these responses. Immunization with live virus, but not IN 
immunization with adjuvanted virosomes or IM immunization with FI-RSV, 
induced nasal S-IgA. All immunized groups showed reduced viral lung titers 
upon challenge. Immunization with FI-RSV, but not IN immunization with 
adjuvanted virosomes or live virus, induced immunopathology (ERD). We 
conclude that mucosal immunization with RSV virosomes with incorporated 
TLR2 and/or NOD2 ligands is a promising approach to induce RSV-specific 
immunity in a safe fashion.
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1. Introduction
Respiratory syncytial virus (RSV) infection causes viral bronchiolitis in 
infants and young children but also forms a serious risk for the elderly 
and for immunocompromised individuals [1-3]. RSV infection does not 
provide life-long protection and multiple reinfections can occur throughout 
the life of an individual. Despite the burden of RSV disease, there is still no 
registered vaccine available. This is in part due to the disastrous outcome of 
a clinical trial in 1960s using formalin-inactivated, alum-adjuvanted, whole 
RSV vaccine (FI-RSV) [4], which has considerably slowed down vaccine 
development. In this trial, young vaccinees developed enhanced respiratory 
disease (ERD) upon subsequent natural exposure to RSV and two of them 
died [4,5]. Recent progress in the understanding of the mechanisms 
underlying vaccine-induced ERD, however, has revived the development of 
inactivated RSV vaccine candidates [6].
 Although many vaccines are administered through IM injection, 
the development of an RSV vaccine for mucosal administration, including 
intranasal (IN) administration, remains of great interest. IN administration 
forms an attractive alternative to IM injection, because it is an accessible, 
non-invasive and highly acceptable route of administration [7]. Clear benefits 
are that, in addition to the induction of systemic antibody responses, mucosal 
vaccine delivery potentially induces local secretory-IgA (S-IgA) responses 
that further aid in protection against respiratory viral infections, including 
RSV infection [8,9]. Also, mucosal immunization does not readily prime for 
enhanced disease in animal models, underlining the importance to explore 
this route for future vaccination strategies against RSV [9]. However, to 
break mucosal immune tolerance mechanisms, suitable mucosal adjuvants 
are likely to be needed in such an approach. In this respect, we previously 
showed, in a murine model system, that Toll-like receptors (TLR) ligands and 
NOD-like receptor ligands, admixed with inactivated whole RSV particles or 
incorporated in RSV virosomes,  hold promise as adjuvants in mucosal RSV 
vaccine candidates [8]. 
 Although mice are the most commonly used animal models for 
assessment of vaccine immunogenicity and efficacy, they are not very 
permissive for RSV replication. Cotton rats (Sigmodon hispidus) are 
approximately 100-fold more permissive to RSV infection than mice and 
can also mimic FI-RSV-induced immunopathology as seen in humans 
[10-12]. This model is, therefore, highly suitable for evaluation of the 
immunogenicity, safety and protective capacity of an intranasal virosomal 
RSV vaccine adjuvanted with TLR and NOD2 ligands.  
 Here we demonstrate that incorporation of a TLR2 ligand (Pam3CSK4) 
in RSV virosomes boosts RSV-specific serum IgG and mucosal IgA responses 
after IN immunization of cotton rats. Incorporation of a NOD2 ligand (L18-
MDP) in RSV virosomes carrying TLR2 ligand further enhanced local IgA 
and serum IgG antibody responses. Finally, RSV virosomes supplemented 
with TLR2 and NOD2 ligands protected cotton rats against challenge with 
infectious RSV without inducing ERD. Taken together, these results show 
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that IN immunization of cotton rats with a virosomal RSV vaccine containing 
incorporated TLR2 and NOD2 ligands represents a safe and efficacious 
potential  RSV vaccine candidate.
2. Materials and Methods
2.1 Ethical statement
Animal experiments were evaluated and approved by the Committee for 
Animal Experimentation (DEC) of the University Medical Center Groningen, 
University of Groningen, The Netherlands, according to the guidelines 
provided by the Dutch Animal Protection Act (permit number DEC 5239E). 
Immunizations and challenges were carried out under isoflurane anesthesia 
and every effort was made to minimize suffering of the animals.
2.2 Virus and cell culture
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, 
The Netherlands). The virus was grown in roller bottles on HEp-2 cells (ATCC, 
CL-23, Wesel, Germany) in HEp-2 medium: DMEM (Invitrogen, Breda, 
The Netherlands) supplemented with Pen/Strep, L-Glutamine, Sodium 
bicarbonate, HEPES, Sodium pyruvate, 1X non-essential Amino Acids (all 
from Invitrogen) and 2% FBS (Lonza-Biowhittaker, Basel, Switzerland) and 
purified on sucrose gradient as described before [8]. 
2.3 Vaccine formulations
Virosomal RSV vaccine was produced as described earlier [13]. Briefly, purified 
virus was dissolved in 100 mM 1,2-dicaproyl-sn-glycero-3-phosphocholine 
(DCPC) in HNE buffer (5 mM Hepes, 145 mM NaCl, 1 mM EDTA, pH 7.4) and 
the viral nucleocapsid was removed by ultracentrifugation. Then, a 2:1 molar 
mixture of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine 
(PE) (Avanti Polar Lipids, Alabaster, AL, USA) in 2:1 chloroform/methanol 
at 850 nmol/mg protein was evaporated to a dry film in a glass tube and 
traces of the solvents were removed at a high vaccuum. The lipopeptide 
adjuvant,N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-
cysteinyl-[S]-seryl-[S]-(lysyl)3-lysine (Pam3CSK4, EMC Microcollections 
GmbH, Tubingen, Germany, lyophilized from the HCl solution), and/ or L18 
muramyldipeptide (L18-MDP) (6-O-stearoyl-N-Acetyl-muramyl-L-alanyl-
D-isoglutamine; Invivogen, Toulouse, France) was dissolved in 100 mM 
DCPC in HNE buffer and the solution was filtered through a 0.22 µm filter. 
To prepare virosomes, viral DCPC supernatant was combined with a thin 
film of dry lipid mixture in glass tube and, in case of adjuvanted-virosomal 
formulations, the lipopeptide solution (Pam3CSK4) alone or Pam3CSK4 and 
L18-MDP-adjuvants together (1 mg of adjuvant(s) per mg of viral protein) 
was added. The mixture was incubated for 15 min at 4oC, filtered through a 
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0.22 µm filter and dialyzed against HNE buffer in a sterile slide-A-lyzer (10 
kD cut-off; Thermo Scientific, Etten, Leur, the Netherlands) for 48 h. The 
virosomes were harvested and the protein concentration was determined by 
a Bio-Rad Bradford protein assay. 
 FI-RSV was prepared as reported elsewhere [12]. This vaccine was 
diluted in HNE buffer to contain 5 µg of RSV protein in a 50 µL volume.   
2.4 Cotton rat immunizations and RSV challenge
Female outbred cotton rats (Hsd: Cotton Rat) of 4-6 weeks old were 
purchased from Harlan (Indianapolis, IN, USA). Cotton rats (6 animals per 
group) were immunized IN with 100 µL of RSV-virosomes (5 μg protein) 
alone or with incorporated innate receptor ligands, i.e. TLR2 (Pam3CSK4) and 
NOD2 ligands (L18-MDP) at approximately a 1:1 ratio of ligand to vaccine 
antigen, respectively. Control rats received 100 µL of live virus (1x 106 
TCID50) or HNE or 50 µL (5 µg viral proteins) of FI-RSV IM. Cotton rats were 
immunized on days 0 and 21, under 3-4.5% isoflurane anesthesia in O2. 
On day 28, animals were challenged with 1x 106 TCID50 RSV IN. At the time 
of second immunization and challenge, blood was drawn by retro-orbital 
puncture in order to analyze post-prime and post-booster immunization 
antibody levels. Animals were sacrificed four days after the challenge and 
lung washes (bronchoalveolar lavages; BAL) were performed as described 
before [8]. Subsequently, the lungs were removed aseptically and one of the 
primary bronchi was ligated just below the tracheal bifurcation with suture 
wire. Half of the lung was kept on ice in HEp-2 medium containing 2% FBS 
for virus titration. The other half of the lung was fixed in 4% formaldehyde 
in PBS under 20 cm of water pressure to preserve the structure of the lungs 
for lung histopathology analysis.
2.5 Immunological assays
RSV-specific antibody titers were determined using enzyme-linked 
immunosorbent assay (ELISA) as described earlier [8]. Briefly, 96-well ELISA 
plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) were coated 
with beta-propiolactone (BPL) inactivated whole RSV (BPL-RSV) at 0.5 μg 
protein per well in coating buffer (0.05M carbonate–bicarbonate, pH 9.6–
9.8) overnight at 37oC. Plates were washed three times with coating buffer 
and blocked with a 2.5% solution of milk powder (Protifar Plus, Nutricia, 
Zoetermeer, The Netherlands) in coating buffer. Plates were incubated for 
90 min with two-fold serial dilutions of sera or nasal/lung washes starting 
at dilutions of 1:200 for serum or 1:1 dilutions of washes.  After washing, 
plates were incubated with a 1:5000 dilution of horseradish-peroxidase 
conjugated goat anti-mouse IgG, or IgA; Southern Biotech, Birmingham, 
AL, USA)  which bind to both mouse and cotton rat IgG and IgA, respectively. 
Subsequently, the plates were stained with o-Phenylenediamine (OPD; 
Sigma-Aldrich, St Louis, MO, USA) in 50 mM phosphate buffer pH 5.6 with 
0.02% H2O2 for 30 min. Then, the reaction was stopped by adding 2M H2SO4 
and absorption was measured at 490 nm. 
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2.6 Virus titration and micro-neutralization assay
Virus titers were determined by TCID50 as described before [14]. Briefly, 
lungs were removed aseptically after euthanasia of the animals. Lungs were 
then homogenized in 1 mL of 2% FBS containing HEp-2 medium using an 
automated Potter homogenizer Polytron-Aggregate® (Thomas Scientific, 
Swedesboro, NJ, USA). Next, homogenates were centrifuged at 1400 rpm 
for 10 min at 4oC, and supernatants, diluted to a 1:8 starting dilution, 
were used to determine viral titers using the TCID50 method as previously 
described [14].
 For determination of RSV virus-neutralization titers, sera 
were decomplemented by heat inactivation for 30 min at 56oC. Then, 
serum neutralization was evaluated by incubating different dilutions 
of decomplemented sera with 70 TCID50 of RSV for 2 h and addition of 
this mixture to HEp-2 cells in 96-well plates. Following 5 day incubation, 
wells positive for RSV infection were scored and the neutralizing titer was 
calculated [14]. The neutralization titer was calculated by using the Reed & 
Muench method for determination of the 50% end point titer. 
2.7 Lung histopathology
The inflated cotton rat lungs were embedded in paraffin and 4 µm slices 
were prepared. Then, the slides were stained with hematoxylin and eosin 
(H & E) using standard protocols and photographed using NanoZoomer 
(Hamamatsu Photonics, Hamamatsu city, Japan). Each lung section was 
analyzed for one of the following four parameters of pulmonary inflammatory 
changes: peribronchiolitis (inflammatory cells surrounding a bronchiole), 
perivasculitis (inflammatory cells surrounding a small blood vessel) and 
alveolitis (inflammatory cells within alveolar spaces) by light microscopic 
analysis of slides.
2.8 Data analysis
Statistical analyses were performed using Graphpad Prism v5.0 (Graphpad 
Software, San Diego California, USA). Statistical significance was determined 
using unpaired Mann-Whitney U test. P values ≤ 0.05 were considered to 
represent statistically significant differences.
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3. Results
3.1 Immunogenicity in cotton rats
To evaluate the immunogenicity of the virosomal RSV vaccine upon mucosal 
administration, cotton rats were immunized IN with RSV virosomes alone 
or RSV virosomes with incorporated Pam3CSK4, or RSV virosomes with 
incorporated Pam3CSK4/L18-MDP adjuvants. Control groups included cotton 
rats immunized IN with buffer (“HNE” group), immunized by live virus 
infection, or immunized IM with a FI-RSV adsorbed to alum. A priming IN 
immunization with (adjuvanted) virosomal RSV vaccine induced only low 
levels of serum IgG, but levels could be increased by giving a booster 
immunization (Figure 1). IN immunization with RSV virosomes containing 
both adjuvants induced significantly higher serum IgG levels compared to 
IN immunization with non-adjuvanted virosomes or virosomes containing 
Pam3CSK4 alone (Figure 1). Both IM immunization with FI-RSV or live virus 
infection induced high levels of RSV-specific serum IgG which were not 
increased by giving a booster immunization (Figure 1).
  In order to determine mucosal immune responses, we analyzed lung 
wash samples for analysis of RSV-specific IgA and IgG antibody levels. We 
found a significant induction of RSV-specific IgA antibodies in cotton rats 
immunized IN with live virus or RSV virosomes with incorporated adjuvant(s) 
(Pam3CSK4 alone or combined with L18-MDP; Figure 2). We also determined 
IgG antibody levels in lung washes. RSV-specific IgG was detected in 
animals immunized with FI-RSV, live virus and adjuvanted RSV virosomes 
and levels reflected serum IgG levels (Figure 2). In addition to lung wash 
antibody levels, antibody levels were also determined in nasal washes. RSV-
specific nasal IgA was detected in cotton rats that received live virus, but 
not in other groups. Nasal wash IgG was detected in cotton rats immunized 
with FI-RSV and cotton rats that received live virus immunization. Thus, 
IN immunization with RSV virosomes containing innate receptor ligands 
induces RSV-specific serum IgG and mucosal IgA and IgG antibodies, the 
latter mainly in the lung.  
3.2 Virus neutralization
Next, the virus-neutralization capacity of the sera was evaluated. Sera 
from non-immune  cotton rats (HNE group) did not show any neutralizing 
activity, while sera from cotton rats that received live virus infection showed 
the highest level of neutralization, which was significantly higher than the 
level observed in FI-RSV-immunized cotton rats. Inclusion of adjuvant in IN-
administered RSV virosomes significantly stimulated the mean neutralizing 
titer of the immune sera (Figure 3). However, a number of animals that 
received adjuvanted RSV virosomes IN did not show neutralizing capacity 
in their sera (Figure 3), probably due to a too low concentration of RSV-
specific IgG in the serum.  
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3.3 Protection from live RSV challenge
In addition to immune parameters, protection against viral infection was 
measured. For this, immunized cotton rats were infected by IN inoculation 
of live virus, one week after the booster immunization. Four days later, lung 
viral titers were measured. All immunized cotton rats showed significant 
reduction of viral titers compared to viral titers seen in non-immune cotton 
rats (HNE group; Figure 4). Cotton rats immunized with RSV virosomes 
adjuvanted with Pam3CSK4 had significantly reduced viral titers in their 
lungs when compared to titers seen in non-immune animals. Cotton rats 
immunized IN with RSV virosomes containing both ligands, live virus or FI-
RSV had undetectable viral titers (Figure 4). 
3.4 Lung immunopathology upon RSV infection
To evaluate the safety of IN administration of RSV virosomes adjuvanted with 
Pam3CSK4 and/or L18-MDP adjuvants, we harvested the lungs of immunized 
and challenged cotton rats and assessed lung histology. The lungs of non-
immune animals did not show signs of enhanced disease, i.e. no symptoms 
of alveollitis, and the peribronchial and perivascular regions were free of 
cell infiltrates (Figure 5A,B). In contrast, lungs from cotton rats immunized 
IM with FI-RSV showed prominent alveollitis as well as peribronchial and 
perivascular infiltrates (Figure 5E,F). On the other hand, the lungs of 
the animals immunized IN with RSV virosomes alone (Figure 5G,H), RSV 
virosomes adjuvanted with Pam3CSK4 (Figure 5I,J), RSV virosomes with 
incorporated Pam3CSK4 and L18-MDP adjuvants (Figure 5K,L), or live virus 
(Figure 5C,D) did not show any signs of ERD.  
4. Discussion
Mucosal administration of vaccines has been recognized as an attractive route 
for vaccine administration and can induce mucosal in addition to systemic 
antibody responses. Non-replicating virus vaccines, like RSV virosomes, 
administered through mucosal routes generally are not very immunogenic. 
To potentiate immune responses, we have incorporated lipophilic TLR2 and 
NOD2 ligands in the RSV virosomal membrane. In order to study whether 
the immune responses induced by IN immunization are capable of inhibiting 
pulmonary RSV replication and are safe with respect to the occurrence 
of ERD, we here used the cotton rat model. Cotton rats are much more 
permissive to RSV infection than mice and can mimic the characteristic FI-
RSV-induced immunopathology seen in humans [10-12]. We demonstrate 
that incorporation of Pam3CSK4 and L18-MDP in RSV virosomes potentiates 
systemic IgG and respiratory tract S-IgA antibody responses capable of 
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RSV targets mucosal surfaces of the respiratory tract and protection against 
infection depends on the presence of virus-neutralizing antibodies. Previous 
studies in humans have shown that the presence of RSV-specific serum 
antibodies mainly correlates with protection against symptomatic disease 
and that the levels negatively correlate with severity of disease in risk 
groups such as the elderly [15]. Furthermore, Walsh et al. found that low 
nasal IgA levels correlate with a higher risk to develop RSV infection [16]. 
Our data show that IN immunization with RSV virosomes, supplemented 
with built-in innate receptor ligands, induces serum IgG that contributes 
to protection of the lungs. It is likely that the lung S-IgA induced by the 
vaccine contributes to protection as well. For example, sera from a number 
of animals that received virosomes adjuvanted with Pam3CSK4/L18-MDP had 
Figure 1. RSV-specific systemic IgG antibody responses in cotton rats. Cotton rats 
were immunized IN with virosomal RSV vaccine formulations (5 μg of protein) or HNE. Control 
groups were either immunized IM with FI-RSV or IN with live RSV (L-RSV). Immunizations 
were done on day 0 and 21 (primary and booster immunization, respectively). Blood was 
drawn on day 21  and one week after the booster immunization. RSV-specific IgG antibody 
responses were determined by ELISA. Data was analyzed by a Mann-Whitney U test and a 
p-value of ≤ 0.05 was considered to represent a significant difference.  * p≤0.05, ** p≤0.01.
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undetectable virus-neutralization activity but, yet, these animals did not 
show viral shedding in their lungs. This could mean that lung S-IgA aids in the 
protection as well. Nasal S-IgA was not detected after IN immunization with 
RSV virosomes, supplemented with innate receptor ligands, but an efficient 
S-IgA response was induced by IN immunization with live virus (Figure 2). 
In preliminary experiments, we found that cotton rats immunized with live 
Figure 2. RSV-specific mucosal IgA and IgG antibody in lung and nasal washes. 
Cotton rats were immunized IN with virosomal RSV vaccine formulations (5 μg of protein) 
or HNE. Control groups were either immunized IM with FI-RSV or IN with live RSV (L-RSV). 
Immunizations were done on day 0 and 21 (primary and booster immunization, respectively). 
Four days after challenge with live RSV (day 32), RSV-specific IgA the lung washes (A), nasal 
washes (C) were determined by ELISA. RSV-specific IgG in lung washes (B) and nasal washes 
(D) were also determined. Panels A-D: Bars represent the mean titers (2 log) and standard 
deviation. Data was analyzed by a Mann-Whitney U test and a p-value of ≤ 0.05 was considered 
to represent a significant difference. * p≤0.05, ** p≤0.01.
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virus did not show virus shedding in the nasal tissue while other immunized 
groups usually did show nasal viral shedding, although at very variable 
levels (data not shown).  Although this suggests that S-IgA inhibits virus 
infection in the nasal tissue, it cannot be excluded that nasal IgG contributes 
to protection as well. Our data suggest that some IgG transudates to the 
nasal tissue when serum IgG levels are high. For example, IM injection of 
alum-adjuvanted FI-RSV for example, leads to high RSV-specific serum IgG 
and the appearance of these antibodies at the nasal mucosa (Figure 1, 2). 
It remains to be further investigated if a lack of nasal S-IgA reduces local 
protection against RSV, like in humans [16].
 Whereas, in the present study in cotton rats, we did not find nasal 
S-IgA induction upon IN immunization with adjuvanted RSV virosomes, 
it is of interest to note that, in mice, the RSV virosomes adjuvanted 
with TLR2/NOD2 ligands induced higher nasal S-IgA responses upon IN 
immunization than responses induced by live virus infection (Chapter 3). 
The relative lack of stimulatory activity of TLR ligand adjuvants on nasal 
S-IgA antibody responses in the cotton rat was also observed when we 
tested an IN virosomal RSV vaccine adjuvanted with MPLA (a TLR4 ligand) 
in mice or cotton rats (Chapter 5). Why RSV virosomes, supplemented 
Figure 3. Virus neutralization in cotton rats. Cotton rats were immunized as described in 
Figure 1. Virus-neutralizing antibody titers were determined in serum samples taken at day 
28. Data was analyzed by a Mann-Whitney U test and a p-value of ≤ 0.05 was considered to 
represent a significant difference. * p≤0.05
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with innate receptor ligands, efficiently induce nasal S-IgA in mice, but 
not in cotton rats, remains unclear. A possible explanation could be that 
the dose of antigen and/or adjuvant given to the cotton rats was too low. 
In our studies, a similar dose of antigen and adjuvant (i.e. 5 µg of protein 
and 5 µg of the respective adjuvants) was given to mice and cotton rats, 
while cotton rats weigh approximately 10 times more than mice. In studies 
employing IN immunization of cotton rats, Prince et al. used a lower dose of 
RSV antigen (up to 1.25 µg), yet a much higher dose of adjuvant (20-100 
µg of the TLR9 ligand CpG DNA) for induction of full protective antibody 
responses [17]. In comparison, we previously found that a 4 µg dose of CpG 
DNA, co-administered IN with inactivated RSV, could potentiate nasal S-IgA 
responses in mice. Therefore, increased doses of innate receptor ligand 
adjuvants could possibly potentiate nasal S-IgA responses in cotton rats. 
 In conclusion, our data demonstrate that an IN administered 
virosomal RSV vaccine adjuvanted with TLR2/NOD2 ligands induces serum 
IgG along with lung IgA as well as lung IgG antibodies in cotton rats. This 
response provides protection against challenge with infectious virus and, 
importantly, does not lead to enhanced immunopathology in the lungs upon 
infection of the animals with RSV. The IN virosomal vaccine, adjuvanted 
with TLR2/NOD2 ligands, therefore holds promise for further development 
as a potential RSV vaccine.
Figure 4. Protection in cotton rats from challenge with live RSV. Cotton rats were 
immunized IN with virosomal RSV vaccine formulations (5 μg of protein) or HNE. Control mouse 
groups were either immunized IM with FI-RSV or IN with live RSV (L-RSV). Immunizations were 
done on day 0 and 21 (primary and booster immunization, respectively). Cotton rats were 
challenged with live RSV on day 28 and four days after challenge (day 32) cotton rats were 
sacrificed and lungs were harvested and viral titers were determined. Viral titers are expressed 
as TCID50. Bars and error bars represent means ± SD. Data was analyzed by a Mann-Whitney 
U test and a p-value of ≤ 0.05 was considered to represent a significant difference. * p≤0.05, 
** p≤0.01.
99
Evaluation of RSV-Pam3CSK4/L18-MDP virosomes in cotton rats
Figure 5: Lung pathology in cotton rats. Cotton rats were immunized, challenged and 
terminated as in Figure 4. After termination, one lung lobe was fixated with 4% formalin 
under 20 cm water pressure to retain the structure of the lung. After fixation, the lungs were 
embedded in paraffin and 4 µm slices were cut and stained with H&E. The lungs were evaluated 
by light microscopy. Panels are representative pictures of the lungs of immunized group. 
Groups: HNE (A,B); live virus (C,D); FI-RSV (E,F); RSV virosomes (G,H); RSV virosomes 
+ Pam3CSK4 (I,J); RSV virosomes + Pam3CSK4 + L18-MDP (K,L). Red arrows: peribronchial 
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Respiratory syncytial virus infection remains a serious health problem, not 
only in infants but also in immunocompromised adults and the elderly. An 
effective and safe vaccine is not available due to several obstacles: non-
replicating RSV vaccines may prime for excess Th2-type responses and 
enhanced respiratory disease (ERD) upon natural RSV infection of vaccine 
recipients. We previously found that inclusion of the Toll-like receptor 
4 (TLR4) ligand monophosphoryl lipid A (MPLA) in reconstituted RSV 
membranes (virosomes) potentiates vaccine-induced immunity and skews 
immune responses toward a Th1-phenotype, without priming for ERD. As 
mucosal immunization is an attractive approach for induction of RSV-specific 
systemic and mucosal antibody responses and TLR ligands could potentiate 
such responses, we explored the efficacy and safety of RSV-MPLA virosomes 
administered intranasally (IN) to mice and cotton rats. In mice, we found 
that incorporation of MPLA in IN-administered RSV virosomes increased 
both systemic IgG and local secretory-IgA (S-IgA) antibody levels and 
resulted in significantly reduced lung viral titers upon live virus challenge. 
Also, RSV MPLA virosomes induced more Th1–skewed responses compared 
to responses induced by FI-RSV. Antibody responses and Th1/Th2-cytokine 
responses induced by RSV-MPLA virosomes were comparable to those 
induced by live RSV infection. By comparison, formalin-inactivated RSV 
(FI-RSV) induced serum IgG that inhibited viral shedding upon challenge, 
but also induced Th2-skewed responses. In cotton rats, similar effects of 
incorporation of MPLA in virosomes were observed with respect to induction 
of systemic antibodies and inhibition of lung viral shedding upon challenge, 
but mucosal S-IgA responses were only moderately enhanced. Importantly, 
IN immunization with RSV-MPLA virosomes, like live virus infection, did 
not lead to any signs of ERD upon live virus challenge of vaccinated 
animals, whereas IM immunization with FI-RSV did induce severe lung 
immunopathology under otherwise comparable conditions. Taken together, 
these data show that mucosally administered RSV-MPLA virosomes hold 
promise for a safe and effective vaccine against RSV.
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1. Introduction
Respiratory syncytial virus (RSV) infection causes viral bronchiolitis in infants 
and young children but also significant health problem in the elderly and 
immune-compromised individuals [1-3]. RSV infection at young age does 
not lead to life-long protection and multiple reinfections occur throughout 
life [2,4,5]. Vaccination of risk groups would be an effective approach to 
reduce the burden of disease. Although RSV has been recognized as an 
important vaccine target, no vaccine is available. This is, in part, due to 
the fact that immunization with inactivated RSV formulations or purified 
protein preparations can prime for enhanced respiratory disease (ERD) 
upon natural infection [6], as did a formalin-inactivated RSV vaccine (FI-
RSV),  evaluated in young children in the 1960s [7-9]. Hallmarks of ERD 
are neutrophilic alveolar infiltrates as well as perivascular and peribronchial 
infiltration of lymphocytes [10]. Immunization with FI-RSV also led to the 
induction of poorly neutralizing antibodies [11,12] as a result of impaired 
affinity maturation, probably because of a lack of Toll-like Receptor (TLR) 
signaling by FI-RSV [13]. Subsequent work in animal models showed that 
FI-RSV also induces Th2-skewed immune responses, as opposed to Th1-
type responses that are better suited to protect against viral infections 
[14]. An approach to induce better neutralizing antibodies and Th1-skewed 
responses and to avoid priming for ERD, is to incorporate TLR ligands as 
immunomodulators in candidate non-replicating RSV vaccines [15]. 
 RSV enters through the mucosal surface of the respiratory tract. A 
desirable feature of RSV vaccines would therefore be the capacity to induce, 
besides systemic antibody responses, also local immunity against RSV like 
secretory IgA antibodies (S-IgA). Mucosal immunization, through intranasal 
(IN) administration, could achieve such responses. It not only is a non-
invasive and highly acceptable route of administration [16], in addition, 
it does not readily prime for enhanced disease, at least in animal models 
[17]. However, as mucosal surfaces are continuously exposed to antigens, 
mucosal immune tolerance mechanisms prevent untoward immune 
reactions. Therefore, inclusion of TLR ligands in an IN-administered RSV 
vaccine may well represent an essential prerequisite for induction of robust 
RSV-specific mucosal as well as systemic antibody responses [18]
 A TLR ligand currently used in two registered intramuscular (IM) 
human vaccines is monophosphoryl lipid A (MPLA) [19,20]. We found that 
MPLA in RSV virosomes induces safe and protective immune responses 
in mice and cotton rats upon IM injection [21]. Interestingly, MPLA has 
also been reported to have adjuvant activity when co-administered IN 
with different vaccine antigens [22,23]. These findings therefore prompted 
further exploration of our candidate MPLA-adjuvanted RSV virosomal vaccine 
for induction of RSV-specific immunity upon IN administration. 
 Incorporation of MPLA in RSV virosomes administered IN to mice 
potentiated protective RSV-specific serum IgG and respiratory tract S-IgA 
antibody responses and induced Th1-skewed T cell responses. Incorporation 
of MPLA in RSV virosomes administered IN to cotton rats significantly increased 
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virus-neutralizing serum IgG responses and protection against infection but 
only moderately stimulated mucosal S-IgA responses. In contrast to IM 
injection of FI-RSV, IN administration of RSV-MPLA virosomes did not prime 
for lung immunopathology upon challenge. These data combined show that 
mucosally administered RSV-MPLA virosomes hold promise for induction of 
protective immunity without priming for enhanced disease. 
2. Materials and Methods
2.1 Ethical statement
Animal experiments were approved by the Committee for Animal 
Experimentation (DEC) of the University Medical Center Groningen, 
according to the guidelines provided by the Dutch Animal Protection Act 
(permit number DEC 5239A and 5239D). Immunizations and challenges 
were conducted under isoflurane anesthesia and every effort was made to 
minimize suffering of the animals.
2.2 Virus 
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV (Leiden, 
The Netherlands). The virus was grown in HEp-2 cells (ATCC, CL-23, Wesel, 
Germany) and purified as described before [21]. 
 
2.3 Vaccine formulations
RSV virosomes were generated as described previously [24]. Briefly, 
RSV membranes were  dissolved in 100 mM 1,2 dicaproyl-sn-glycero-
3-phosphocholine (DCPC) in HNE (5 mM Hepes, 145 mM NaCl, 1 mM 
EDTA, pH 7.4) and the nucleocapsid was removed by ultracentrifugation. 
The supernatant was applied to a dried film of a 2:1 mixture of egg 
phosphatidylcholine (PC) and egg phosphatidylethanolamine (PE) (Avanti 
Polar Lipids, Alabaster, AL, USA) at a ratio of 850 nmol lipid per mg of 
supernatant protein. For incorporation of MPLA, monophosphoryl lipid A 
from Salmonella minnesota Re 595 (Invivogen, Toulouse, France) dissolved 
in 100 mM DCPC in HNE was added to the protein lipid mixture at 1 mg 
MPLA per mg supernatant protein, incubated for 15 min at 4˚C, filtered 
through a 0.1 µm filter and dialyzed in a sterile Slide-A-lyzer (10 kD cut-off; 
Thermo Scientific, Geel, Belgium) against HNE. After dialysis, virosomes 
were kept at 4˚C. FI-RSV was produced as reported before [10]. 
2.4 Mouse immunization and challenge experiments
Female BALB/c OlaHsd mice (6-8 weeks old) were purchased from Harlan 
(Zeist, The Netherlands). For immunization and challenge, mice were 
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anesthetized using isoflurane. Mice received RSV(-MPLA) virosomes (5 µg 
viral protein) IN in 50 µL HNE. Control mice received 25 µL of FI-RSV (5 µg 
viral protein) IM, 50 µL (106 TCID50) of live RSV IN or 50 µL of HNE IN. Using 
this procedure, part of the IN inoculated volume may distribute further 
down to the lower respiratory tract. Vaccinations were given on day 0 and 
day 14 and on day 28 mice were challenged with 106 TCID50 of live RSV IN, 
in a similar setup as a previous study on RSV-MPLA virosomes injected IM in 
mice [21]. On time points of vaccination and challenge, blood was drawn by 
retro-orbital puncture. Four days after challenge, mice were sacrificed and 
blood was sampled. Nose washes and broncho-alveolar lavages were done 
by incising the trachea and flushing of 1 mL PBS with protease inhibitors 
(Roche, Mannheim, Germany). Spleens were harvested for analysis of RSV-
specific T cell cytokine responses and lungs for analysis of viral titers.
2.5 Cotton rat immunization and challenge experiments
Female outbred cotton rats (Hsd:Cotton Rat) of 4-6 weeks old were 
obtained from Harlan (Indianapolis, IN, USA). Rats received RSV(-MPLA) 
virosomes IN (5 µg viral protein). Control rats received 100 µL live virus 
(106 TCID50) IN, 100 µL of HNE IN or 50 µL (5 µg viral protein) of FI-RSV IM. 
Vaccinations were given on day 0 and day 21 and on day 49, cotton rats were 
challenged with 106 TCID50 RSV IN, in a similar setup as a previous study 
on RSV-Pam3CSK4  virosomes injected IM in cotton rats [24]. At the time 
of immunization and challenge, blood was drawn by retro-orbital puncture. 
Five days after challenge, rats were sacrificed and blood was sampled. 
Lung and nose washes were performed using similar techniques as in mice. 
Subsequently, the lungs were removed aseptically and one of the primary 
bronchi was ligated just below the tracheal bifurcation with suture wire. Half 
of the lung was kept on ice in HEp-2 medium containing 2% FBS, for virus 
titration. The other half of the lung was fixed in 4% formaldehyde in PBS 
under 20 cm of water pressure to preserve the structure of the lungs for 
lung histopathology analyses. 
2.6 Immunological assays 
RSV-specific antibody titers were determined as described before [24]. 
Briefly, 96-well plates were coated with betapropiolactone-inactivated RSV 
and blocked with 2.5% milk powder in coating buffer. Plates were incubated 
for 90 min with two-fold serial dilutions of serum or broncho-alveolar 
lavages, starting at dilutions of 1:200 for serum or 1:1 for BAL or nose 
washes. After washing, plates were incubated with a 1:5000 dilution of 
horseradish-peroxidase-coupled goat anti-mouse IgG, or IgA which bind to 
both mouse and cotton rat IgG and IgA, respectively (Southern Biotech 1030-
05, 1040-05) for 1 h and subsequently stained with o-Phenylenediamine 
(OPD; Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining was 
stopped by addition of 2M H2SO4 and absorption was measured at 492 nm. 
IFN-γ and IL-5 secretion in splenocyte cultures that were re-stimulated with 
inactivated RSV particles were assessed as described before [21]. 
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2.7 Virus titration and microneutralization assay 
Virus titers were determined by TCID50 as described previously [21]. For 
determination of RSV virus neutralization titers, serum was decomplemented 
by heat inactivation for 30 min at 56˚C. Neutralization titers were determined 
by incubation of two-fold serially diluted decomplemented serum with 70 
TCID50 of RSV for 2 h and subsequent titration of this mixture on HEp-2 cells 
as described before [21]. The neutralization titer was calculated with the 
Reed & Muench method as the dilution that neutralizes infection in 50% of 
the wells. 
2.8 Histopathology
The inflated cotton rat lungs were embedded in paraffin and 4 µm slices 
were cut. The slides were stained with hematoxylin and eosin (H & E) using 
standard procedures. Subsequently, perivasculitis, peribronchiolitis and 
alveolitis were assessed by light-microscopy.  Histopathology was assessed 
in more than one experiment and always included at least 3 animals per 
group.
2.9 Statistical analysis
Statistical analyses were performed with Graphpad Prism 5.00 for Mac 
OSX, (GraphPad Software, San Diego California USA, www.graphpad.com) 
using a Mann-Whitney U test. P values of 0.05 or lower were considered to 
represent significant differences. 
3. Results
3.1 Immunogenicity in mice
To determine the adjuvant effect of MPLA in IN-administered RSV virosomes, 
we immunized mice with RSV virosomes or RSV-MPLA virosomes. RSV-naïve 
mice and mice immunized with FI-RSV or live virus, served as controls. RSV-
MPLA virosomes, but not virosomes without MPLA, induced RSV-specific 
serum IgG, although levels were significantly lower than those induced 
by IM injection with FI-RSV or live RSV infection (Figure 1A). One of six 
mice receiving a second IN immunization with RSV virosomes developed 
detectable RSV-specific serum IgG antibodies. In contrast, all mice that 
received a second IN immunization with RSV-MPLA virosomes developed IgG 
antibodies, to similar levels as in mice that received a second immunization 
with FI-RSV or a live virus infection (Figure 1A).
 For assessment of local immune responses, we analyzed lung and 
nose wash RSV-specific IgA antibodies. Mice immunized twice IN with 
RSV-MPLA virosomes showed significantly higher S-IgA levels in lungs 
compared to mice immunized with non-adjuvanted virosomes, FI-RSV 
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or live virus infection. Both RSV-MPLA virosomes and live virus infection 
induced significantly higher nasal S-IgA compared to levels induced by non-
adjuvanted virosomes and FI-RSV (Figure 1B,C). 
 To determine protection against infection, immunized mice were 
infected with live RSV. Non-vaccinated mice or mice immunized IN with non-
adjuvanted virosomes showed virus titers of approximately 104 TCID50 , 4 
days post-infection.  On the other hand, animals immunized with RSV-MPLA 
virosomes, FI-RSV or live virus had no detectable lung virus titers (Figure 
1D). 
3.2 Cellular immune response in mice
Next, we determined Th1-type cytokine (IFN-γ) and Th2-type cytokine (IL-
5) levels in RSV-restimulated splenocytes from immunized and subsequently 
challenged animals of all groups (Figure 2). IFN-γ production in splenocyte 
cultures from mice immunized with RSV-MPLA virosomes was significantly 
higher than that in cultures from mice immunized with non-adjuvanted 
virosomes or FI-RSV. In contrast, IL-5 production in splenocyte cultures 
from mice immunized with FI-RSV was significantly higher than that in 
cultures from mice immunized with non-adjuvanted RSV virosomes, RSV-
MPLA virosomes or live virus infection. Therefore, RSV-MPLA virosomes 
induced more Th1-skewed responses compared to responses induced by 
FI-RSV.   
3.3 Immunogenicity in cotton rats 
Next, we evaluated immune responses, protection and vaccine-induced 
immunopathology in the cotton rat model. Cotton rats, compared to mice, 
are more permissive to RSV and more prone to develop ERD. Similar to 
antibody responses in mice, low levels of RSV-specific serum IgG were 
detected in cotton rats immunized IN with non-adjuvanted RSV virosomes 
(Figure 3A). However, incorporation of MPLA in the IN-administered 
virosomes significantly increased systemic IgG levels. Animals immunized 
once with RSV-MPLA virosomes showed significantly lower titers compared 
to those in cotton rats immunized once with FI-RSV or live virus.  However, 
serum IgG antibody levels increased after the booster immunization to 
similar levels as seen in cotton rats primed and boosted with FI-RSV or live 
virus (Figure 3A).
 Next, the virus-neutralizing capacity of the sera were assessed. Sera 
from RSV-naïve cotton rats or rats immunized IN with non-adjuvanted RSV 
virosomes, did not have any significant neutralizing capacity (Figure 3B). 
RSV-MPLA virosomes induced significantly increased levels of neutralizing 
antibodies compared to RSV virosomes without MPLA. These levels were, 
on average, also higher than those induced by IM immunization with FI-
RSV, although the difference did not reach statistical significance. Live RSV 
infection, however, induced significantly higher neutralizing antibody levels 




Finally, the local antibody responses were determined. Although MPLA 
increased nasal S-IgA levels, levels of S-IgA in nose and lung induced by 
live virus infection were significantly higher than those observed in the other 
groups (Figure 4).
3.4 Protection from RSV challenge in cotton rats
To determine protection against infection, immunized cotton rats were 
infected with live RSV. Significant lung virus titers were detected in RSV-
naïve cotton rats and cotton rats immunized IN with non-adjuvanted RSV 
virosomes (Figure 5A). Five out of seven cotton rats immunized IN with 
RSV-MPLA virosomes showed no lung virus titers, while two cotton rats had 
detectable virus titers, but at levels that were significantly lower compared 
to those in animals immunized IN with non-adjuvanted RSV virosomes. All 
animals immunized with FI-RSV or live virus had non-detectable lung viral 
shedding (Figure 5A). 
Figure 1. Immunogenicity and protection in mice. Mice were immunized twice (“prime” 
on day 0 and “boost” on day 14) with RSV virosomes IN, RSV-MPLA virosomes IN, FI-RSV IM, 
and live virus IN. Control mice received buffer IN. Fourteen days after the immunizations blood 
was drawn and RSV-specific IgG in serum was determined (A). The immunized mice were 
challenged on day 28 with 106 TCID50 RSV and terminated 5 days later. After termination IgA 
titers were determined in lung wash (B) and nose wash (C). RSV virus titers were determined 
by TCID50 on lung homogenates. (Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, 
***p<0.001). Bars represent the geometric mean titer ± SD (Panels A-C). Horizontal lines 
represent mean TCID50  values (Panel D).
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3.5 Histopathology analyses
To evaluate the safety of IN administration of RSV virosomes and RSV-MPLA 
virosomes, we harvested the lungs of immunized and challenged cotton rats 
and assessed lung pathology by light microscopy. Lungs from cotton rats 
immunized IM with FI-RSV showed clear signs of ERD, with perivascular and 
peribronchial infiltration and alveolitis with influx of predominantly neutrophils 
(Figure 6C,D). The lungs of non-immunized animals (Figure 6A,B), animals 
immunized IN with RSV virosomes (Figure 6E,F), RSV-MPLA virosomes 
(Figure 6G,H) or live virus (Figure 6I,J), however, did not show signs of 
ERD. Finally, immunization with  FI-RSV, but not with RSV(MPLA) virosomes 
or live virus, lead to high neutrophil influx upon challenge of  immunized 
animals (Figure 7). This confirms the occurrence of immunopathology in 
the FI-RSV-immunized group and absence of this complication in animals 
immunized IN with RSV virosomes, RSV-MPLA virosomes or live virus. 
Figure 2. Cellular immune response in mice. Mice were immunized, challenged and 
terminated as in Figure 1. After termination, spleens were harvested and splenocytes were 
restimulated in vitro with BPL-inactivated RSV for three days. After three days IFN-γ (A) and 
IL-5 (B) were determined in the supernatants. (Mann-Whitney U test:,*p<0.05, ***p<0.001). 




Intranasal administration represents an attractive route of administration for 
vaccines, including RSV vaccines. Effective induction of immune responses 
with non-replicating vaccine antigens through this route usually requires the 
use of adjuvants [25]. The adjuvant MPLA has an acceptable safety profile 
in humans and is currently being used in a number of licensed vaccines 
[26,27]. It does not only have immunomodulatory properties for induction 
of safe Th1-skewed responses against RSV [15,21], but also has been 
reported to have mucosal immunoadjuvant properties [22,23]. However, 
MPLA has not been tested before for its capacity to potentiate immune 
responses to a non-replicating RSV vaccine, such as RSV virosomes, upon 
IN administration. Here, we show that RSV virosomes with incorporated 
MPLA have the capacity to induce protective immune responses upon IN 
administration to mice and cotton rats, without priming for ERD. 
 IN administration of RSV-MPLA virosomes effectively induces serum 
IgG antibody responses and Th1-skewed immune responses, similar to 
RSV-MPLA virosomes administered by IM injection [21]. This is line with 
previous findings by others who compared the immunoadjuvant activity of 
MPLA co-administered IN or parenterally with antigen [28]. The adjuvant 
effect of MPLA is likely caused by the direct interaction of MPLA with TLR4 
on dendritic cells (DC) that are abundantly present in draining lymph nodes, 
nasal or bronchus-associated lymphoid tissue, or even directly lining the 
respiratory tract. The activation leads to secretion of IL-12 and type I IFN, 
Figure 3. Immunogenicity in cotton rats. Cotton rats were immunized with the same 
preparations as given to mice (Figure 1) on day 0 and 21. On day 21 and 49, blood was 
taken en RSV specific IgG was determined in serum (A). RSV-virus neutralizing antibodies 
were determined in the day 49 serum (B). (Mann-Whitney U test: ns not significant,*p<0.05, 
**p<0.01, ***p<0.001).  Bars represent the geometric mean titer ± SD
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which skew T cell responses toward a Th1-phenotype [29]. Such responses 
may more safe with respect to the occurrence of ERD as they are likely to 
be associated with more safe Th1-skewed responses in RSV-infected lungs 
too, similar to responses we previously observed in mice immunized IN with 
inactivated RSV supplemented with TLR9/NOD2 ligands [18]. Similar to DC, 
B cells may be directly activated through TLR4 signaling which, together 
with aid of the induced T cell response, stimulates antibody responses 
[30]. Although many cell types in the respiratory mucosa express TLR4, 
the receptor for MPLA, the expression of the co-receptors CD14 and MD2, 
which are crucial for the initiation of TLR4-mediated cell signaling, are 
expressed at a lower level compared to their expression on, for instance, 
DC [31]. This reduced expression of CD14 and MD2 on the mucosal cell 
surfaces, e.g. epithelial cells, may reduce their susceptibility to endotoxins 
but possibly also to stimulatory effects of vaccine adjuvants such as MPLA 
[32]. This could explain the lower levels of RSV-neutralizing antibodies 
induced by IN immunization compared to IM immunization [21]. Other 
TLRs, such as TLR2 and TLR5, do not require these adaptor molecules and 
are also abundantly expressed on cells in the mucosal surfaces [31] and 
ligands for these receptors have been reported to have strong mucosal 
immunoadjuvant properties too [33,34]. How the mucosal immunoadjuvant 
activity of MPLA, co-administered in RSV virosomes, compares with that 
of other virosome-incorporated TLR ligands, such as a TLR2 ligand [24], 
remains to be investigated further. 
Figure 4. Mucosal immune response in cotton rats. Cotton rats were immunized as in 
Figure 3 and challenged with 1x 106 TCID50 live RSV on day 49. Five days after challenge, the 
rats were s acrificed and lung and nose washes were taken. RSV specific IgA was determined 
in nose washes (A) and lung washes (B). (Mann-Whitney U test:*p<0.05, **p<0.01, 
***p<0.001). Bars represent mean OD values ± SD of 1:1 diluted washes.
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Mucosal immunization can induce local S-IgA antibodies. More robust 
local S-IgA was induced by RSV infection in cotton rats, particularly when 
compared to responses induced by IN immunization with virosomes. In 
mice, differences in levels of S-IgA induced by infection or IN immunization 
were less pronounced. This difference may be related to the much higher 
permissiveness of the cotton rat for RSV infection than that of mice [35], 
leading to higher levels of viral replication and stronger local immune 
activation and, consequently, to higher S-IgA responses. Because FI-
RSV also induces serum IgA (unpublished results), IgA found in washes 
of cotton rats or mice immunized with FI-RSV may originate from serum 
and translocate to the mucosa by transudation (in case of monomeric 
IgA) or through transcytosis mediated by the polymeric immunoglobulin 
receptor (pIgR; in case of polymeric IgA) [36]. Interestingly, TLR4 signaling 
Figure 5. Protection in cotton rats. Cotton rats were immunized, challenged and sacrificed as 
in Figure 4. After termination, the lungs were removed and RSV titers in lungs were determined 
by TCID50. (Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, ***p<0.001). 
Horizontal lines represent mean TCID50  values.
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upregulates expression of pIgR responsible for polymeric IgA transcytosis 
[36,37]. Clearly, RSV-specific serum IgG alone, for example induced by 
IM injection of RSV-MPLA virosomes, inhibits virus shedding in the lung. 
In this respect, we previously observed that lung viral titers negatively 
correlate with RSV-specific serum IgG levels [18], pointing to (sufficient 
levels of) serum IgG, as an important mediator of protection of the lungs. 
The upper respiratory tract, however, may not benefit so much from serum 
IgG for protection against infection, as transudation of antibody to this site 
is less efficient [38]. Rather, local S-IgA antibody may be more important 
for protection against viral infection at this site, as has previously been 
reported for influenza [39]. Further studies should clarify if S-IgA protects 
the upper respiratory tract by specifically analyzing nasal virus shedding in 
cotton rats immunized IN. 
Figure 7. Neutrophil infiltration in lungs of immunized and RSV-challenged cotton 
rats. Cotton rats were immunized, challenged and sacrificed as in Figure 4. Lungs were 
removed, fixated and slices were stained with H & E. The numbers of infiltrating neutrophils 
were evaluated using light microscopy.  Bars represent mean numbers ± SD.
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Figure 6. Lung pathology in cotton rats. Cotton rats were immunized, challenged and 
sacrificed as in Figure 4. After termination, one lung lobe was fixated with 4% formalin 
under 20 cm water pressure to retain the structure of the lung. After fixation, the lungs 
were embedded in paraffin and 4 µm slices were cut and stained with H & E. The lungs were 
evaluated by light microscopy. Left panels show lungs at a 200x magnification, right panels 
show lungs at a 400x magnification. Groups: No vaccine (A,B), FI-RSV (C,D), RSV virosomes 
(E,F), RSV-MPLA virosomes (G,H), Live virus (I,J). Red arrows, alveolar infiltrates, green 
arrows, perivascular infiltrates, green arrowheads, peribronchial infiltrates. The histopathology 
shown is representative of the histopathology observed in 3 animals per group.
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Together our data show that RSV-MPLA virosomes have the capacity to 
induce protective immunity upon IN administration to mice and cotton rats, 
without priming for enhanced disease. IN-administration forms an attractive 
alternative to IM injection, as it is a non-invasive route of administration. 
Clearly, to potentiate RSV virosome-induced immune responses through 
this route, adjuvants are needed, which could be MPLA or possibly other TLR 
ligands with mucosal immunoadjuvant properties.  
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Each year, respiratory syncytial virus (RSV) infection is responsible for 
180,000 hospitalizations and 14,000 deaths among the elderly in the USA 
alone, causing a disease burden similar to that of influenza in this population. 
Vaccination could significantly lower morbidity and mortality due to RSV 
among the elderly. Here, we investigated whether a virosomal RSV vaccine 
has the capacity to induce protective immune responses upon intramuscular 
(IM) injection in aged cotton rats and whether supplementation of RSV 
virosomes with monophosphoryl lipid A (MPLA) further stimulates antibody 
responses. Furthermore, we studied the induction and waning of serum 
antibody responses induced by a priming infection early in life and the 
capacity of virosomal RSV vaccine to boost these antibodies after ageing 
of the animals. Intramuscular (IM) injection of RSV virosomes induced 
protective RSV-specific serum IgG antibody responses in aged cotton rats. 
Immunization with RSV-MPLA virosomes further enhanced serum IgG levels 
compared to non-adjuvanted virosomes, without priming for enhanced lung 
pathology. RSV-specific serum antibodies, induced by infection early in life, 
waned significantly upon aging, but protective levels of specific antibody 
were still present at old age. RSV-specific serum antibody levels, however, 
increased after IM injection of RSV virosomes, irrespective of whether the 
virosomes were adjuvanted with MPLA or not. RSV-specific secretory IgA 
(S-IgA) in the respiratory tract of primed and aged cotton rats increased 
after intranasal (IN) immunization, but not after IM immunization, with 
virosomal RSV vaccine, and incorporation of MPLA in the virosomes boosted 
this response. Taken together these data show that RSV-MPLA virosomes are 
immunogenic in an aged immune system and are able to boost preexisting 
immunity against RSV. 
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1. Introduction
Respiratory syncytial virus (RSV) is the major cause of viral bronchiolitis 
in children and also a significant problem in the elderly. By the age of two, 
nearly all children have been infected with RSV at least once [1]. RSV 
infection does not lead to life-long protection and multiple reinfections occur 
throughout life. Previous studies pointed to RSV-specific serum IgG, but 
also mucosal secretory IgA (S-IgA), as protective effector mechanisms in 
RSV infection of adults [2]. In healthy adults with insufficient immunity, 
reinfections may lead to mild disease with common cold-like symptoms [3]. 
At older age, however, the immune system weakens and RSV infections 
can induce severe disease [4,5]. In the elderly, RSV is responsible for 
approximately 180,000 hospitalizations and 14,000 deaths each year in the 
USA alone [6]. Compared to influenza, RSV contributes to a similar extent 
to severe lower respiratory infections in the elderly [6]. Treatment of elderly 
suffering from RSV is mainly supportive and consist of administration of 
fluids and in some cases bronchodilatators [5]. A vaccine against RSV, 
however, could significantly reduce the burden of disease in the elderly. 
 We previously showed that reconstituted RSV membranes, 
adjuvanted with the Toll-Like Receptor 4 (TLR4) ligand monophosphoryl 
lipid A (MPLA) represent a promising vaccine candidate. Studies in mice 
and cotton rats showed that RSV-MPLA virosomes induce high levels of 
serum RSV-specific, virus-neutralizing, antibodies and a balanced Th1/Th2 
response [7]. Immunization of mice or cotton rats with RSV-MPLA virosomes 
does not prime for lung pathology (i.e. enhanced respiratory disease [8-10]) 
upon natural infection in contrast to immunization with formalin-inactivated 
RSV (FI-RSV). It is not known whether the RSV virosomal vaccine has the 
capacity to potentiate immune responses in an aged immune system and, 
if MPLA has the capacity to boost responses under these conditions.
 A suitable animal model to study the efficacy of RSV vaccines is the 
cotton rat (Sigmodon hispidus). Cotton rats are more permissive than mice 
for RSV and show signs of enhanced disease lung pathology similar to that 
seen in humans [9,11,12]. However, RSV protection studies in aged cotton 
rats, as a model for the elderly, are scarce. One previous study showed that 
nine-month-old cotton rats have a more prolonged RSV infection compared 
to young cotton rats [13]. This coincides with a delay in cytokine expression 
patterns in the lungs of infected cotton rats [14]. These data indicate that 
aged cotton rats indeed show signs of compromised antiviral immunity and 
would be a suitable model to study immune responses induced by RSV 
vaccines, including (MPLA-adjuvanted) RSV virosomes. 
 Here, we investigated the efficacy and safety of an RSV virosomal 
vaccine in old cotton rats that were either naïve to RSV or primed for RSV-
specific immunity by infection early in life, similar to the general situation in 
humans. We show that intramuscular (IM) injection of RSV virosomes induce 
protective antibody responses in aged cotton rats and that incorporation of 
MPLA in the virosomes significantly boosts these responses without priming 
for enhanced lung pathology. Immunity to RSV induced by infection early in 
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life, as demonstrated by RSV-specific serum antibodies, waned significantly 
but protective antibody levels were still detected at old age. Levels of RSV-
specific serum antibodies could, however, be boosted by IM injection of RSV 
virosomes, whether or not adjuvanted with MPLA. Finally, levels of respiratory 
tract RSV-specific secretory IgA (S-IgA), a correlate of protection against 
RSV in the elderly, could be boosted by intranasal (IN) administration of RSV 
virosomes to primed and aged cotton rats and incorporation of MPLA in the 
virosomes boosted this response. These data together suggest that RSV-
MPLA virosomes have the capacity to boost protective RSV-specific immune 
responses in an aged immune system. Therefore, RSV-MPLA virosomes 
represent a promising vaccine candidate RSV vaccine for the elderly.
2. Materials and Methods
2.1 Ethical statement
Animal experiments were approved by the Committee for Animal 
Experimentation (DEC) of the University Medical Center Groningen, 
according to the Dutch Animal Protection Act (permit number DEC 5266E). 
Immunizations and challenges were conducted under isoflurane anesthesia, 
and every effort was made to minimize suffering of the animals.
2.2 Cells and virus
RSV strain A2 (ATCC VR1540) was kindly donated by Mymetics BV 
(Leiden, The Netherlands). The virus was grown in Vero cells (ATCC, CL-
81, Wesel Germany): in SMF-4 Megavir (Thermo scientific, Etten-leur, The 
Netherlands), supplemented with L-glutamine, and penicilline/streptomycin 
(Invitrogen, Breda, Netherlands). After 5 days of infection the cell debris 
was cleared by low-speed centrifugation, the virus was concentrated and 
frozen in liquid nitrogen and stored at –80˚C to be used for live virus 
immunizations, challenge and microneutralization assays. 
 
2.3 Vaccine formulations
RSV virosomes were generated as described previously [15]. Briefly, 
the RSV membrane was dissolved in 100 mM 1,2 dicaproyl-sn-glycero-
3-phosphocholine (DCPC) in HNE and the nucleocapsid was removed by 
ultracentrifugation. The supernatant was applied to a dried film of a 2:1 
mixture of egg phosphatidylcholine (PC) and egg phosphatidylethanolamine 
(PE) (Avanti Polar Lipids, Alabaster, AL, USA) at a ratio of 850 nmol lipid 
per mg of supernatant protein. For incorporation of MPLA, monophosphoryl 
lipid A from Salmonella minnesota Re 595 (Invivogen, Toulouse, France), 
was converted to 3-o-desacyl monophosphoryl lipid A by alkaline hydrolysis 
[16], dissolved in 100 mM DCPC in HNE, and added to the protein/lipid 
mixture at 1 mg MPLA per mg supernatant protein, incubated for 15 min at 
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4˚C, filtered through a 0.1 µm filter and dialyzed in a sterile Slide-A-lyzer 
(10 kD cut-off; Thermo Scientific, Geel, Belgium) against HNE buffer pH 
7.4. After dialysis, virosomes were kept at 4˚C.
 FI-RSV was produced as reported before [9]. FI-RSV was diluted 
with HNE to contain 5 µg of RSV protein in a 50 µL volume.
2.4 Animals and immunizations
Female outbred cotton rats (Hsd:Cotton Rat) of 18 to 21 days old were 
obtained from Harlan (Indianapolis, IN, USA). One group of animals was 
housed conventionally for 34 weeks before immunization. Another group of 
animals received an infection with 106 TCID50 live RSV and was housed in 
individually ventilated cages (IVC). The infected animals showed no signs 
of illness after infection. Blood was sampled at 4 weeks post infection to 
determine the RSV-specific IgG response. In a number of animals, ageing 
was associated with development of disease symptoms including damaged 
eyes, abscess or tumor formation or group B Streptococcus infection of the 
uterus. Animals with more severe symptoms were terminated and excluded 
from the experiment. RSV infection at a young age did not correlate with 
the onset of the symptoms. 
 Cotton rats that were not infected at a young age were immunized 
at the age of 37 weeks (priming immunization) and 40 weeks (boosting 
immunization) with RSV virosomes or RSV-MPLA virosomes intramuscularly 
(IM; 50 µL). Virosome preparations contained 5 µg of viral protein. Control 
rats received 50 µL of HNE IM or 50 µL (diluted to contain 5 µg viral protein) 
of FI-RSV IM. At week 44, cotton rats were challenged with 106 TCID50 RSV 
IN. Cotton rats that  received a primary infection (referred to as RSV-primed 
cotton rats) were immunized once, at the age of 37 weeks with virosomes 
as described above. To assess the capacity of intranasally (IN) administered 
RSV virosomes to boost serum IgG responses and mucosal antibody 
responses in RSV-primed cotton rats, 100 µL (adjuvanted) virosomes were 
administered IN to anesthetized cotton rats. At 41 weeks, the cotton rats 
were challenged as described above.
 At the time of immunization and challenge, blood was drawn by 
retro-orbital puncture. Five days after challenge, the cotton rats were 
sacrificed and blood was drawn by heart puncture. The cotton rats were 
resected and a small incision was made in the trachea. From this incision, 
nose washes and broncho-alveolar lavages were performed with 1 mL of 
PBS with protease inhibitors (Roche, Mannheim, Germany). Lungs were 
removed aseptically and one of the primary bronchi was ligated just below 
the tracheal bifurcation with suture wire. One half of each lung was kept on 
ice in HEp-2 medium containing 2% FBS, for virus titration. The other half of 
each lung was fixed in 4% formaldehyde in PBS at 20 cm of water pressure 
to preserve the structure of the lungs for lung histopathological analyses. 
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2.5 IgG antibody ELISA
RSV-specific antibody titers were determined as described before [15]. 
Briefly, 96-well plates were coated with β-propiolactone-inactivated RSV 
and blocked with 2.5% milk powder in coating buffer. Plates were then 
incubated for 90 min with two-fold serial dilutions of serum, BAL or nose 
washes, starting at dilutions of 1:200 for serum or 1:1 for BAL or nose 
washes. After washing, plates were incubated with a 1:5000 dilution of 
horseradish-peroxidase-coupled goat anti-mouse IgG, or IgA which are cross 
reactive with cotton rat IgG and IgA, respectively (Southern Biotech 1030-
05, 1040-05) for 1 h and subsequently stained with o-phenylenediamine 
(OPD; Sigma-Aldrich, St Louis, MO, USA). After 30 min the staining was 
stopped by addition of 2M H2SO4 and absorption was measured at 492 nm. 
2.6 Virus titration and microneutralization assay
 
Virus titers were determined by TCID50 as described previously [7]. For 
determination of RSV virus neutralization titers, serum was decomplemented 
by heat inactivation for 30 min at 56˚C. Neutralization titers were determined 
by incubation of two-fold serially diluted decomplemented serum with 70 
TCID50 of RSV for 2 h and subsequent titration of this mixture on HEp-2 
cells as described before [7]. The neutralization titer was calculated with 
the Reed & Muench method as the dilution that neutralizes infection in 50% 
of the wells. 
2.7 Lung histopathology
The inflated lungs were embedded in paraffin and 4 µm slices were cut. The 
slides were then stained with hematoxylin and eosin (H & E) using standard 
procedures. Subsequently, perivasculitis, peribronchiolitis and alveolitis 
were assessed by light-microscopy.
2.8 Statistical analyses
All statistical analyses were performed with Graphad Prism 5.00 for Mac 
OSX, (GraphPad Software, San Diego California USA; www.graphpad.com). 
Statistical significance was assessed using a Mann-Whitney U test. P values 
of 0.05 or lower were considered to represent significant differences. 
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3. Results
3.1 RSV-MPLA virosomes in RSV-naïve old cotton rats
To determine whether RSV virosomes or RSV-MPLA virosomes are 
immunogenic in cotton rats with an aged immune system, aged (i.e. 
8-months-old) cotton rats were immunized twice  intramuscular (IM) 
injections, three weeks apart, with RSV virosomes or RSV-MPLA virosomes. 
As controls, we included cotton rats that received no immunization or were 
immunized with FI-RSV by IM injection. We then analyzed levels of RSV-
specific serum IgG, virus-neutralization capacities of sera obtained from the 
immunized cotton rats and protection against infection. Immunization with 
Figure 1. Immunogenicity and protection induced by vaccine in RSV-naive aged 
cotton rats. Cotton rats were immunized IM twice, once at 37 and once at 40 weeks old with 
RSV virosomes, RSV-MPLA virosomes, FI-RSV or live virus. Control mice were not vaccinated 
and received buffer. Fourteen days after the immunizations blood was drawn and RSV-specific 
IgG in serum was determined (A) (white bar:14 days after 1st immunization, black bar 14 
days after second immunization). Serum virus-neutralization titers were determined after the 
first (black squares) and after the second immunization (white squares) by microneutralization 
assay (B). The immunized cotton rats were challenged on week 44 with 106 TCID50 RSV and 
terminated 5 days later. After termination, RSV virus titers were determined by TCID50 on lung 
homogenates (C). (Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, ***p<0.001)
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RSV virosomes in aged cotton rats gave rise to RSV-specific serum IgG with 
a geometric mean titer (GMT) of 2.7 (Figure 1A). Incorporation of MPLA 
in the virosomes significantly enhanced the levels of RSV-specific serum 
IgG. These levels were comparable to those induced by FI-RSV. A second 
immunization further stimulated IgG responses in the group vaccinated 
with RSV virosomes, but the levels were lower than those induced by two 
immunizations with RSV-MPLA virosomes or FI-RSV (Figure 1A).
 Antiviral antibody titers in the sera were also analyzed in an in vitro 
micro-neutralization assay (Figure 1B). A single immunization with RSV 
virosomes, RSV-MPLA virosomes or FI-RSV induced detectable neutralizing 
antibody titers only in a fraction of animals (Figure 1B). After a second 
immunization, the number of animals with detectable neutralizing antibody 
titers increased in the groups that received RSV virosomes, but not in 
the group that received FI-RSV. However, all animals in the RSV-MPLA-
immunized group then developed neutralizing antibodies (Figure 1B). 
Figure 2. Lung pathology after immunization and challenge in aged cotton rats. The 
cotton rats were immunized challenged and terminated as in figure 1 with buffer (A), FI-RSV 
(B) RSV virosomes (C) and RSV-MPLA virosomes (D). The lungs were inflated and fixed with 4% 
formaldehyde and slices were stained with H&E. Lung pathology presenting as  alveolitis and 
perivascular and peribronchial infiltrations was determined by light microscopy. Red arrows, 
alveolar infiltrates, green arrows, perivascular infiltrates, green arrowheads, peribronchial 
infiltrates.
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The aged and immunized cotton rats were challenged with live RSV, 49 
days after the first immunization, to analyze the protection afforded by 
vaccination. After five days, the animals were sacrificed and virus titers 
were measured in the lungs (Figure 1C). The lungs from non-immunized 
animals all had virus titers of, on average, 4.39 log TCID50. Cotton rats 
that received FI-RSV, RSV virosomes or RSV-MPLA virosomes did not have 
detectable lung virus titers (Figure 1C). 
Figure 3. Immunogenicity and protection in RSV-primed and aged cotton rats 
immunized IM with RSV virosomes and RSV-MPLA virosomes. Cotton rats were 
infected with RSV at the age of 27 days. Four and 34 weeks after infection blood was drawn 
to determine RSV-specific serum IgG in 14 and all the animals respectively (A). At 37 weeks, 
the cotton rats were immunized with RSV virosomes or RSV-MPLA virosomes. Control cotton 
rat received buffer. Three weeks after immunization blood was drawn for RSV-specific serum 
IgG (B) and virus neutralization (C) determinations before (white bars) and after (black bars) 
immunization. The cotton rats were challenged with 106 TCID50 RSV. Five days after challenge 
the cotton rats were terminated and RSV virus titers were determined in lung homogenates 
(D). (Mann-Whitney U test: ns not significant,*p<0.05, **p<0.01, ***p<0.001)
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3.2 Enhanced respiratory disease
To determine the safety of RSV and RSV-MPLA virosomes with respect to 
immunopathology upon RSV infection following vaccination, we performed 
histopathological analyses on the lungs of immunized and challenged aged 
cotton rats. We compared the lungs from animals immunized with RSV 
virosomes and RSV-MPLA virosomes to the lungs of animals immunized 
with FI-RSV, which is known to prime for enhanced lung pathology [17]. 
The lungs from non-immunized aged cotton rats that were infected with 
RSV showed no signs of lung pathology: there were no alveolar infiltrates 
and no infiltration in the peribronchial and perivascular regions (Figure 2A). 
In contrast, aged cotton rats immunized with FI-RSV showed severe lung 
inflammation with peribronchial and perivascular infiltrates upon infection 
(Figure 2B). High numbers of neutrophils were also visible in the alveoli close 
to the bronchi. The lungs of the animals immunized with RSV virosomes 
showed some infiltrates in the peribronchial regions but no perivasculitis or 
alveolitis, as observed in animals immunized with FI-RSV. The lungs of aged 
cotton rats immunized with RSV-MPLA virosomes were similar to the lungs 
from non-immune animals and showed no signs of immunopathology upon 
infection (Figure 2D). 
 
3.3 RSV virosomes in aged cotton rats infected with RSV early in life
The above data indicate that RSV-naïve aged cotton rats have an intact 
immune response, and are susceptible to priming for enhanced disease 
like young cotton rats.  Practically all humans are exposed to RSV during 
childhood, and develop anti-RSV antibodies that remain present throughout 
life. To mimick this process, 27 day-old cotton rats were infected with RSV 
and, immunized with RSV virosomes 8 months later with or without MPLA 
as an adjuvant. Inoculation of live RSV to the young cotton rats induced an 
infection in all animals, as evidenced by the presence of RSV-specific serum 
IgG in all animals, 4 weeks after infection (Figure 3A). The levels of RSV-
specific serum IgG were significantly decreased after 8 months, but still 
detectable in all animals (Figure 3A).  At that time, the animals received a 
single IM injection with RSV virosomes or RSV-MPLA virosomes. A control 
group was not immunized. Three weeks after immunization, we observed 
significant increases in RSV-specific serum IgG levels with respect to pre-
immunization levels (Figure 3B). RSV-specific serum IgG was not different 
for animals immunized with virosomes with or without adjuvant (Figure 
3B). We also observed a significant increase in virus-neutralizing capacity 
of sera from the animals that were immunized with RSV virosomes (Figure 
3C). The virus-neutralizing capacity of sera from RSV-MPLA-immunized 
animals also increased, but the enhancement did not reach a statistically 
significant difference, probably due to a higher base-line neutralizing titer 
in pre-immunization sera from animals that received RSV-MPLA virosomes 
(Figure 3C). 
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Three weeks after immunization, the animals were challenged and five 
days later, RSV titers were determined in the lungs of the animals. RSV 
virus was not detected in the lungs from any group (Figure 3D). Therefore, 
RSV infection in young cotton rats induces immunity capable of protection 
against infection at 9-10 months. 
Figure 4. Immunogenicity and protection in RSV-primed and aged cotton rats 
immunized IN with RSV virosomes and RSV-MPLA virosomes. The cotton rats were 
infected and aged as in figure 3. At 37 weeks, the cotton rats were immunized IN with RSV 
virosomes or RSV-MPLA virosomes. Control cotton rat received buffer. Three weeks after 
immunization blood was drawn for RSV-specific serum IgG (A) determinations before (white 
bars) and after (black bars) immunization. The cotton rats were challenged with 106 TCID50 
RSV. Five days after challenge the cotton rats were terminated and RSV virus titers were 
determined in lung homogenates (B). (Mann-Whitney U test: ns not significant,*p<0.05)
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3.4 Boosting of serum IgG and S-IgA antibodies levels by IN immunization 
in RSV-primed and aged cotton rats
IN administration of vaccines represents an attractive alternative to 
IM injection and may also induce mucosal S-IgA. The latter responses 
have also been linked with protection against RSV in the elderly [2]. We 
therefore determined if local IN administration of RSV virosomes or RSV-
MPLA virosomes could boost serum IgG and mucosal S-IgA responses in 
RSV-primed and aged cotton rats. To this end, two groups of animals were 
immunized IN with RSV virosomes or RSV-MPLA virosomes. Three weeks 
after immunization, we observed significant increases in RSV-specific serum 
IgG levels in the group immunized IN with RSV-MPLA virosomes, but not in 
the group immunized IN with non-adjuvanted RSV virosomes  (Figure 4A). 
At this time point, the animals were challenged and, five days later, RSV 
titers were determined in their lungs. Similar as in cotton rats immunized 
IM, RSV virus was not detected in the lungs of any of the animals (Figure 
4B). 
 S-IgA responses were also analyzed in these groups and compared 
to responses seen in groups that received the vaccine IM. Lung and nasal 
washes were taken at time of sacrifice of the animals (i.e. 5 days post-
challenge) to determine RSV-specific S-IgA. (Figure 5). IN immunization 
with RSV virosomes or RSV-MPLA virosomes resulted in significantly higher 
levels of S-IgA in lung and nasal washes as compared to those in washes from 
cotton rats that received the vaccine IM (Figure 5A and B). Incorporation of 
MPLA in IN-administered virosomes significantly boosted lung S-IgA levels, 
but not nasal S-IgA levels (Figure 5A and B). Thus, IN immunization with 
RSV-virosomes, adjuvanted with MPLA, is an effective approach to boost 
protective serum IgG and S-IgA antibody responses in RSV-primed and 
aged cotton rats.
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Figure 5. Mucosal IgA responses in RSV-primed and aged cotton rats immunized IM 
or IN with RSV virosomes and RSV-MPLA virosomes. The cotton rats were infected and 
aged as in figure 3. Subsequently the cotton rats were immunized with RSV virosomes and 
RSV-MPLA virosomes either intramuscularly (white bars) or intranasally (black bars). Control 
animals received buffer (grey bars). Three weeks after immunization the cotton rats were 





An efficacious RSV vaccine could significantly decrease morbidity and 
mortality in the elderly. Immunosenescence in the elderly causes them to 
gradually become more susceptible to infections and, at the same time, less 
responsive to vaccinations [18,19]. Here we show that RSV virosomes and 
RSV virosomes adjuvanted with MPLA are efficacious and safe in boosting 
RSV-specific immunity in aged cotton rats. 
 The adjuvant effect of the TLR4 ligand MPLA on vaccine-induced 
immune responses in RSV-naive aged cotton rats is similar to the effect 
seen in young cotton rats (manuscript submitted for publication). This 
means that TLR4-mediated signaling is still intact in aged cotton rats. The 
available knowledge of TLR expression and function in the aged immune 
system is mainly derived from studies in mice which have shown decreased 
expression [20] or decreased function of several TLR, including TLR4 
[21,22]. One study in elderly people did show reduced a cytokine response 
to TLR1/2 ligands, but not to TLR4 ligands [23]. Therefore, differences may 
exist in the responses to different TLR ligands in aged immune systems 
from different species. An intact response to the TLR4 ligand MPLA in aged 
cotton rats, as shown in this study, but also in elderly people (17), suggests 
that MPLA is suitable as an adjuvant in RSV vaccines for the elderly. 
 Cotton rats that experienced an RSV infection early in life did not 
become susceptible for RSV at old age. We did observe a decline in serum 
IgG levels upon aging, however, this reduction was smaller than the decline 
reported in humans after infection [24] and the reduced levels if IgG were 
still able to afford protection. Co-evolution of RSV and the human immune 
system produced RSV strains capable of evading the human immune 
response to leave a previously infected person susceptible for subsequent 
infection. This is often referred to as ‘incomplete’ immunity induced by natural 
infection. Two possible mechanisms by which RSV inhibits the formation of 
effective immunity could involve inhibition of induction of type 1 IFN [25,26] 
or skewing the immune response to infection to a Th2-phenotype [27]. It 
is not clear if similar mechanisms are operational in RSV infection of cotton 
rats. Previous studies in cotton rats have shown, however, that RSV infection 
does not lead to a Th2-skewed response [11]. Also, cotton rats primed early 
in life were still protected against infection at old age (Figure 3), which 
argues against the presence of an efficient immune evading mechanism of 
RSV in cotton rats.
 In primed and aged cotton rats, a similar increase in RSV-specific 
serum IgG was seen after IM immunization with RSV virosomes or RSV-
MPLA virosomes. MPLA, although effective in aged cotton rats (Figure 1 and 
5), does not seem to further boost serum IgG responses. An explanation for 
this may be the relatively high antibody levels in aged cotton rats induced 
by the infection early in life. Although these levels declined upon aging, 
they remained sufficiently high to provide protection. It is known that pre-
existing antigen-specific antibodies negatively influence activation of B cells 
with the same antigen specificity, thereby avoiding unnecessary excess 
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antibody production. This mechanism is also operational after influenza 
vaccination. For example, vaccination with a similar strain as that used in 
the preceding years reduces further increases in antibody levels to that 
strain [28]. It is therefore likely that an enhancing effect of MPLA on serum 
antibody levels can only be observed when levels have sufficiently waned. 
RSV-MPLA virosomes administered IN to primed and aged cotton rats induce 
significant increases in serum IgG and respiratory tract S-IgA levels. A study 
in elderly people has shown that the levels of mucosal S-IgA correlated with 
protection against RSV infection [2]. Induction of S-IgA by vaccination is 
most efficiently induced by mucosal vaccination, e.g., IN immunization [29]. 
As the function of the nasal-associated lymphoid tissue remains relatively 
intact during aging, mucosal vaccination through the intranasal route seems 
attractive in, for example, approaches to induce (mucosal) immunity to RSV 
in the elderly [30]. In this respect, TLR ligands show promise as adjuvants 
in mucosal vaccines for the elderly [30]. In line with this, we found that the 
TLR4 ligand MPLA has the capacity to boost lung S-IgA responses upon IN 
immunization of aged cotton rats (Figure 5).
 Taken together, our data indicate that RSV virosomes adjuvanted 
with MPLA have the capacity to induce and boost RSV-specific protective 
immune responses in an aged immune system. These data warrant further 
exploration of MPLA-adjuvanted RSV virosomes as a candidate vaccine for 
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Despite more than five decades of research, there is no licensed RSV vaccine 
available so far. This is partly due to the negative outcome of a clinical 
trial among infants in the 1960s using a formalin-inactivated, parentally 
administered, RSV vaccine, which did not confer protection but rather primed 
for enhanced respiratory disease (ERD) upon natural infection, to the extent 
that two of the vaccinated children even died after exposure to live RSV. Animal 
studies later showed that non-replicating vaccines, like (alum-adjuvanted) 
formalin-inactivated whole-virus RSV vaccine, wrongly instruct the immune 
system leading to, for example, non-neutralizing antibodies with low affinity 
and excessive Th2-skewed immune responses. With the recent discovery 
of Toll-like receptors (TLR) and other innate immune receptors as well as 
identification of their ligands, new opportunities for immunomodulation are 
now becoming increasingly available. For example, addition of TLR ligands to 
inactivated RSV vaccine antigens induce an altered immune activation upon 
immunization, leading to Th1-skewed responses and antibody responses with 
higher virus-neutralizing capacity, without priming for ERD. Recently, TLR 
ligands have also been  recognized as potential mucosal immunoadjuvants. 
This would mean that TLR ligands could be employed in non-replicating RSV 
vaccines for mucosal delivery. Such approaches would represent attractive 
strategies for induction of RSV-specific immunity as mucosal (i.e. intranasal; 
IN) delivery is a highly accepted route of vaccine administration. Also, it 
could induce mucosal in addition to the systemic antibodies, which would 
further contribute to protection. In the studies on development of novel RSV 
vaccination strategies, described in this thesis, the IN route of immunization 
was explored using whole inactivated virus or reconstituted viral envelopes 
(virosomes) as non-replicating vaccine modalities. These vaccines were 
supplemented with different innate receptor ligands like TLR and/or NOD-
like receptor (NLR) ligands. The capacity of different vaccine-incorporated 
innate receptor ligands to boost systemic and mucosal antibody responses, 
to induce safe Th1-type cellular responses and protection against infection, 
was studied in mice and (aged) cotton rats. Additionally, the safety of the 
vaccines was assessed by investigating the occurrence of ERD in immunized 
and subsequently challenged animals. 
Mucosal vaccination strategies against RSV and immunoadjuvant 
properties of innate receptor ligands
IN administration of vaccines can induce, in addition to systemic immunity, 
local immune responses, i.e. secretory IgA (S-IgA), at mucosal sites, which 
could aid in the protection from infection with the pathogen involved  [1-3]. 
In order to potentiate systemic and local antibody responses, non-replicating 
vaccines have to be supplemented with mucosal immunoadjuvants. As 
indicated above, TLR ligands form a new class of adjuvants that show 
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promise in this respect [4].  In Chapters 2-5, we show that IN immunization 
of mice and/or cotton rats with non-replicating RSV vaccine, supplemented 
with TLR ligands (e.g. MPLA, CpG or Pam3CSK4), significantly stimulates 
systemic and mucosal antibody responses. These immune responses were 
further augmented by adding a NOD2 ligand, i.e. L18-MDP (Chapters 2-4). 
TLR ligands exhibit their adjuvant function after binding to a wide range of 
cells within the mucosal tissue of the respiratory tract. These cells include 
not only cells of the immune system but also epithelial cells. Different 
TLR ligands, including ligands for TLR2 (Pam3CSK4), TLR4 (MPLA) or TLR9 
(CpG DNA) ligands, can potentiate immune responses through induction 
of (pro-inflammatory) cytokines in macrophages and dendritic cells (DC), 
after binding to their specific TLRs, and engagement of the MyD88-
mediated and/or TRIF-mediated signaling pathway [5]. Cytokines induced 
in these cell types, like IL-12 and type 1 IFNs, skew towards Th1-type 
responses with production of IFN-γ. These factors, contribute to antibody 
class switching to IgG2a [6]. Indeed, after mucosal co-administration of 
vaccines supplemented with TLR ligands, a switch towards the production 
of IgG2a was seen and splenocyte recall responses showed a clear skewing 
towards a Th1-type phenotype with IFN-γ production (Chapters 2, 3 
and 5). Interestingly, different TLR ligands, including TLR9 ligand, induce 
B-lymphocyte-Activating Factor (BAFF) and A-Proliferation-Inducing-Ligand 
(APRIL) production in lung DCs and alveolar macrophages. These cytokines 
augment antibody responses upon interaction with B cells [7-9]. TLR ligands 
also directly interact with B cells. TLR ligands, such as TLR2, TLR4 and 
TLR9 ligands, can directly induce (T cell-independent) B cell activation and 
may help to induce mucosal antibody responses by enhancing class-switch 
recombination to IgA [10-14].  It is likely that direct activation of B cells by 
TLR ligands, mixed with inactivated RSV particles or incorporated in RSV 
virosomal membranes, contributed to the potentiation of S-IgA responses 
in the upper and lower respiratory tract (Chapters 2-6). Besides an activity 
on immune cells, TLR ligands may also act on other cell types, such as 
epithelial cells, endothelial cells and M-cells. Activation of epithelial cells by 
TLR ligands induces the release of certain pro-inflammatory cytokines and 
chemokines that can attract inflammatory cells. For example, activation 
of a human bronchial epithelial cell line (BEAS-2B) and primary human 
bronchial epithelial cells (PBEC) with TLR ligands significantly upregulated 
BAFF mRNA [15]. In another study, Sha et al. reported that stimulation of 
epithelial cells with TLR ligands, including TLR4 ligand, induced expression of 
macrophage inflammatory protein-3 (MIP-3) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), which may help in DC maturation and 
migration [16]. A recent paper showed that Pam3CSK4, the TLR2 ligand 
used in the present study, not only up-regulates pro-inflammatory cytokine 
genes, but also genes involved in transendothelial migration of leukocytes at 
the site of vaccine administration [17]. Whether the latter mechanism would 
also be operational after mucosal immunization is not known. Finally, TLR 
ligands may enhance uptake of antigens by M cells, as has been described 




In the studies described in this thesis, a NOD2 ligand (L18-MDP) was used 
to further potentiate immune responses induced by the TLR ligands. This 
ligand has been reported to have mucosal immunoadjuvant activity [20], 
and can directly induce B cell activation in the absence of T cell help [21]. 
However, when incorporated in RSV virosomes, L18-MDP alone showed 
poor immunostimulation upon IN immunization of mice (Chapter 3). 
Interestingly, when added together with TLR ligands, it was effective in 
further boosting serum IgG and mucosal antibody responses in a synergistic 
fashion (Chapter 2 and 3). Possibly, these effects result from a boosting 
of the TLR signaling pathways by L18-MDP, rather than from induction of 
signaling events downstream of the NOD2 receptor, as described by Strober 
et al. [22].   
 In Chapter 4, we also observed an enhanced lung IgA response, 
in conjunction with systemic antibody responses, upon IN immunization 
of cotton rats with RSV virosomes carrying Pam3CSK4 and L18-MDP.  Nasal 
IgA responses were poorly boosted, however. In contrast, IN immunization 
of mice with RSV virosomes, adjuvanted with Pam3CSK4/L18-MDP, did 
boost both lung IgA and nose IgA as well as serum IgG antibody responses 
(Chapter 3). A similar observation was made when IN virosomal RSV 
vaccine, adjuvanted with MPLA, was tested in cotton rats (Chapter 5). 
Currently, it is unclear why RSV virosomes adjuvanted with TLR ligands 
more efficiently induce nasal S-IgA in mice compared to cotton rats. Serum 
IgG and lung IgA responses in cotton rats were, however, effectively boosted 
by TLR ligands incorporated in RSV virosomes. Therefore, it is unlikely that 
the observed difference is due to a difference in a species-intrinsic capacity 
to respond to these ligands, as has been demonstrated, for example, for 
mouse vs. human cells in response to LpxL1, a TLR4 ligand [23]. An increase 
in the dose of adjuvants could perhaps boost nasal S-IgA to levels observed 
after RSV infection of cotton rats.   
Role of T cells in vaccine-enhanced respiratory disease 
The exact role of T cell responses associated with the FI-RSV vaccine-
enhanced disease is not clear yet. Accumulated data from studies in mice 
suggest that Th2-associated immunity could be one of the possible factors 
responsible for disease enhancement [24-26]. Furthermore, previous studies 
have shown that FI-RSV-induced Th2-skewed cytokine responses (e.g. IL-
5)  in mice lead to infiltration of different cell types, including eosinophils, 
into the lungs upon infection [24]. The data described in Chapter 2 show 
that mice vaccinated with FI-RSV not only had Th2-skewed splenocyte recall 
responses, but also had increased levels of IL-5 in their lungs at the time 
of RSV challenge infection. This may point to a role of Th2 cytokines in the 
observed lung pathology with eosinophil infiltration (Chapter 2), alveolitis, 
peribronchiolitis and perivasculitis (Chapters 3-6). IL-5, for example, can 
activate eosinophils while other Th2 cytokines (e.g. IL-4, IL-9 and IL-13) 




Th2 responses could also play a role in activation/recruitment of IgE 
antibody-producing B cells, mast cells and eosinophils [28]. The data from 
Chapter 3 show that mice vaccinated with (alum-adjuvanted) FI-RSV 
vaccine elicited a significantly enhanced induction of serum IgE antibody 
responses compared to these responses in mice immunized with other 
vaccine formulations. It is not unlikely that the Th2 cytokine IL-4 causes 
a switch towards IgE antibody production by differentiating B cells. On the 
other hand, the Th1 cytokine IFN-γ (a cytokine prominently produced upon 
immunization with TLR ligand-adjuvanted vaccine (Chapters 2, 3 and 5), 
can inhibit the switch to IgE and prevent the production of specific IgE. Th2 
cells, through production of IL-4, IL-5, IL-9, and IL-13, are also important 
for mast cell recruitment, development, and function [29], which further 
contributes to immunopathology. 
RSV vaccination and TLR activation under conditions of 
immunosenescence
RSV infection does not only affect infants, it is also a major cause of 
severe respiratory disease in the elderly [30]. It has been reported that 
RSV causes approximately 10,000 deaths annually in the United States in 
people over the age of 65 years [31]. Immunosenescence during aging not 
only makes elderly individuals more prone to infections but also suppresses 
the immune response to vaccines [32]. In order to investigate whether a 
candidate virosomal RSV vaccine, supplemented with a TLR4 ligand (MPLA), 
has the capacity to efficiently induce immune responses under conditions 
of potential immunosenescence, aged cotton rats were used in Chapter 6. 
RSV-MPLA virosomes effectively potentiated serum IgG responses upon IM 
administration, similar to responses observed in young cotton rats [33]. In 
aged cotton rats primed to RSV early in life, IN administration of RSV-MPLA 
virosomes could boost mucosal as well as systemic antibody responses 
(Chapter 6). Some studies, however, showed a decline in TLR expression 
and function with aging [34], which could imply that TLR ligands included in 
vaccines have a reduced adjuvant activity with increasing age. On the other 
hand, there is evidence showing that decreased cytokine production by 
human peripheral blood lymphocytes, activated with a TLR4 ligand (LPS), 
occurs only over the age of 85 years [35]. Therefore, the use of TLR ligands 
as adjuvants in vaccines for the elderly does appear to remain promising.  
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Chapter 7
Future perspectives on RSV vaccination in specific target groups
 
Collectively, our data demonstrate that mucosal immunization with a 
virosomal RSV vaccine containing incorporated TLR and/or NOD2 ligands 
represents a promising approach to induce RSV-specific immunity. Upon IN 
administration, such adjuvanted candidate RSV vaccines induce protective 
mucosal as well as systemic antibody responses and Th1-skewed T cell 
responses in mice and (aged) cotton rats without priming for enhanced 
respiratory disease.  The primary target groups for RSV vaccines are young 
infants and the elderly. In addition, older high-risk children would also 
benefit from RSV immunization. Furthermore, pregnant women may also 
represent a target group for vaccination with the aim to protect infants with 
maternal antibodies. It is likely that different vaccines will be required for 
these different target groups.  Live-attenuated (LA) virus vaccines are likely 
to be best suited for use in RSV-naive infants, while non-replicating vaccines 
may be preferable for use in high-risk older children, pregnant women and 
the elderly [36]. The elderly represent the largest potential target group that 
may benefit from an adjuvanted virosomal RSV vaccine. Previous studies 
have shown that classical adjuvant systems, such as alum, have limited 
or no beneficial effects when co-administered with a non-replicating RSV 
vaccine [37]. TLR ligands are new-generation adjuvants that have shown 
to be highly efficacious in IM injected vaccines [38-40], and, based on the 
results presented in this thesis, show considerable promise for use in future 
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Respiratory syncytial virus (RSV) infection is a major cause of severe 
respiratory disease in infants and children worldwide and also forms a 
serious threat for the elderly. Vaccination could significantly relieve the 
burden of RSV disease. However, unfortunately, there is no licensed RSV 
vaccine available so far. RSV vaccine development has been hampered by 
the dramatic outcome of a clinical trial among infants in the 1960s with 
a formalin-inactivated, parentally administered, RSV vaccine, which did 
not confer protection. Rather, the vaccine primed for enhanced respiratory 
disease (ERD) upon natural infection, to the extent that two of the 
vaccinated children died after exposure to live RSV. The development of 
an RSV vaccine for mucosal administration, for example intranasal (IN) 
administration, is of great interest and would represent an attractive 
alternative to intramuscular (IM) injection. Intranasal delivery is a non-
invasive and readily accepted route of administration and it can, in addition 
to systemic antibodies, induce local secretory-IgA (S-IgA) that may further 
contribute to protection. Also, mucosal immunization does not readily prime 
for ERD. However, since mucosally administered antigens are generally not 
very immunogenic, adjuvants are likely to be needed in intranasal vaccine. 
Recently, innate receptor ligands, including Toll-like receptor (TLR) ligands 
and NOD-like receptor (NLR) ligands, have been recognized as potential 
mucosal immunoadjuvants. In this thesis, an approach towards mucosal 
vaccination against RSV was explored which uses intranasal administration 
of RSV vaccine (inactivated RSV or RSV virosomes) supplemented with TLR 
and/or NLR ligands. 
 In Chapter 2, we demonstrate that mucosal immunization of mice 
with RSV whole virions, inactivated with β-propiolactone (BPL-RSV) and 
supplemented with innate receptor ligands (TLR9 ligand CpG ODN and NOD2 
ligand L18-MDP), through the upper or total respiratory tract is an effective 
and safe approach to induce RSV-specific immunity. First, the data show that 
BPL-RSV, supplemented with CpG ODN and L18-MDP, potentiates activation 
of antigen-presenting cells (APC) in vitro, as demonstrated by NF-κB 
induction in a model APC cell line. In vivo, BPL-RSV, supplemented with CpG 
ODN/L18-MDP, induces local IgA responses and augments Th1-signature 
IgG2a subtype responses after immunization of the total respiratory tract 
(TRT) or the  upper respiratory tract (intranasal, IN), albeit less efficiently 
via the latter route.  Addition of TLR9/NOD2 ligands to the inactivated RSV 
also promoted affinity maturation of RSV-specific IgG antibodies and shifted 
T cell responses from mainly IL-5-secreting cells to predominantly IFN-γ-
producing cells, indicating a Th1-skewed response. This effect was seen 
for both IN and TRT immunization. Finally, BPL-RSV, supplemented with 
TLR9/NOD2 ligands, significantly improved the protection of mice against 
a challenge with infectious virus, without stimulating ERD, as evidenced by 
the lack of eotaxin mRNA expression and eosinophil infiltration in the lungs 
of the animals. 
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In Chapter 3, the capacity of a virosomal RSV vaccine with incorporated 
lipophilic TLR and/or NOD2 ligand has been explored in vitro and in vivo in 
mice. Incorporation of Pam3CSK4 (a TLR2 ligand) and/or L18-MDP (a NOD2 
ligand; see above) potentiated the capacity of the virosomes to activate 
(antigen-presenting) cells in vitro, as demonstrated by NF-κB induction. 
In vivo, incorporation of Pam3CSK4 in virosomes boosted serum IgG 
antibody responses and mucosal antibody responses after IN immunization 
of mice. While L18-MDP incorporated in RSV virosomes was not effective, 
incorporation of L18-MDP in Pam3CSK4-containing virosomes further boosted 
mucosal antibody responses. Finally, IN immunization with adjuvanted 
virosomes protected mice against infection with RSV, without priming for 
enhanced disease. 
 In Chapter 4, the efficacy of an IN virosomal RSV vaccine, with 
incorporated Pam3CSK4 or Pam3CSK4 together with L18-MDP, was investigated 
in cotton rats. The cotton rat represents an animal model that is more 
permissive for RSV infection in comparison with mice. The responses induced 
by the virosomal vaccine were compared with responses induced by IM 
immunization with a mock-up of the 1960s FI-RSV vaccine (alum-adjuvanted 
FI-RSV) and IN immunization with live virus. Incorporation of Pam3CSK4 in 
RSV virosomes potentiated systemic IgG and lung S-IgA antibody responses 
capable of inhibiting viral replication in cotton rat lungs upon challenge. 
Inclusion of L18-MDP in virosomes carrying Pam3CSK4, further potentiated 
these responses. Immunization with live virus, but not IN immunization 
with adjuvanted virosomes or intramuscular (IM) immunization with FI-RSV, 
induced nasal S-IgA. All immunized groups showed reduced viral lung titers 
upon challenge. Immunization with FI-RSV, but not IN immunization with 
adjuvanted virosomes or live virus, induced immunopathology (ERD) after 
challenge with live virus. 
 In Chapter 5, the efficacy and safety of RSV virosomes with 
incorporated monophosphoryl lipid A (MPLA, a TLR4 ligand) was studied after 
IN immunization of mice and cotton rats.  MPLA is the only TLR ligand that 
is registered for use in human vaccines and holds promise for use in an IN 
virosomal RSV vaccine. In mice, we found that incorporation of MPLA in IN-
administered RSV virosomes stimulated both systemic IgG and local S-IgA 
antibody levels as well as Th1-type skewing, and resulted in significantly 
reduced lung viral titers upon live virus challenge. Again, responses induced 
by the IN virosomal vaccine were compared with responses induced by 
IM immunization with FI-RSV vaccine and IN immunization with live virus. 
Antibody responses and Th1/Th2-cytokine responses induced by RSV-MPLA 
virosomes were comparable to those induced by live RSV infection. FI-RSV 
induced serum IgG, which inhibited viral shedding upon challenge, but also 
induced unfavourable Th2-skewed responses. In cotton rats, similar effects 
of incorporation of MPLA in virosomes were observed with respect to induction 
of systemic antibodies and inhibition of lung viral shedding upon challenge, 
but mucosal S-IgA responses were only moderately enhanced. Importantly, 
IN immunization with RSV-MPLA virosomes, like live virus infection, did not 
prime for  ERD upon live virus challenge of immunized animals. In contrast, 
IM-immunization with FI-RSV induced severe lung immunopathology. 
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In Chapter 6, we tested the immunogenicity and safety of an MPLA-
adjuvanted virosomal RSV vaccine in aged cotton rats as a model for the 
elderly human population in which RSV represents a serious health threat. 
Here, responses were studied upon IM and IN administration of vaccine to 
animals that were either RSV-naive or RSV-primed through RSV infection 
earlier in life. IM injection of RSV virosomes induced protective RSV-
specific serum IgG antibody responses in aged cotton rats. Immunization 
with RSV-MPLA virosomes further enhanced serum IgG levels compared to 
non-adjuvanted virosomes, without priming for enhanced lung pathology. 
RSV-specific serum antibodies, induced by infection early in life, waned 
significantly upon aging. However, protective levels of antibody were still 
present at old age. RSV-specific serum antibody levels did increase after 
IM injection of RSV virosomes, irrespective of whether the virosomes were 
adjuvanted with MPLA or not. After IN administration, virosomes adjuvanted 
with MPLA, but not non-adjuvanted RSV virosomes, significantly enhanced 
serum IgG levels in RSV-primed and aged cotton rats. RSV-specific S-IgA in 
the respiratory tract of RSV-primed and aged cotton rats increased after IN 
immunization, but not after IM immunization, with virosomal RSV vaccine. 
Incorporation of MPLA in the virosomes boosted this response. 
 Finally, Chapter 7 presents a discussion of the research described in 







Respiratoir syncytieel virus (RSV) is een belangrijke veroorzaker van ernstige 
luchtweginfecties bij pasgeborenen en jonge kinderen en vormt ook een 
bedreiging voor ouderen. Vaccinatie tegen RSV zou infectie en complicaties 
veroorzaakt door het virus kunnen verminderen, maar tot nu toe is er geen 
RSV vaccin  beschikbaar. De ontwikkeling van een RSV vaccin is mede 
vertraagd door de desastreuze uitkomst van een klinische vaccinatiestudie 
in de zestiger jaren van de vorige eeuw. In deze studie werd een formaline-
geïnactiveerd vaccin gebruikt. Dit vaccin bleek geen bescherming teweeg 
te brengen, maar induceerde juist immunopathologie (”enhanced disease”) 
na natuurlijke infectie van de gevaccineerde kinderen met RSV, als gevolg 
waarvan twee jonge kinderen kwamen te overlijden. De ontwikkeling van 
een nieuw veilig RSV vaccin blijft echter onverminderd is belangrijk. 
 Mucosale toediening zou een goed uitgangspunt kunnen vormen 
voor een effectief RSV vaccin. Mucosale toediening, zoals bijvoorbeeld 
intranasale (IN) toediening met een neusspray, is een geaccepteerde, niet-
invasieve, toedieningsroute. Via deze route kunnen, naast RSV-specifieke 
serum IgG antistoffen, ook lokale IgA antistoffen opgewekt worden, die 
zouden kunnen bijdragen aan bescherming. Mucosale toediening van 
vaccin lijkt ook minder snel “enhanced disease” te veroorzaken.  Om via 
de mucosale route effectieve immuunresponsen te induceren zijn echter 
adjuvantia nodig. Liganden voor “Toll-like” receptoren (TLRs) of  “NOD-
like” receptoren (NLRs) vormen een veelbelovende categorie nieuwe 
adjuvantia, die in een geïnactiveerd RSV vaccin gebruikt zouden kunnen 
worden. In dit proefschrift is onderzocht of intranasale toediening van een 
geïnactiveerd RSV vaccin, (zoals geïnactiveerde maar verder intacte RSV-
virusdeeltjes of virosomen afgeleid van RSV), gesupplementeerd met TLR 
en/of NOD liganden, een geschikt methode is om op een veilige manier 
een beschermende immuunrespons tegen RSV op te wekken bij proefdieren 
zoals muizen en katoenratten (“cotton rats”).   
 In Hoofdstuk 2 wordt beschreven zien dat intranasale toediening 
aan muizen van RSV, geïnactiveerd met β-propiolactone (BPL-RSV) en 
gesupplementeerd met een TLR9 ligand (CpG) en een NOD2 ligand (L18-
MDP), een effectieve en veilige manier is om RSV-specifieke immuniteit te 
induceren. De resultaten lieten allereerst zien dat BPL-RSV, gesupplementeerd 
met CpG en  L18-MDP, de activatie van antigeen-presenterende cellen in 
vitro stimuleert. Na IN toediening aan muizen induceert deze formulering 
ook een lokale IgA respons in de luchtwegen; ook werd  een verhoogde 
productie van Th1-type IgG2a subklasse antistoffen waargenomen. TLR9 
en NOD2 liganden bleken daarnaast de affiniteit van RSV-specifieke IgG 
antistoffen te bevorderen. Tenslotte werd een verschuiving in het type T cel 
respons waargenomen van een IL-5-producerende T cel naar een IFN-γ-
producerende T cel. Dit betekent dat er voornamelijk een Th1-type respons 
wordt opgewekt. Dit effect was te zien na toediening van de formulering in de 
neus of de gehele luchtwegen. Toevoeging van de TLR9/NOD2 liganden aan 
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BPL-RSV bleek de vaccin-geïnduceerde bescherming tegen een “challenge” 
met infectieus virus significant te verbeteren. Hierbij werd geen expressie 
van mRNA voor eotaxine waargenomen en er werd ook geen infiltratie in 
de long van eosinofiele cellen gedetecteerd: er wordt dus geen “enhanced 
disease” geïnduceerd. 
 In Hoofdstuk 3 werd een virosomaal RSV vaccin onderzocht. 
Virosomen zijn gereconstitueerde virusmembranen. Omdat deze deeltjes 
geen genoom meer bevatten kunnen ze niet repliceren. In deze studie werden 
lipofiele TLR en/of NOD2 liganden in de virosomale membraan ingebouwd 
en werd de immuunpotentiërende capaciteit van deze deeltjes in vitro en  in 
vivo (bij muizen) onderzocht. Inbouw van een TLR2 ligand (Pam3CSK4) en/
of een NOD2 ligand  (L18-MDP) bleek de capaciteit van de virosomen om, in 
vitro, (antigeen-presenterende) cellen te activeren te versterken. Dit werd 
vastgesteld door de inductie van NF-κB te meten. Inbouw van Pam3CSK4 
in de virosomen stimuleert ook de IgG antistofrespons en de mucosale IgA 
antistofrespons na IN toediening van het vaccin aan muizen. Inbouw van 
L18-MDP alleen bleek niet effectief te zijn. Echter, bij inbouw van  L18-
MDP in virosomen waarin tevens Pam3CSK4 aanwezig was werd wel een 
verhoging van de mucosale antistofrespons waargenomen. Tenslotte bleek 
IN immunizatie van muizen met RSV virosomen met ingebouwde lipofiele 
TLR/NOD2 liganden, volledige bescherming tegen een “challenge” met actief 
RSV virus te induceren, waarbij er geen immunopathologische afwijkingen 
(duidend op “enhanced disease”) werden geconstateerd.  
 In Hoofdstuk 4 werd het IN virosomale RSV vaccin, met en zonder 
ingebouwd Pam3CSK4/L18-MDP, onderzocht bij katoenratten (“cotton rats”). 
Cotton rats zijn proefdieren die, in vergelijking met muizen, verhoogd 
permissief zijn voor RSV-infectie. De immuunresponsen geïnduceerd door 
IN-toegediend virosomaal RSV vaccin werden vergeleken met de responsen 
geïnduceerd door IM-toegediend FI-RSV vaccin  en IN immunisatie met 
actief virus. Inbouw van Pam3CSK4 in de RSV virosomen bleek de  serum 
IgG en de lokale S-IgA respons in de longen te versterken.  Inbouw van 
L18-MDP in virosomen waarin ook Pam3CSK4 was ingebouwd, versterkte 
de antistofresponsen verder. IN immunisatie met actief  virus, maar niet 
IN immunisatie met (geadjuvanteerde)  virosomen of IM immunisate met 
FI-RSV, bleek een S-IgA respons in de neusholte van cotton rats teweeg te 
brengen. Bij alle geïmmuniseerde groupen werd een verlaagde virustiter 
in de longen gemeten na “challenge” met actief levend virus. Immunisatie 
met FI-RSV, maar niet IN immunisatie met (geadjuvanteerde) virosomen 
of actief virus, bleek immunopathologie, karakteristiek voor “enhanced 
disease”, te induceren na “challenge” met levend virus.  
 In Hoofdstuk 5 werd een virosomaal RSV vaccin onderzocht 
waarin het lipofiele monophosphoryl lipid A (MPLA, een TLR4 ligand) was 
geïncorporeerd. MPLA is het enige geregistreerde TLR ligand dat momenteel 
gebruikt wordt in humane vaccins.  Daarom was het van belang om te 
onderzoeken of MPLA ook gebruikt zou kunnen worden in een IN virosomaal 
RSV vaccin. Na IN toediening van het vaccin aan muizen vonden we dat 
virosoom-geïncorporeerd MPLA zowel de serum IgG respons als de lokale 
S-IgA respons in de luchtwegen versterkt. MPLA bleek ook een verschuiving 
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naar een Th1-type respons te induceren. Daarnaast werd bescherming 
tegen een “challenge” met actief virus waargenomen. De immuunresponsen 
werden ook in deze studie vergeleken met de responsen geïnduceerd door 
IM immunisatie met FI-RSV vaccin en IN immunisatie met actief virus. De 
antistofresponsen en Th1/Th2-cytokine responsen geïnduceerd door RSV-
MPLA virosomen bleken vergelijkbaar te zijn met de responsen geïnduceerd 
door IN immunisatie met actief virus. IM immunisatie met FI-RSV bleek 
antistofresponsen te induceren die de virusreplicatie in de longen konden 
terugdringen, maar het FI-RSV vaccin bleek ook een ongwenste Th2-type 
respons op gang te brengen. Ook in cotton rats bleken RSV-MPLA virosomen 
een versterkte serum antistofrespons te induceren en virustiters in de 
longen na “challenge”met actief virus te verlagen. Inbouw van MPLA in de 
virosomen gaf echter maar een geringe versterking van de mucosale S-IgA 
respons te zien. IN immunisatie met RSV-MPLA virosomen veroorzaakt 
geen immunopathologie na “challenge” met actief virus en lijkt dus veilig 
voor wat betreft de mogelijke inductie van “enhanced disease”.  
 In Hoofdstuk 6 werd de immunogeniciteit en veiligheid van het 
virosomale RSV vaccin,  met en zonder ingebouwd MPLA, getest in oude 
cotton rats. Omdat ouderen een belangrijke doelgroep voor een vaccinatie 
tegen RSV vormen, was het van belang om te onderzoeken wat het effect 
van het vaccin op een verouderend immuunsysteem zou zijn. Er werden 
immuunresponsen gemeten na zowel IM als IN toediening van het vaccin 
aan oude cotton rats. Hierbij werden twee verschillende groepen getest: 
RSV-naïeve cotton rats and cotton rats die op jonge leeftijd met RSV waren 
geïnfecteerd. IM toediening van RSV virosomen bleek een beschermende 
serum IgG antistofrespons in de RSV-naïeve cotton rats te induceren. 
Inbouw van MPLA in de virosomen versterkte deze beschermende respons 
en de geïnduceerde responsen gaven ook geen aanleiding tot “enhanced 
disease” na “challenge” van de dieren met actief virus. In de cotton rats 
die op jonge leeftijd geïnfecteerd waren met RSV, bleken de concentratie 
van RSV-specifieke serum IgG antistoffen significant verlaagd te zijn na de 
veroudering van de dieren. De spiegels van deze antistoffen bleek verhoogd 
te kunnen worden door vaccinatie van de dieren via IM toediening van RSV-
virosomen, onafhankelijk van de inbouw van MPLA in de virosomen. Na IN 
toediening van virosomen met daarin ingebouwd MPLA, maar niet na IN 
toediening van virosomen zonder MPLA, konden de RSV-specifieke serum 
IgG spiegels ook worden verhoogd in deze groep. De concentratie RSV-
specifiek S-IgA in de luchtwegen werd hierbij ook verhoogd, wat niet werd 
waargenomen na IM toediening van het vaccin. Inbouw van MPLA in de 
virosomen bleek deze S-IgA respons te versterken.  
 In Hoofdstuk 7 worden de in dit proefschrift behaalde resultaten 
bediscussieerd en worden perspectieven voor toekomstige RSV vaccinatie 
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